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III. Abstract 
Interferon regulatory factor 1 (IRF-1), the founding member of IRF family, is a 
nuclear transcription factor first described as a transcription factor that binds to the 
upstream region of interferon induced genes following viral infection. In addition, 
IRF-1 has been reported to be involved in cell growth regulation, induction of 
apoptosis, immune responses, post-transcriptional modification, and cell 
transformation by oncogenes. Thus, IRF-1 shows accumulative evidence supporting 
the theory that IRF-1 functions as a tumour suppressor. 
However, we still lack the knowledge in the regulation and function behind IRF-1 
and many other tumour suppressors due to the lack of synthetic tools that can aid in 
understanding the mechanism of cancer biology. Here we described the creation of 
synthetic tools that can be applied to study the role of a transcription factor(s) in 
cancer biology. 
Firstly, we described the creation, using recombineering technology, of universal 
bacterial artificial chromosome (BAC) targeting vector. This targeting vector, carry a 
cre-conditioned STOP cassette that can be targeted at a desired specific area. The 
resulted targeting vector can aid the generation of mice models with a conditioned 
knock-in subtle mutation(s). The resulted cre-conditioned mice models are an 
essential tool for any outstanding research project in cancer biology. 
Secondly, we described the development of Flp-In System™ from Invitrogen; the 
system can ease the generation of isogenic stable mammalian expression cell lines. 
Using this system, we created two isogenic stable cell lines expressing wild-type 
IRF-1 and a mutant that abolish IRF-1 DNA binding ability (W11R). Both cell lines 
were investigated using microarray analysis revealing new IRF-1 target genes.  
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We reported the up-regulation of expected standard interferon regulatory genes such 
as, interleukin-24 (IL-24) and interferon regulatory factor-2 binding protein-2 
(IRF2BP2) and the up-regulation of standard apoptotic genes such as, early growth 
response-1 (EGR-1) and prostate transmembrane protein, androgen induced-1 
(PMEPA1) confirming the role of IRF-1 as a tumour suppressor. However, we also 
reported the up-regulation of secreted phosphoprotein-1 (SPP1) and SH3 and PX 
domains-2A (SH3PXD2A) which are matricellular protein produced by cancer cells 
playing a role in cellular adhesion, invasion, tumour growth progression and 
metastasis. Thus, we proposed a new biological role of IRF-1 in cellular movement. 
Thirdly, we described the development of a synthetic stable reporter cell line which 
can report IRF-1 transcriptional activity; such reporter cell line can be used once 
large scale screening is needed. The created stable reporter cell line was used to 
screen a kinase inhibitor library which has revealed C3 as an IRF-1 modifier. The 
newly identified IRF-1 modifier regulates IRF-1 transcriptional activity by inhibiting 
platelet-derived growth factor receptor (PDGFR) and/or vascular endothelial growth 
factor receptor (VEGFR) tyrosine kinase.  
Finally, we validated the synthetic Flp-In System™ by testing the system using a 
novel oncoprotein model. We have developed a stable cell line that overexpresses an 
oncoprotein named Anterior Gradient 2 (AGR-2). We have found that AGR-2 can 
attenuate IRF-1 protein levels dependent of p53. In addition, AGR-2 has been 
identified as a cellular survivor factor during unfolding protein response. 
In conclusion, this study descried the creation and the validation of synthetic tools: 
synthetic cassette for cre-conditioned mice creation, the Flp-In System™ for 
isogenic stable cell line creation, and IRF-1 reporter cell line for high throughput 
screening. All synthetic tools were validated and used to investigate IRF-1, a 
transcription factor that plays a role in cancer and immune system. 
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IV. Abbreviation 
AGR-2 Anterior gradient 2 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
ATR Ataxia telangiectasia and Rad3-related 
BAC Bacterial artificial chromosome 
BP Gateway® BP clonase® enzyme mix 
BSA Bovine serum albumin 
cDNA Complementary deoxyribonucleic acid 
CHIP C terminus of Hsc70-interacting protein 
CHOP CCAAT/enhancer binding protein (C/EBP), epsilon 
CK2 Casein kinase 2 
cRNA Complementary ribonucleic acid 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dsDNA Double-stranded deoxyribonucleic acid 
EBV Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum  
FLT3 Fms-related tyrosine kinase 3 
FRT Flp recombination target 
GAF/AAF Interferon-γ activated factor/interferon-α activated factor 
GC Glucocorticoids 
GRIP-1 Glutamate receptor-interacting protein 1 
Hsp Heat shock protein 
HTS High throughput screening  
IC50 The half maximal inhibitory concentration 





iNOS Nitric oxide synthase 
IRF Interferon regulatory factor 
IRF-E Interferon regulatory factor element 
ISG-20 Interferon stimulated gene 20 
ISGF3 Interferon stimulated gene factor 3 
ISGs Interferon stimulated genes 
ISRE Interferon sensitive response element 




 Joule per meter squared 
Jak1 Janus kinase 1 
kDa Kilodalton 
KEGG Kyoto encyclopedia of genes and genomes 
KI Knock-in 
KO Knock-out 
KPNA2 Karyopherin alpha 2 
LB Luria-Bertani broth 
LR Gateway® LR clonase® enzyme mix 
MAPK Mitogen-activated protein kinase 
MDA-7 Melanoma differentiation-associated gene-7 
MEFs Mouse embryonic fibroblasts 
MHC Major histocompatibility complex 
mRNA Messenger ribonucleic acid 
MyD88 Myeloid differentiation primary gene 88 
NK Natural killer 
nm Nanometer 
NPM Nucleophosmin 
ORF Open reading frame 
PAC P1 artificial chromosome 
PBS Phosphate buffer saline 
PCAF P300/CBP-associated factor  
PCR Polymerase chain reaction  
PDGFR Platelet-derived growth factor receptor 
PEL Primary effusion lymphoma 
PKA Protein kinase A 
PKR Protein kinase R (RNA activated) 
PPS Popliteal pterygium syndrome 
PRDI Positive regulatory domain I 
QC Quality check 
qRT-PCR Quantitative real time polymerase chain reaction 
RANTES Regulated on activation normal T-cell expressed and secreted 
rpm Round per minute 
RSN Robust spline normalisation 
RT Reverse transcription 
RTK Receptor tyrosine kinase 
RT-PCR Reverse transcription polymerase chain reaction 
RVD Repetitive variable di-residues 
S33Y Serine 33 to tyrosine 
S45∆ Serine 45 deletion 
SDS Sodium dodecyl sulfate 
SLE systemic lupus erythematosus 
SPP1 Secreted phosphoprotein 1 
ssDNA Single-stranded deoxyribonucleic acid 
SUMO Small ubiquitin-like modifier 
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TALENs Transcription activator-like effector nucleases 
TALEs Transcription activator-like effectors 
TAT Trans-activator of transcription 
TLR3 Toll-like receptor 3 
TPP Tecno plastic products 
Tyk2 Tyrosine kinase 2 
UPS Ubiquitin-proteasome system 
UV Ultraviolet 
VEGF Vascular endothelial growth factor  
VEGFR Vascular endothelial growth factor receptor 
VRE Virus response element 
VST Variance stabilizing transformation 
W11R Tryptophan 11 to arginine 
YAC Yeast artificial chromosome 
ZFNs Zinc-finger nucleases 
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1.1 Introduction 
According to the World Health Organization, cancer is the second most common cause 
of death in the developed world; only cardiovascular disease mortality exceeds that of 
malignancy. The last two decades have seen enormous advances in our understanding of 
the cellular and molecular basis of malignancy, its initiation, promotion, and 
progression. There is no single molecular cause of cancer, and for each different cancer 
type, many genes are involved. 
Scientists and clinicians have become more interested in cancer biology due to recent 
developments in molecular biology, genetics, virology and immunology leading to new 
and better approaches for studying the nature of cancer cells and the mechanism of 
tumour induction. Here we will review the basic pathology of cancer, followed by a 
brief introduction on the interferon system and interferon regulatory factors. Finally, a 
detailed description of a distinct tumour suppressor gene termed interferon regulatory 
factor 1 (IRF-1) and its cooperation in tumorigenesis will be highlighted. 
Cancer is a broad medical term that describes a group of diseases that involves 
unregulated cellular growth. Cancer is a cellular state in which cells grow and divide 
uncontrollably forming a tumour which could be malignant or benign. Malignant 
tumours can invade nearby parts of the body and spread to more distant locations 
through the lymphatic system and/or bloodstream. Cancer Research UK indicated there 
are more than 200 types of cancer which can develop in more than 60 organs. 
Many factors can increase the risk and contribute toward cancer, including internal 
factors, such as inherited mutation, hormones, and immune condition, and 
environmental factors, such as smoke exposure, alcohol consumption, diet, radiation, 
and infectious organism (Anand et al., 2008). All cancers result from multiple mutations 
(Loeb and Loeb 2003) where these factors directly or indirectly can cause a defect in an 
oncogene and a tumour suppressor gene resulting in uncontrolled cellular growth where 
cells keep growing and multiplying without regulation.  
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1.2 The interferon system 
Interferons (INFs) were first reported by Isaacs and Lindenmann back in 1957 as 
proteins that could make other cells resistant to viruses following infection of cells with 
a supernatant from other cells already infected with the same virus (Isaacs and 
Lindenmann 1957). Today, interferons are known to be a class of proteins produced by 
cells in response to antigen such as viral infection or any external agent, and act as a 
natural barrier in order to protect the body from infections. Interferons are considered to 
be cytokines belonging to the group of interleukins and they are classified into four 
types: interferon-α, interferon-β, interferon-γ and recently interferon-λ. Both interferons 
α and β are categorized into subclass I, whereas interferon-γ is considered to be in 
subclass II and finally interferon-λ is classified as subclass III. Interferons are well 
studied for their role in antiviral response, immune modulation, haematopoietic 
development and their antiproliferative response by regulation of the cell cycle 
(Taniguchi et al., 2001; Nguyen et al., 1997; Stark et al., 1998).  
 
1.2.1 The old interferons 
Till a few years ago, interferons were thought to be divided into the type I and type II 
subgroups only. Interferon-α or “leukocyte” interferon are cytokines to type I interferon 
having multiple effects on cell function (Vilcek, 2006). The interferon-α family is 
composed of at least 13 interferon subtypes, coded by more than 15 genes and 9 
pseudogenes found on human chromosome 9 and murine chromosome 4 (De Andrea et 
al., 2002).  Interferon-α genes do not contain introns and the whole gene codes for the 
interferon-α protein (De Andrea et al., 2002). All interferon-α proteins are produced 
from macrophages, particularly lymphocytes, cells that use similar receptor systems and 
have similar biological activities. Interferon-α has been used in clinical oncology for 
treating more than 14 different cancer types (Ferrantini et al., 2007) including 
haematological malignancies and certain solid tumours such as melanoma and 
carcinoma (Ferrantini et al., 2007).  
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Despite many years of interferon-α research in animal models, the different mechanism 
of action is still a matter of debate. The direct inhibitory effect on tumour cell growth 
and function was the major anti-tumour response seen as a result of treating patients 
with interferon-α. In fact, interferon-α can directly down-regulate oncogene expression, 
induce tumour suppressor activity, and inhibit the proliferation of normal and tumour 
cells in vitro and in vivo (Ferrantini et al., 2007).  
Interferon-β or “fibroblast” interferons are cytokines of the type I interferon family with 
interferon-α. Interferon-β is mainly produced in epithelial cells and fibroblasts under the 
action of foreign nucleic acids, such as viral genomes or other types. Interferon-β is also 
coded by a gene with no introns found on human chromosome 9 (De Andrea et al., 
2002). However, interferon-γ belongs to a separate subclass, so-called type II interferon, 
named as “immune” interferon. Interferon-γ is produced especially by lymphocytes 
sensitized with the help of macrophages and only under the action of external mitogens. 
Unlike interferon-β, interferon-γ is transcribed from a single gene containing three 
introns located on human chromosome 12 (De Andrea et al., 2002). 
1.2.2 The new interferon 
Interferon-λ was just identified few years ago and classified as a new group: type III 
interferon. In humans, there are three distinct interferon-λ proteins termed INF-λ1, INF-
λ2, and INF-λ3 (Donnelly and Kotenko 2010). They are also named interleukin-29 (IL-
29), IL-28A, and IL-28B, respectively (Sheppard et al., 2002). The members of this new 
interferon family were found to interact through unique receptors (distinct from those 
used by type I and type II interferons) composed of the unique IFN-λR1 chain, called IL-
28AR, and the IL-10R2 chain which is shared with IL-10, IL-22, and IL-26 receptor 
complexes (Lasfar et al., 2011).  
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Although type III interferons bind to a specific receptor, the downstream signalling is 
similar to that induced by type I interferon and consists of the activation of janus kinase 
(Jak1) and tyrosine kinase 2 (Tyk2) kinases (section 5.2.1) leading to the activation of 
the interferon stimulated gene factor 3 (ISGF-3) transcription complex (Lasfar et al., 
2011). 
Although type I and type III interferons induce similar cell signalling, the intensity of 
cell signalling as measured by signal transduction and transcription (STAT1) activation 
appeared to be lower for type III interferon (Lasfar et al., 2006). In addition, antiviral 
studies in vivo and in vitro have shown that both interferon-α and interferon-λ contribute 
toward antiviral response (Ank et al., 2006), and other studies showed that type III 
interferon can inhibit the replication of hepatitis C and B viruses (Hong et al., 2007), 
which suggests an alternative to interferon-α treatment among patients with interferon-α 
resistance hepatitis. Another group showed that interferon-λ can inhibit human 
immunodeficiency virus type 1 (HIV-1) infection of blood monocyte-derived 
macrophages (Hou et al., 2009) suggesting that interferon-λ exerts immunomodulatory 
effects that overlap those of type I interferons (Lasfar et al., 2011). 
In addition to antiviral and immunomodulatory activity, type I interferons demonstrate 
antiproliferative activities in most cell lines, whereas this activity is restricted within 
interferon-λ (Li et al., 2009). Type I interferons have been shown to induce apoptosis in 
cancerous cells by inducing a quick and potent signalling leading to the expression of 
more than 300 interferon stimulated genes (ISGs) (Der et al., 1998), many of which are 
involved in encoding apoptosis related proteins (Clemens 2003). However, interferon-λ 
does not inhibit the proliferation of many types of tumour cell lines, though some reports 
showed an inhibition in some cell lines, such as human glioblastoma (Meager et al., 
2005). 
  
20 | P a g e  
 
1.3 The interferon regulatory factors 
A key factor in interferon induce response is the interferon regulatory factors (IRFs). 
IRFs are a group of transcription mediators of bacteria, viruses, and interferon-induced 
signalling that result in different responses within immune response, cell growth 
regulation, and apoptosis. To date, nine members belong to the human IRF family 
including IRF-1, IRF-2, IRF-3, IRF-4 (Pip or ICSAT), IRF-5, IRF-6, IRF-7, IRF-8 
(ICSBP), and IRF-9 (ISGF3γ or p48). In addition, IRF-10 was identified in chicken; 
however, it is absent in humans and mice (Nehyba et al., 2002). All ten factors share 
significant homology in the N-terminal 115 amino acids, which contain the DNA 
binding domain characterized by five tryptophan repeats (Figure 1.1).  
The C-terminal regions of most IRFs carry an IRF association domain (IAD) that is 
responsible for homo- and heteromeric interaction with other family members or other 
transcription factors such as PU.1 and STAT (Taniguchi et al., 2001). However, the 
unique function of a particular IRF is influenced by a combination of cell-type specific 
expression and its ability to interact with other family members and transcriptional 
activators (Taniguchi et al., 2001). 
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Figure 1.1: All interferon regulatory factors are composed of a DNA binding domain 
(navy blue) and a regulatory domain (light blue). For all IRFs, the DNA binding 
domain is characterized by 5 tryptophan repeats that are 10–18 amino acids apart. 
Most IRFs contain an IRF association domain (IAD) of either type I (Dark green) or 
type 2 (light green). Some IRFs contain a repression domain (purple) and a nuclear 
localization signal (orange). The size of each IRF in number of amino acids is 
indicated on the right. 
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1.3.1 The first IRF: IRF-1 and IRF-2 
The first two members, IRF-1 and IRF-2, were discovered through their ability to bind 
to the positive regulatory domain I (PRDI) in the virus response element (VRE) of 
interferon-β genes, suggesting a function as an activator and repressor of interferon-β 
genes (Fujita et al., 1989); however, IRF-1 null mice did not have impaired activation of 
interferon-α and interferon-β genes in mouse embryonic fibroblasts (MEFs) (Reis et al., 
1994). Further studies showed that IRF-1 is involved in antiviral defence mediated by 
interferon-γ, as the induction of nitric oxide synthase (iNOS) and guanylate binding 
protein was impaired in interferon-γ treated IRF-1 deficient MEFs (Kimura et al., 1994). 
Later, it was shown that IRF-1 is induced by interferon-γ and the induction of iNOS 
genes by interferon-γ is mediated by IRF-1 (Coccia et al., 2000). Further studies 
suggested that IRF-1 has an essential function in the development and activation of 
various immune cells (Duncan et al., 1996). In addition, IRF-1 also plays a critical role 
in the inducible expression of major histocompatibility complex (MHC) class I and 
apoptosis, as cells from IRF-1 null mice are resistance to UV and drug-induced 
apoptosis (Reis et al., 1994). In humans, polymorphism in IRF-1 has been associated 
with predisposition to asthma in the paediatric population (Wang et al., 2006), and 
deletions in IRF-1 has been observed in myelodysplastic syndrome and leukaemia 
(Willman et al., 1993). 
Harada et al (1989) reported the discovery (by cross hybridization with IRF-1 cDNA) of 
another distinct interferon regulatory factor, IRF-2, that binds to the same cis-regulatory 
element of IRF-1 (Harada et al., 1989). IRF-1 and IRF-2 show 62% homology in the 
first 154 residues (amino-terminal region) and 25% homology in the remaining structure 
(Harada et al., 1989). IRF-2 overexpression in fibroblasts results in oncogenic 
transformation of these cells (Paun and Pitha 2007); also, IRF-1 has been shown to 
activate the transcription of histone 4 gene (Vaughan et al., 1995).  
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The role of IRF-2 in the innate antiviral defence has not been clearly established, results 
from IRF-2 null mice showed impaired natural killer (NK) cells, which displayed  an 
immature phenotype and compromised receptor expression, suggesting that IRF-2 
deficiency results in a defect in the late stages of NK cells maturation (Taki et al., 2005).  
1.3.2 The antiviral IRF: IRF-3 and IRF-7 
IRF-3 and IRF-7 are closely related to each other based on their primary structure 
(Figure 1.1). IRF-3 was discovered by searching the expressed sequence tag database for 
IRF-1 and IRF-2 homologues (Au et al., 1995). IRF-3 mRNA levels were found to be 
expressed constitutively in all tissues and not induced by viral infection or interferon 
treatment (Au et al., 1995). IRF-7 discovery was reported by Zhang et al (1997), and its 
expression is considered ubiquitous; however, it’s totally dependent on type I interferon 
signalling, unlike IRF-3 (Marie et al., 1998 and Sato et al., 1998). The role of their 
transcriptional activation of interferon genes and the identification of IRF-3 and IRF-7 
had an outbreak in understanding the mechanism in which a pathogen induces innate 
antiviral response (Ronco et al., 1998; Au et al., 1998; Marie et al., 1998).  
Upon recognition of dsRNA by a cellular receptor, IRF-3 is ubiquitously expressed 
(Ronco et al., 1998). The signalling pathway of Toll-like receptor 3 (TLR3) or the 
cytoplasmic RNA helicases (RIG-1) both characterized by the presence of caspase 
recruitment domain (CARD) will phosphorylate IRF-3 at the C-terminal region, at serine 
386, using two non-canonical IkB kinases, TBK-1 and IKKε (Fitzgerald et al., 2003). 
Further crystal structure showed IRF-3 activation by structural changes following that 
specific phosphorylation (Takahasi et al., 2003). 
This activated IRF-3 will then homo/hetero dimerize with IRF-7 and translocate to the 
cellular nucleus where it associates with the CREB binding protein CBP and p300 to 
stimulate transcription of interferon-β genes and some other interferon stimulated genes 
such as ISG-54 and RANTES (regulated on activation normal T-cell expressed and 
secreted) (Yoneyama et al., 1998 and Lin et al., 1999). Phosphorylated IRF-3 is under 
negative regulation by the ubiquitin proteasome pathway (Lin et al., 1998).  
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It has been shown that propyl isomerase (Pin1) targets activated IRF-3 for ubiquitin-
mediated degradation (Saitoh et al., 2006). ISG-15, an interferon-induced ubiquitin-like 
protein, initiates the ubiquitin-mediated degradation of IRF-3, stabilizes IRF-3, and 
increases nuclear retention (Lu et al., 2006). Thus, ISG-15 plays an important role in 
enhancing host antiviral response. 
IRF-7 was discovered as a factor binding to the Qp promoter of the Epstein-Barr Virus 
(EBV), and a splice variant of IRF-7 was identified as a key player in the induction of 
interferon-α genes (Zhang et al., 1997). Human IRF-7 is located on chromosome 11 at 
position 15.5 in a CpG-rich region that is methylated in some cancers (Lu et al., 2002). 
IRF-7 transcription can be induced using type I interferon and tumour necrosis factor 
(TNF-α) (Lu et al., 2002). Further results suggested that IRF-7 is a master regulator of 
type I interferon expression as IRF-7 overexpression in infected human fibroblasts, 
which express only interferon-β, conferred expression of several interferon-α genes  
(Yeow et al., 2000). In addition, mice with homozygous deletion of IRF-7 were unable 
to express type I interferon genes following viral infection or activation of TLR9 using 
CpG-rich DNA (Honda et al., 2005). 
IRF-7 is also phosphorylated by the signalling pathway mediated by TLR3, TLR7, 
TLR8 and TLR9, in which serine 477 and serine 479 appear to be critical targets for 
activation using TBK-1 kinase activity (Sharma et al., 2004); however, TLR7- and 
TLR9-stimulated phosphorylation of IRF-7 is dependent not on TBK-1 but rather on 
MyD88, IRAK-4, IRAK-1, and TRAF6 (Uematsu et al., 2005).  
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1.3.3 The hematopoetic IRF: IRF-4 and IRF-8 
IRF-4 and IRF-8 show a degree of structural homology. Both are expressed mainly in 
lymphocytes, B-cells, and dendritic cells (Eisenbeis et al., 1995). Both proteins show a 
weak DNA binding affinity which can be increased with the association of other 
transcription factors (Tailor et al., 2006). IRF-4 has been characterized in the literature 
with different terminology: (i) Pip, a stabilized binding protein which heterodimerizes 
with the transcription factor PU.1, and where such heterodimerization was shown to 
bind to the IgG enhancer and activate the expression of the immunoglobulin (Ig) light 
chain in B-cells (Eisenbeis et al., 1995); (ii) LSIRF, a new IRF family member 
expressed in lymphoid cells (Mittrucker et al., 1997); and (iii) ICSAT, a factor that binds 
to the regulatory element of the human interleukin-5 gene (Yamagata et al., 1996). 
IRF-4 has also been reported to be a natural antagonist of both IRF-1 and IRF-5 
transactivation (Yoshida et al., 2005). Mice IRF-4 null models were deficient in mature 
T and B-cells suggesting a role of IRF-4 in such cells maturation (Lu et al., 2003). In 
addition, IRF-4 null mice also showed a developmental block at several steps of T and 
B-cells differentiation (Mittrucker et al., 1997). The function of IRF-4 can also be 
revoked by an inability to associate with PU.1 transcription factor as observed in 
primary effusion lymphoma (PEL), which is characterized by an arrest in B-cell 
differentiation (Arguello et al., 2003), suggesting any defect in IRF-4 expression or 
function will lead to immune deficiency. In multiple myeloma cells, IRF-4 has been 
found to be translocated near the immunoglobulin heavy chain locus and consequently 
overexpressed, leading to the suggestion that uncontrolled expression of IRF-4 may lead 
to multiple myeloma phenotype (Iida et al., 1997). 
IRF-8 or interferon consensus sequence binding protein (ICSBP) shares some 
similarities with IRF-4. The expression of IRF-8 is restricted to myeloid and lymphoid 
cell lineages and is induced by interferon-γ but not interferon-α or interferon-β (Driggers 
et al., 1990). IRF-8 binds DNA after interaction with other IRF members such as IRF-1 
and IRF-2 and other transcription factors such as PU.1 and E47 (Politis et al., 1992).  
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However, the IRF-8 and IRF-1 transcriptional complex serves as a suppressor of 
transcription, whereas the IRF-8 and IRF-4 heterodimer activates transcription of ISG-
15 (Meraro et al., 2002). The IRF-8 and IRF-1 complex also induces the transcription of 
genes for macrophage differentiation and macrophage-induced inflammation (Liu et al., 
2004). 
1.3.4 The surprising IRF: IRF-5 and IRF-6 
Both IRF-5 and IRF-6 show completely different functions even though they share a 
similar structure. IRF-5 is induced by interferon-α and interferon-β stimulation 
(Tadatsugu et al., 2001) and has a role in apoptosis and the immune response to 
pathogen (Paun and Pitha 2007). However, IRF-6 has been reported to be a key player in 
the switch between keratinocyte proliferation and differentiation (Richardson et al., 
2006). In addition, the IRF-6 null mouse model showed embryonic lethality with 
abnormal external morphology (Ingraham et al., 2006). 
Human IRF-6 is located on chromosome 1 position q32, which is defined as the Van der 
Woude syndrome locus. This genetic disorder is associated with a nonsense mutation in 
IRF-6 causing an autosomal dominant form of cleft lip and palate (Mostowska et al., 
2005). Further mutation of IRF-6 is also associated with popliteal pterygium syndrome 
(PPS) characterized by similar orofacial phenotype skin lesions and genital 
abnormalities (Kondo et al., 2002). These unexpected properties of IRF-6 indicate that 
IRFs may also have basic roles unrelated to the immune response and the immune 
system.  
IRF-5 has been implicated in the innate inflammatory response. Human IRF-5 protein 
shows some properties distinct from IRF-3 and IRF-7: the IRF-5 protein structure 
contains two nuclear localization signals (Figure 1.1) and consequently nuclear IRF-5 
can be detected in untransfected cells (Barnes et al., 2001). IRF-5 can be induced by 
type I interferon and viral stimulation (Mancl et al., 2005); also IRF-5, can be induced 
by the tumour suppressor p53 (Mori et al., 2002), suggesting a connection between these 
two proteins inducing pro-apoptotic pathways. Similar to p53, IRF-5 stimulates the 
cyclin-dependent kinase inhibitor p21
(WAF1/ CIP1)
, while repressing cyclin B1 and 
stimulating the expression of pro-apoptotic genes such as Bak1, Bax, Caspase 8, and 
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DAP kinase 2 (Hu et al., 2006). In addition, IRF-5 overexpression specifically up-
regulates many early inflammatory genes including RANTES, MIP-1β, I-309, MCP-1 
and IL-8, suggesting a very important role for IRF-5 in early inflammatory cytokines 
and chemokines response, maturation, development, and expression. (Barnes et al., 
2004).  
Human IRF-5 protein is expressed in multiple splice variants, some of which are 
transcriptionally inactive and others function as dominant negative mutants (Mancl et 
al., 2005). Mutations in human IRF-5 have been associated with autoimmune diseases, 
such as systemic lupus erythematosus (SLE) which is characterized by interferon-α 
overproduction and polymorphism in the Tyk2 and IRF-5 genes. This observation 
suggests a connection between IRF-5 expression, interferon-α production, and 
autoimmunity (Graham et al., 2006). 
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1.3.5 The last IRF: IRF-9 and viral IRF 
IRF-9, known in the literature as p48 or ISGF3-γ, plays an important role in the antiviral 
effect of type I interferon. IRF-9 forms a tertiary complex with interferon stimulated 
gene factor 3 (ISGF3), which binds to the interferon stimulated response element (ISRE) 
found in the regulatory element of interferon stimulated genes (Veals et al., 1992). 
Within this complex, STAT1 and STAT2 are included where IRF-9 is the major DNA 
binding component. In addition, IRF-9 can form further complexes by binding 
individually to STAT1 or STAT2 with the same DNA specificity as ISGF3 (Kraus et al., 
2003). As IRF-1 and IRF-2, IRF-9 is expressed in a variety of tissues and shown to be 
essential for the antiviral response by interferon-α, interferon-β, and interferon-γ 
(Bluyssen et al., 1996). 
Kaposi’s sarcoma-associated herpes virus (KSHV) or human herpes virus-8 (HHV-8) is 
a member of the (γ) herpes virus family, and causes Kaposi’s sarcoma and primary 
effusion lymphoma. Sequence analysis of the KSHV genome revealed the presence of 
about 80 different open reading frames (ORF) where few showed similarity to other 
genes that regulate cell growth, immune function, inflammation and apoptosis (Moore et 
al., 1998), including a cluster of four ORFs that showed homology to cellular 
transcription factor of the IRF family (Cunningham et al., 2003). 
Three viral IRFs (vIRF) have been cloned and characterized. The first is the K9- vIRF-1 
which encodes a hypothetical 449aa protein with 13.4% identity to human IRF-8 (Moore 
et al., 1998). vIRF-1 binds with several IRFs including IRF-1 and inhibits IRF-mediated 
transcriptional activation (Gao et al., 1997). vIRF-1 has been shown to inhibit both the 
virus-mediated induction of type I interferon genes and interferon stimulated genes, 
where its overexpression in fibroblasts initiates tumorigenicity when injected into nude 
mice (Gao et al., 1997). vIRF-1 binds to CBP/p300 and inhibits its acetyl transferase 
activity resulting in the global inhibition of histones H3 and H4 acetylation (Li et al., 
2000). The vIRF-1 anti-apoptotic effect of vIRF-1 is thought to be related to p53, and 
IRF-1 (Burysek et al., 1999 and Seo et al., 2001). 
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The second vIRF is vIRF-2, which is encoded by ORF K11.1, makes a small nuclear 
protein with 163aa (Burysek et al., 1999). Unlike cellular IRF members, vIRF-2 binds to 
oligodeoxynucleotides corresponding to the NF-κB site and associates with other IRF 
members and p300 (Burysek et al., 1999). Also, vIRF-2 has been reported to bind to 
protein kinase RNA-activated (PKR) inhibiting its kinase activity and blocking the 
phosphorylation of its substrate, eukaryotic translation initiation factor 2α (Burysek et 
al., 2001). 
The third vIRF characterized is vIRF-3 or LANA2 encoded by ORFs K10.5 and K10.6 
(Lubyova and Pitha 2000). vIRF-3 is a multifunctional nuclear protein, and binds to 
IRF-3, IRF-7, and CBP/p300. In addition, vIRF-3 can also stimulate IRF-3/IRF-7 
mediated transcription of type I interferon genes (Lubyova et al., 2000). Further, 
interaction of vIRF-3 with p53 results in inhibition of p53 mediated transcriptional 
activation and p53 induced apoptosis (Rivas et al., 2001). 
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1.4 Interferon regulatory factor 1 
1.4.1 IRF-1 and cancer association 
Ectopic IRF-1 overexpression in a wide range of different cell types obtained from many 
different mammalian species, such as human, mouse and hamster, has been reported to 
cause growth inhibition (Kirchhoff et al., 1993; Tanaka et al., 1996; Kirchhoff et al., 
1996; Coccia et al., 1999). It was concluded that this suggested antiproliferative effect of 
IRF-1 was caused by the potential ability of IRF-1 to stimulate transcription of 
antiproliferative acting genes (Nguyen et al., 1997). IRF-1 causes cell growth inhibition 
by inducing interferon-β gene expression or other secreted factors (Kroger et al., 2002). 
Several IRF-1 induced antiproliferative genes have been characterized (Kroger et al., 
2002), of which PKR is the most studied. PKR function is thought to prevent viral 
mRNA translation in infected cells. In addition to PKR, 2',5'-oligoadenylate synthetase 
(2',5'-OAS), whose product activates the mRNA degradation enzyme RNase L, is also 
induced by IRF-1 stimulation (Kroger et al., 2002). The products of many other IRF-1 
induces antiproliferative genes lead to G1 cell cycle specific arrest such as the tumour 
suppressor protein p53 and the cell cycle-dependent kinase inhibitor p21 (Kroger et al., 
2002). The expression of many other genes, such as IL-4, IL-5, IL-7 receptor, E-
cadherin, ISG, and MHC HIL class I genes are induced by IRF-1 (Tanaka et al., 1993) 
and contributes to the growth-suppression effect. Thus, IRF-1 is considered to be a novel 
tumour suppressor. 
Clinically, mutation in IRF-1 genes has been observed in variety of human cancers. One 
of the most frequent cytogenetic abnormalities in human leukaemia and myelodysplasia 
(MDS) is an interstitial deletion within chromosome 5 location 31 (5q31) (Willman et 
al., 1993). This deletion has been reported to be the smallest commonly deleted site 
where IRF-1 has been mapped (Willman et al., 1993).  
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Only IRF-1 has been consistently deleted at one or both alleles in 13 cases of leukaemia 
or myelodysplasia within the area of 5q31. Thus IRF-1 may be a critical deleted gene in 
human leukaemia and myelodysplasia. This IRF-1 tumour suppressor inactivation is 
caused by accelerated exon skipping of IRF-1 mRNA. The exon skipped form of IRF-1 
lacks exons 2 and 3 displaying neither DNA binding or tumour suppressor activity; thus 
this exon skipping may cause the inactivation of IRF-1 (Harada et al., 1994). 
Other pathological effects of IRF-1 mutation have been reported. Moriyama et al (2001) 
reported that IRF-1 expression was reduced in 53% of human hepatocellular carcinomas 
with both wild-type p53 and reduced expression of p21. Further, loss of heterozygosity 
on the long arm of chromosome 5 has been reported to be associated with stomach 
adenocarcinoma (Tamura et al., 1996). One of the targets of 5q loss of heterozygosity in 
colorectal carcinoma is certainly the adenomatous polyposis coli (APC) gene on 5q21. 
However, other evidence suggested the presence of another tumour suppressor gene 
within that area that might be inactivated in gastric carcinoma. Minimum regions of 
deletions including the IRF-1 locus have been identified in gastric carcinoma using nine 
microsatellite loci (Tamura et al., 1995). Further study revealed this deletion in IRF-1 
tumour suppressor activity in gastric carcinoma is due to missense mutation in exon 2 
where the ATG to TTG mutation caused a methionine to leucine substitution at amino 
acid 8 (Nozawa et al., 1998). Such a substitution allows mutant IRF-1 to bind to DNA 
with similar affinity as the wild-type protein, but abolishes its ability to induce 
interferon-β p125 luciferase promoter or inhibit cell growth when overexpressed 
(Nozawa et al., 1998). 
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1.4.2 Induction of IRF-1 
IRF-1 mRNA is expressed at a low basal level in all cell types with the exception of 
early embryonic cells (Kroger et al., 2002). IRF-1 mRNA levels accumulate in response 
to many stimuli, including viruses, lipopolysaccharide (LPS), interferon, double stranded 
RNA, cytokines (IL-1, IL-2, IL-6, IL-12) and some hormones such as prolactin 
(Miyamoto et al., 1988; Harada et al., 1989; Barber et al., 1995; Galon et al., 1999; 
Coccia et al., 2000; McAlexander; Yu-Lee 2001). All these factors are part of a 
signalling network that indicates the presence of infection and their induction of IRF-1 is 
an important host-defence mechanism. Interferon-γ is the strongest IRF-1 stimulus, and 
other combinations of stimuli, such as interferon-γ and tumour necrosis factor (TNF-α), 
induce even higher levels of IRF-1 mRNA (Kroger et al., 2002).  
Further, IRF-1 expression can be induced in response to DNA damage (Pamment et al., 
2002). Other molecules can antagonize IRF-1 induction, as is the case with IL-4, which 
reduces interferon-γ stimulated IRF-1expression (Coccia et al., 2000). 
IRF-1 mRNA levels are cell-cycle regulated (Stevens et al., 1992), with mRNA levels 
increasing in serum-starved cells in G0 and decreasing following serum-induced growth. 
In addition, IRF-1 mRNA levels increase before and during S phase of the cell cycle 
(Kroger et al., 2002), confirming the short half-life of IRF-1 mRNA. IRF-1 can also 
activate the IRF-2 promoter, whereas IRF-2 inhibits the transcription of IRF-1 induced 
genes acting as a negative-feedback mechanism to limit post-induction IRF-1 activity. 
IRF-1 is mainly induced using interferon alpha/beta receptor (IFNARs) receptor 
compartment using JAK and STAT pathways (section 5.2.1). In addition to this, IRF-1 
has been reported to be induced by nuclear factor kappa B (NF-κB) signalling, where 
binding of the p50/p65 heterodimer form of NF-κB to the IRF-1 promoter region has 
been shown to stimulate IRF-1 expression and co-acts with NFκB to stimulate other 
downstream targets (Moschonas et al., 2008).  
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Finally, IRF-1 stimulation by DNA damage is induced through the ataxia telangiectasia 
mutated (ATM) signalling pathway, where DNA-damage induced IRF-1 was only 
reported when ATM is present (Pamment et al., 2002). 
1.4.3 Function of IRF-1 
IRF-1 was first recognized for its role in viral response; however, recently IRF-1 was 
known for its tumour suppressor activity. In order to link these two functions together it 
is important to understand the concept of “immune surveillance of tumours” (Burnet and 
Thomas 1957). This concept proposes that the immune system can specifically identify 
and eliminate tumour cells on the basis of their expression of certain tumour-specific 
antigens (Swann and Smyth 2007). However, this hypothesis of Burnet and Thomas 
(1957) was under question until recently when new data clearly show the existence of 
cancer immune surveillance and also indicated that it may function as a component of a 
more general process of cancer immunoediting (Dunn et al., 2002).  
Evidence to support the immune surveillance of tumours includes the fact of 
spontaneous tumour development in immunodeficient mice as reported by Shankaran et 
al (2001) and Smyth et al (2000). In addition, carcinogen-induced tumours in 
immunodeficient mice also provided a great tool to study immune surveillance of 
tumours (Engel et al., 1997 and Svane et al., 1996). 
Further on, a number of clinical observations have provided evidence supporting the 
idea of tumour immune surveillance in humans. The increased risk of tumour 
development in immunosuppressed patients (Penn 1988), instances of spontaneous 
tumour regression (Buckowitz et al., 2005), and the appearance of tumour-reactive T-
cells and B-cells in relation to improved prognosis all point to a role for the immune 
system in suppressing tumour growth (Scanlan et al., 2004). 
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This following section explains IRF-1’s role in the immune system, cell growth and 
apoptosis linking all three areas together as these functions are not totally separated; 
however, they all help toward understanding IRF-1’s role in tumour suppressor activity. 
Following stimulation of the IRF-1 pathway, IRF-1 can initiate immune response 
(1.4.3.1), inhibit cellular proliferation (1.4.3.2), or initiate programmed cell death 
“apoptosis” (1.4.3.3). 
1.4.3.1 The immune response and IRF-1 
The host defence against extracellular pathogens is a notable example of a complex 
cellular response coordinated by a genetic regulatory network in which a given 
transcription factor controls the expression of a diverse set of target genes. Notable 
example of such case is the host defence against extracellular pathogen which is based 
on such alteration in the genetic regulatory network. The innate and adaptive immune 
systems are tightly connected within each other. As explained before, IRF-1 was 
discovered as a regulator of innate immunity through the interferon system suggesting a 
link between these two immune systems. 
Following microbial invasion and interferon stimulation, IRF-1 protein levels get 
elevated to initiate the host defence mechanism. It has been shown that IRF-1 in wild-
type macrophages, induced by interferon-γ and/or lipopolysaccharide, can form a 
complex with IRF-8 and bind ISRE at the regulatory element of iNOS resulting in the 
production of nitric oxide (Taniguchi et al., 1997); however, this complex formation 
between IRF-1 and IRF-8 does not occur in IRF-1
-/- 
macrophages (Kamijo et al., 1994). 
This nitric oxide enzyme plays a vital role in the effector phase of the T-helper 1 (TH1) 
response, which causes macrophage cytotoxicity against tumour cells, bacteria and other 
invading bodies through DNA damage (Wink et al., 1991). Thus, IRF-1 may be a master 
gene playing a role in TH1 immune response. 
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In addition, IRF-1 has been reported to play a major role in the transcriptional activation 
of the IL-12 p35 gene (Liu et al., 2003). IL-12 is a heterodimeric cytokine consisting of 
p40 and p35 chains together; however, these two chains are encoded by two separate 
genes on two separate chromosomes.  Coordination of expression of these two genes is 
crucial for an appropriate immune response in macrophages induced by interferon-γ 
following pathogen stimulation. Evidence showed IRF-1 deficient macrophages have 
impairment in mRNA synthesis of IL-12 p35 but not p40 and a strong deficiency in the 
production of IL-12 p70 but not p40 (Liu et al., 2003). In addition, the same group 
reported that IRF-1 physically interacts with an inverted IRF element within the IL-12 
p35 promoter after interferon-γ activation (Liu et al., 2003). 
Additionally, IRF-1 has been reported to initiate the induction of type I interferon 
(interferon- and -β). Overexpression of IRF-1 in human fibroblasts, IRF-1 induction by 
poly (I:C) treatment or Newcastle disease virus infected fibroblast cells expressed higher 
levels of interferon-β mRNA and protein than control cells (Reis et al., 1992). Recently 
Yarilina et al (2008) reported that tumour necrosis factor (TNF) initiated an interferon-β 
mediated autocrine loop that maintained the expression of inflammatory genes and 
delayed the expression of other interferon response genes such as STAT1 and IRF-7 
resulting in an enhancement of the macrophage response to stimulate cytokines and 
Toll-like receptors. This autocrine loop is found to be regulated and depends on IRF-1 
(Yarilina et al., 2008). 
IRF-1
−/−
 mice were also found to have defective thymocyte development and the same 
team observed that IRF-1 is required for the development of the TH1 type immune 
response, and that its absence leads to the inappropriate induction of the TH2 type 
immune response (Taniguchi et al., 1997). Confirming this observation, IRF-1
−/−
 mice 
were also found to be vulnerable to bacterial infection when compared to IRF-1 wild-
type mice (Taniguchi et al., 1997); however, the immune response appeared to be 
normal in p48
−/−
 mice suggesting the unique role of IRF-1 in causing such immune 
effects (Taniguchi et al., 1997). 
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1.4.3.2 The tumour suppressor activity of IRF-1 
After discovery IRF-1 was described as a nuclear transcriptional factor that regulates 
interferon inducible genes and plays a role in the immune response. Further, mouse 
fibroblasts were shown to be arrested in the G1 phase of the cell cycle after culturing 
them in the absence of serum. Re-addition of serum stimulates these cells to continue 
through the cell cycle. However, during the G1 arrest as a result of serum starvation, the 
level of IRF-1 mRNA is remarkably raised. Following the re-addition of serum, the 
amount of IRF-1 mRNA declined 6-fold (Harada et al., 1993). The same study also 
showed that overexpression of IRF-2 in mouse fibroblasts caused cellular transformation 
and enhanced tumorigenicity in nude mice; this observation was reversible as a result of 
IRF-1 overexpression (Harada et al., 1993). IRF-1 can also reverse the transformation of 
fibroblasts following the overexpression of other oncogenic proteins such as c-Myc or 
FosB (Tanaka et al., 1994). These finding suggested the first anti-oncogenic and 
oncogenic potential of IRF-1 and IRF-2 where restraining cellular growth depends on a 
balance between these two mutually antagonistic nuclear factors (Harada et al., 1993). 
The knock-down of endogenous IRF-1 in human myeloid leukaemia cell lines stimulates 
cell proliferation where IRF-2 levels remained unchanged (Sato et al., 1997). This 
notable cellular proliferation occurs following STAT1 and STAT3 phosphorylation 
during interferon-γ pathway stimulation (Sato et al., 1997). In addition, Yim et al (2003) 
reported a similar observation in human breast carcinoma and concluded that growth 
inhibition is initiated with IRF-1 overexpression where such an effect can be overcome 
once IRF-2 is overexpressed. 
Overexpression of IRF-1 using recombinant adenoviral vector (Ad-IRF-1) in mouse 
breast cancer cell lines resulted in apoptosis using the involvement of caspases (Kim et 
al., 2004); in addition, they also reported the suppression of growth for breast cancer cell 
lines in vivo by intratumoral injection of Ad-IRF-1 into established tumours in their 
natural host (Kim et al., 2004).  
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The same group also reported that ectopic expression of IRF-1 promotes breast cancer 
cell death in vitro which has turned to be associated with the down-regulation of 
servivin, an inhibitor of apoptosis protein (Pizzoferrato et al., 2004). Resected tumours 
from IRF-1 treated mice showed IRF-1 positive and servivin negative cells (Pizzoferrato 
et al., 2004); however, the mechanism by which IRF-1 suppresses servivin is still 
unknown.  
Other studies have associated the induction of IRF-1 with cell cycle arrest. Tanaka et al 
(1996) reported the cooperation of the tumour suppressor IRF-1 and p53 in response to 
DNA damage. In mouse embryonic fibroblasts lacking IRF-1, cells are deficient in their 
ability to undergo DNA-damage induced cell cycle arrest as the cells lack p53 (Tanaka 
et al., 1996). Although IRF-1 and p53 expression is independent of each other but their 
cooperation take place in inducing p21, a cell cycle inhibitor, after cells are induced by 
γ-irradiation (Tanaka et al., 1996). Both IRF-1 and p53 can bind to p21 promoter 
directly or indirectly where both transcription factors regulate the cell cycle through the 
activation of certain cell cycle genes. In clinical trials as an attempt to treat patients with 
malignant midgut carcinoids using interferon-α, inhibition of cell proliferation via cell 
cycle arrest in G1-S phase is mediated by the induction of p21 and IRF-1 (Oberg 2000). 
Direct binding of IRF-1 onto the IRF binding element of the p21 promoter has been 
reported (Coccia et al., 1999) and the ability of IRF-1 to activate the p21 promoter 
independently of p53 during DNA damage has also been shown (Tanaka et al., 1996). 
Other examples of IRF-1 acting as an anti-oncoprotein includes the use of a lung 
carcinoma cell line where infecting the cells with measles virus results in IRF-1 up-
regulation and thus G0/G1 cell cycle arrest (Yokota et al., 2004). A similar observation 
was noticed in transformed fibroblasts, where the activation of IRF-1 induces G1 cell 
cycle arrest in c-myc and ras expression NIH3T3 (Kroger et al., 2007).  
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Taken together the finding in these studies, the tumour suppressor role of IRF-1 and its 
role in mediating cell cycle arrest through the induction of p21 has been supported. This 
role of IRF-1 and p21 in cell cycle arrest may be an important element in the 
suppression of cancer growth. 
1.4.3.3 IRF-1 in programmed cell death 
The first role of IRF-1 in apoptosis was reported by Tanaka et al (1994). They reported 
that transformation of embryo fibroblasts requires the introduction of mutated oncogenes 
such as c-ras and myc. However, in wild-type fibroblasts, containing wild-type p53 and 
IRF-1, cells undergo apoptosis following the introduction of mutated c-ras and DNA 





embryo fibroblast cell lines (Tanaka et al., 1994). 
Further, interferon-γ induced apoptosis in interferon-γ sensitive ovarian cancer cells was 
reduced after IRF-1 was knocked down or IRF-2 overexpressed (Kim et al., 2002). In 
addition, a recent study showed that overexpression of IRF-1 can enhance apoptosis in 
gastric cancer cells by the aid of 5-fluorouracil (Gao et al., 2012). Further, IRF-1 has 
been reported to regulate both immune cell apoptosis and autophagy in a murine 
endotoxemia model (Zhang et al., 2012). They also reported decreased apoptosis and 
increased autophagy in IRF-1 knock-out mice (Zhang et al., 2012). 
To confirm the role of IRF-1 in apoptosis, IRF-1 has been shown to bind directly to the 
promoter of many pro-apoptotic genes and thus initiates the process of apoptosis. The 
following section will cover some of these pro-apoptotic genes. Caspases are cysteine 
aspartic proteases that play essential roles in apoptosis, necrosis, and inflammation by 
proteolysis of proteins essential for cell survival (Alnemri et al., 1996; Vermeulen et al., 
2005). Liu et al (2012) reported that overexpression of IRF-1 enhanced glomerular 
mesangial cell’s apoptosis where knock-down of IRF-1 revealed the opposite effect. The 
study was carried out using microarray analysis where results showed IRF-1, caspase-3 
and caspase-8 up-regulation in mesangioproliferative glomerulonephritis mouse model, 
an inflammatory kidney disease in children; they also reported enhanced caspase-8 
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promoter activity by IRF-1 (Liu et al., 2012). A further study showed that IRF-1 can up-
regulate targeted PUMA, a p53 up-regulated modulator of apoptosis which is known to 
activate apoptosis by the intrinsic pathway (Gao et al., 2009). It has been shown that 
IRF-1 binds to unique sites within the promoter of PUMA and activates PUMA 
transcription in cancer cells (Gao et al., 2009). One further IRF-1 target is TRAIL 
(tumour necrosis factor-related apoptosis inducing ligand), which induces apoptosis 
through binding to death receptors (Almasan et al., 2003). Results showed that retinoid-
induced IRF-1 is required for TRAIL induction by both retinoic acid and interferon-γ 
(Clarke et al., 2004), and that exposure of breast cancer cells to both retinoic acid and 
interferon-γ enhances TRAIL promoter activity by IRF-1 (Clarke et al., 2004). Further, 
IRF-1 forms a signalling feedback loop with IRF-7, type I interferon, and STAT1 that 
regulate TRAIL in HIV-1 infected macrophages (Huang et al., 2009). In addition, the X-
linked inhibitor of apoptosis protein (XIAP)-associated factor 1 (XAF1), which is a 
novel tumour suppressor and interferon stimulated gene sensitizing cancer cells to 
apoptosis, is also regulated by IRF-1 in gastrointestinal cancer (Wang et al., 2009).  
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1.4.4 Structure and function of human IRF-1 
The human IRF-1 gene consists of 10 exons, is 325aa in size, and, as shown previously, 
the mutated form of IRF-1 has been associated with cancer and many other disorders. 
Studies based on deletion mutants have helped in mapping the IRF-1 domains. The 
following section will highlight the different domains in IRF-1 structure and their 
distinct regulatory roles. 
 
Figure 1.2: An outline of domain orientation and exon length in human IRF-1. The 
diagram shows the gene structure and domain orientation of IRF-1, which consists 
of 10 exons coding for a protein of 325 amino acids long. Important domains are 
mapped to their corresponding areas. NLS: nuclear localization domain.  
1.4.4.1 The DNA binding domain 
As shown in Figure 1.1, IRFs share a significant homology between their DNA binding 
domains (DBD). IRF-1 DBD is located in the first 124aa and characterized by five 
conserved tryptophan repeats separated by 10 to 18aa from each other. These tryptophan 
repeats mediate IRF-1 binding to the ISRE within the regulatory elements of target 
genes (Schaper et al., 1998).  
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1.4.4.2 The N-terminal transrepressor 
The transrepressor domain in IRF-1 is located in the first 60aa and strongly inhibits its 
transcriptional activity. This fragment is conserved among other IRF members including 
IRF-2, IRF-3, and IRF-8; however, the corresponding sequence in IRF-9 is different so 
it does not show this inhibitory activity. Within the transrepressor domain of IRF-1, 
replacing the unique sequence in IRF-1 with its corresponding sequence in IRF-9 
resulted in a loss of inhibitory activity within IRF-1 (Kirchhoff et al., 2000). 
1.4.4.3 The homodimerization and heterodimerization domain 
IRF-1 homodimerization domain is located within amino acids 90-115, where the 
heterodimerization domain span the area of 125-219aa.  This domain is important for 
IRF-1 heterodimerization with activators and repressors of transcription. In addition, the 
two-hybrid system revealed that this domain aids in IRF-1 homodimerization in vivo 
(Kirchoff et al., 1998). 
1.4.4.4 Nuclear localization domain 
By using IRF-1 mutants fused to the green fluorescent protein and monitoring their 
distribution in living mammalian cells, the IRF-1 nuclear localization domain was 
mapped to amino acids 117–141 (Schaper et al., 1998). 
1.4.4.5 Transactivation domain 
A detailed deletion analysis of IRF-1 revealed the transactivation domain of IRF-1. The 
amino acid segment 217–260aa was necessary and sufficient for transactivation with a 
core activation domain of amino acids 233–255 (Kim et al., 2003). In addition, computer 
analysis predicated this region to be loop-helix-loop-sheet, and both the casein kinase II 
and protein kinase C phosphorylation sites on each of the two loops are not important for 
transactivation (Kim et al., 2003). Deletion of this core region interfered with wild-type 
IRF-1’s ability to stimulate interferon-β expression, induce apoptosis, and inhibit 
cellular growth, possibly by forming inactive homodimers with wild-type IRF-1 or 
competing for target promoters (Kim et al., 2003).  
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1.4.4.6 Enhancer domain 
A further fragment acts as a strong enhancer element located at the C terminus of IRF-1 
at position 257–325 (Kirchhoff et al., 2000). A further enhancer subdomain was 
identified at an exact area of amino acids 301-325 (Eckert et al., 2006). The latter has 
been shown to regulate IRF-1 activity by inducing interferon-β genes and mediates the 
repression of cyclin dependent kinase II (Cdk II) (Eckert et al., 2006). In addition, the 
exact area of Cdk II repression was narrowed down to amino acids 306–310 (Eckert et 
al., 2006).  
Studies performed within the enhancer area revealed that deletion of the last 70 amino 
acids inhibits both IRF-1 poly ubiquitination and degradation (Pion et al., 2009); 
however, deleting the last 25 amino acids (∆C25 mutant) inhibits degradation of IRF-1 
but does not prevent its ubiquitination (Pion et al., 2009). It is known that IRF-1 has a 
very short half-life (20–30min) (Pion et al., 2009) compared to IRF-2 (6–8hr). IRF-1 
stability is controlled by the last 39 amino acids, as truncation of more than the 39 C-
terminal amino acids generates a form of IRF-1 that could resist degradation by the 
ubiquitin-proteasome pathway (Nakagawa et al., 2000). 
1.4.5 Regulation of IRF-1 
As shown previously, IRF-1 expression is a tightly regulated process during the cell 
cycle and infection. IRF-1 can undergo post-translational modification for different 
biological roles including heterodimerization, degradation, and activity. These post-
translational modifications include phosphorylation, ubiquitination, SUMOylation, and 
dimerization with other proteins or co-factors to respond to a different range of stimuli 
such as DNA damage, interferon, and, Toll-like receptor activation. The following 
section will highlight each modification in details. 
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1.4.5.1 IRF-1 phosphorylation 
The role of phosphorylation on IRF-1 regulation is not fully characterized. However, Lin 
et al (1999) reported a kinase activity that co-purified with IRF-1 and IRF-2. The kinase 
activity was identified as two molecules with 43 and 38kDa molecular weight. Further 
biochemical studies revealed that these molecules belong to the alpha catalytic subunit 
of casein kinase II (CKII). In addition, Western blot analysis and Immunoprecipitation 
of protein–protein interactions demonstrated that this kinase interacted directly with 
IRF-1 at two cluster sites (Lin et al., 1999). These sites are located between amino acids 
138–150, where the other is located toward the C terminus between amino acids 219–
231 (Lin et al., 1999). Mutational studies within these two clusters reported a decrease in 
IRF-1 transactivation ability suggesting that CKII phosphorylation is important for 
regulating IRF-1 function. Finally, Sharf et al. (1997) reported IRF-1 phosphorylation 
by tyrosine kinase following interferon-γ stimulation. 
1.4.5.2 IRF-1 ubiquitination 
Proteolysis or protein degradation is an important cellular process to maintain the quality 
of the cellular proteome. In eukaryotic cells, many proteolysis systems are available, and 
among all these, the ubiquitin-proteasome system (UPS) is the most characterized. UPS 
is a critical cellular process where proteins get tagged with poly-ubiquitin chain and 
targeted for degradation by the 26S-protease (Sorokin et al., 2009). The process involves 
the covalent attachment of a small protein (76aa) ubiquitin (Ub) to a chosen protein 
substrate (Sorokin et al., 2009). The conjugation of Ub to the chosen substrate occurs via 
a three-stage cascade reaction: the first stage involves an enzyme termed E1 (Ub-
activating enzyme), which activates ubiquitin in an ATP dependent manner, enabling its 
transfer into the second enzyme termed E2 (Ub-carrier enzyme) (Sorokin et al., 2009). 
The third enzyme is E3 (Ub-protein ligase) transfers Ub from E2 onto a lysine residue of 
the substrate protein. After connecting the first Ub onto targeted protein, E3 attaches 
another Ub molecule to the first attached Ub as poly-ubiquitination is required for 
degradation.   
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The E3 substrate recruiting machinery catalyzes the formation of an isopeptide bond 
between the C-terminal glycine residue of ubiquitin and the ε-amino group of lysine 
residue on the substrate (Sorokin et al., 2009). The minimum signal for degradation by 
the proteasome is a chain of four Ub molecules (Thrower et al., 2000). 
IRF-1 degradation is mediated by poly-ubiquitination, as inhibiting the proteasome 
activity caused an increase of a poly-ubiquitinated form of IRF-1 (Nakagawa et al., 
2000). In addition, the ∆C25 mutant of IRF-1 inhibits the proteasome degradation of 
IRF-1 but does not prevent its ubiquitination (Pion et al., 2009). Within that site, an 
LXXLL motif that is required for binding of heat shock protein 70 (Hsp70) family 
members, and cooperation with Hsp90 to regulate IRF-1 activity has been identified 
(Narayan et al., 2009). Therefore, Hsp70 binding to IRF-1 could regulate and mediate 
IRF-1 degradation using UPS. Further on, CHIP (C terminus of Hsc70-interacting 
protein) was identified as a chaperone of IRF-1 under stressed conditions (Narayan et 
al., 2011). CHIP binds directly to the IRF-1 central domain (residues 106–140), leading 
to IRF-1 ubiquitination reduction and suggesting a role for CHIP as an E3 ligase 
(Narayan et al., 2011).  
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1.4.5.3 IRF-1 SUMOylation 
SUMOylation is another form of protein post-translational modification. Covalent 
modification of cellular proteins by small ubiquitin-like modifiers (SUMO) regulates 
various cellular process including cell cycle, nuclear localization, signal transduction, 
and stress response (Muller et al., 2001); however, SUMOylation is differ from 
ubiquitination as SUMOylation does not tag target protein for degradation but it 
enhances their stability or modulates their subcellular compartmentalization (Muller et 
al., 2001). 
Like ubiquitination, all SUMO forms are initially inactive forms and the carboxyl-
terminal proteolysis cleavage event results in exposing the carboxyl-terminal glycine 
residue to allow isopeptide bond formation between the carboxyl terminus of SUMO 
with the ε-amino group of lysine residue on the substrate (Muller et al., 2001). 
Following SUMO activation, a cascade reaction similar to ubiquitination is required to 
modify the target substrate. 
First IRF-1 SUMOylation was reported in 2002 by Nakagawa and Yokosawa. They 
reported the isolation of an IRF-1 binding protein (using the yeast two-hybrid system), 
which was identified as protein inhibitor of activated STAT3 (PIAS3). PIAS3 was found 
to bind to SUMO-1 and ubiquitin-conjugating enzyme 9, which is an E2 in the SUMO-1 
conjugating system. Co-expression of PIAS3 induces SUMO-1 modification of IRF-1 
and represses IRF-1 transcriptional activity (Nakagawa and Yokosawa 2002). Thus 
PIAS3 functions as a SUMO-1 ligase for IRF-1 resulting in repression of IRF-1 
transcriptional activity.  
A similar yeast two-hybrid screen reported the purification of the SUMO-conjugating 
enzyme Ubc9, which interacts with IRF-1 and IRF-8 (Kim et al., 2008). The interaction 
between IRF-1 and Ubc9 was confirmed in vitro and in vivo and reported to inhibit IRF-
1 transcriptional activity in a dose-dependent manner (Kim et al., 2008). 
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A further study showed that levels of SUMOylated IRF-1 are elevated in tumour cells 
and its tumour suppressive function is reduced (Park et al., 2010). They also reported 
that SUMOylated IRF-1 mimics IRF-2 and displays oncogenic characteristics, as 
transfection of SUMOylated IRF-1 into nude mice resulted in tumour formation and 
infiltration of adipose tissue (Park et al., 2010).  
1.4.6 Co-factors of IRF-1 
1.4.6.1 NF-κB 
Complex formation between IRF-1 and nuclear factor kappa-B (NF-κB) has been 
reported in many different cell types. Sanceau et al (1995) reported that the induction of 
IL-6 by interferon-γ and tumour necrosis factor-α (TNF-α) in monocytic cells involves 
the cooperation between IRF-1 and the NF-κB p65 subunit (Sanceau et al., 1995) or the 
p50 subunit (Neish et al., 1995). In addition, Saura et al (1999) reported both IRF-1 and 
NF-κB co-localize in the nucleus in TNF-α and interferon-γ stimulated macrophages, 
where complex formation between these two transcriptional factors occurs only in 
stimulated cells following binding of their target promoter site (Saura et al., 1999). A 
further study reported a similar cooperation in T-cells following HIV-1 infection 
(Sgarbanti et al., 2008). This functional form of IRF-1 and NF-κB occurs at the long 
terminal repeat kappa sites. 
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1.4.6.2 STAT1 
IRF-1 has been shown to interact with the STAT1 transcription factor. Chatterijee-
Kishore et al (2000) reported this interaction is required to mediate the transcription of 
low molecular mass polypeptide 2 (LMP2). The interaction site on IRF-1 to mediate this 
binding was mapped to amino acids 170–200 (Chatterijee-Kishore et al., 2000). In 
addition, the adenovirus E1A was reported to block the interaction between IRF-1 and 
STAT1 (Chatterijee-Kishore et al., 2000), resulting in the down–regulation of LMP2. 
Recently, Wang et al (2010) showed that the cooperation between the IRF-1 and STAT1 
transcriptional complex mediates interferon-γ induced oligodendrocyte progenitor cells. 
1.4.6.3 IRF-8 
IRF-1 and IRF-8 have been reported to compete for ISRE binding; thus, IRF-8 has been 
shown to have a repressive effect on IRF-1 activity (Weisz et al., 1994). IRF-8 has been 
shown to bind directly to IRF-1 and thus reduces IRF-1 ability to bind to other co-factors 
such as HIV protein trans-activator of transcription (TAT) (Sgarbanti et al., 2002).  
Further, the IRF-1/IRF-8 complex has been shown to transcriptionally activate IL-12 
p35 (Liu et al., 2004) and RANTES (Liang et al., 2006). Recently, Zhang et al (2010) 
reported IL-27 p28 gene transcription is cooperated between IRF-1 and IRF-8, as IRF-8 
deficient macrophages were highly defective in IL-27 p8 expression. They also reported 
that IRF-1 and IRF-8 bind overlapping regions located at 48 to 57 of IL-27 p28 promoter 
regions in vivo following stimulation on interferon-γ (Zhang et al., 2010). 
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1.4.6.4 p300 
Mouse IL-12 promoter activity has been reported to be stimulated by the cooperation of 
IRF-1 and IRF-8 transcriptional complex (Masumi et al., 2002); however, this promoter 
stimulation can be enhanced when p300 is co-transfected (Masumi et al., 2002). Further, 
Dornan et al (2004) reported that p300 binding to IRF-1 stimulates p53 acetylation.  It 
was also revealed that stimulation of p21 transcription by IRF-1 does not require its 
DNA binding activity, but is based on the ability of IRF-1 to bind to p300 and stimulate 
p53 dependent transcription (Dornan et al., 2004). 
1.4.6.5 PCAF 
The p300/CBP-associated factor (PCAF) is a human gene and transcriptional activator 
associated with many other transcriptional factors (Ge et al., 2009; Fuks et al., 1998; Jin 
et al., 2002). DNA affinity binding assays of nuclear extracts showed that endogenous 
IRFs bound to ISRE cooperate with PCAF (a histone acetyl transferase) and p300 
binding proteins (Masumi et al., 1999). PCAF transfection strongly enhances IRF-1 and 
IRF-2 promoter activity (Masumi et al., 1999). 
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1.4.6.6 NPM 
Nucleophosmin (NPM) is a nuclear phosphoprotein that shuttles between the nucleus 
and cytoplasm and regulates ribosomal RNA export from the ribosome (Maggi et al., 
2008). NPM was identified as an IRF-1 binding protein (Kondo et al., 1997), and 
functional analysis showed NPM inhibits the DNA binding and transcriptional activity 
of IRF-1 (Kondo et al., 1997). NPM was classified as an oncogene as its mRNA levels 
were found to be elevated in several leukaemia samples and its overexpression can 
transform mouse embryonic fibroblasts (Kondo et al., 1997). 
1.4.6.7 GRIP-1 
Glucocorticoids (GC) are a class of steroid hormones used in managing patients with 
asthma (Bhandare et al., 2010) their name is derived from its role in glucose regulation, 
adrenal cortex synthesis location, and their steroidal chemical structure. However, 
asthma patients can develop GC insensitivity, which represents a challenge for asthma 
management. Such resistance is meditated by the mutual inhibition of transcriptional 
activity between GC receptor and other regulators such as IRF-1 (Bhandare et al., 2010). 
IRF-1 has been found to promote insensitivity in human airway smooth muscle cells by 
interfering with GC receptor signalling (Tliba et al., 2008), this effect of IRF-1 was 
found to be caused by the cooperation of IRF-1 with GC-receptor interacting protein 1 
(GRIP-1) (Bhandare et al., 2010). Co-immunoprecipitation and GST pull-down showed 
GRIP-1 forms a transcriptional complex with IRF-1. 
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1.4.6.8 MyD88 
Myeloid differentiation primary response gene 88 (MyD88) is an adapter protein 
recruited by Toll-like receptors after microbial and pathogen stimulation of the immune 
response. It has been shown that MyD88 recruits members of IRFs including IRF-5 and 
IRF-7 (Honda et al., 2004 and Takaoka et al., 2005) to activate Toll-like receptor target 
genes. In addition, IRF-1 also has been shown to interact with MyD88 upon Toll-like 
receptor activation (Negishi et al., 2006). IRF-1 has been shown to migrate into the 
nucleus more efficiently once associated with MyD88 as a part of Toll-like receptor 
dependent gene induction programme (Negishi et al., 2006). 
1.4.6.9 KPNA2 
Karyopherin α-2 (KPNA2) is an important protein playing a role in signal transduction 
between the cytosol and nucleus during the course of keratinocyte proliferation and 
differentiation (Umegaki et al., 2007). It has been shown that interferon-γ down 
regulates KPNA2 expression in normal human epidermal keratinocytes at both mRNA 
and protein levels at the promoter level (Umegaki et al., 2007). In addition, KPNA2 has 
been found to physically bound to IRF-1 and induce nuclear translocation of IRF-1 in 
normal human epidermal keratinocytes (Umegaki et al., 2007). 
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1.5 Conclusion and thesis aims 
All the previous studies mentioned in this chapter indicated that IRF-1 can function as a 
part of a transcriptional complex, and that disrupting this complex can influence IRF-1 
regulation and activity. The studies described here support the theory that IRF-1 protein–
protein interaction and IRF-1 post-translational modification play an important role in 
controlling IRF-1 activity and function. However, most of these studies were based on 
transiently transfecting IRF-1 and the use of artificial models for most of their findings. 
It will be interesting to develop synthetic tools that can aid in designing a more 
physiologically relevant micro-environment in which transcriptional factors can be 
studies at their local environment. Such tools will aide in understanding the mechanism 
of cancer initiation and progression and speed up cancer drug screening to identify new 
potential anti-cancer drugs. The research conducted in this thesis is primarily aimed at 
the development of specific molecular tools that can be used to study transcriptional 
factors and other gene of interests at their physiological relevant environment. 
  














Chapter 2: General methods and techniques 
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2.1 Chemicals and reagents 
All chemicals were ordered from BDH Laboratory Supplies or Sigma-Aldrich unless 
otherwise stated in the thesis. Tissue culture medium and supplements were obtained 
from Gibco (Invitrogen), tissue culture plastics and other plasticware were obtained 
from TPP or Nunc. All oligonucleotides were synthesized by Sigma-Genosys. All 
restriction enzymes were supplied by New England Biolabs. 
2.2 Mammalian cell line 
A375, an epithelial like human malignant melanoma derived from a primary melanoma 
lesion of a 54 years old female patient. A375 was used throughout the project; A375 
cells were grown in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 
10% (v/v) fetal bovine serum (Autogen Bioclear) and 1% (v/v) penicillin-streptomycin 
mix (P/S). Cells were maintained 10% CO2 at 37°C in incubators supplied by Hera. 
2.2.1 Mammalian cell line sub-culturing 
When cells were approximately 80–90% confluent, the medium was discarded and cells 
were washed three times with sterile phosphate-buffered saline (PBS), followed by a 
short trypsinisation with 0.05% Trypsin-EDTA at 37°C. Fresh medium was added to 
trypsin to deactivate it and to make the required dilution, followed by seeding the cells 
onto fresh plates containing fresh medium. 
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2.2.2 Freezing and thawing cells from/for liquid nitrogen 
storage  
Cells were frozen at 70–80% confluence to assure viability of the cells. Cells in 10cm 
tissue culture plates were washed and trypsinised as described above and transferred into 
15ml falcon tube and spun down at 1000rpm for 5min at room temperature. The medium 
was then discarded and cells were resuspended in 10ml freezing medium (50% v/v FBS, 
40% v/v DMEM, and 10% v/v DMSO).  
The mixture was transferred into cryogenic vials and placed in a cryo-freezing container 
(Nalgene) at -80°C overnight to ensure gradual freezing. Lastly, cells were transferred to 
liquid nitrogen for long-term storage. 
Liquid nitrogen frozen cells were thawed as fast as possible. Cells were quickly placed 
at 37°C until almost all cells were thawed, then cells were added to a 15ml flacon tube 
containing fresh 9ml of DMEM. Cells were spun down at 1000rpm for 5min and the 
supernatant was discarded. Cells were resuspended in 10ml fresh medium and 
transferred to a sterile culture dish. The medium was replaced after 24hr to boost cells 
growth. 
2.2.3 Mammalian cell line transient transfection 
Cells were transfected using Attractene transfection reagent (Qiagen) as described in the 
manufacturer’s handbook. Briefly, cells were sub-cultured into a10cm tissue culture 
plate 24hr before transfection. 4µg of desired DNA, 15µl of Attractene, and FBS and 
P/S-free DMEM were all mixed together in an Eppendorf tube to make a total volume of 
300µl. Mixture was left at room temperature for 15min then poured onto a 10cm plate. 
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2.2.4 Mammalian cell line treatment 
In order to induce required responses, cells were treated with certain reagents. In all 
cases, cells were seeded onto suitable tissue culture plates 24hr before treatment. The 
following day, cells were washed twice with PBS and then cultured in medium 
containing poly (I:C), interferon-γ, kinase inhibitor, or tunicamycin (table 2.1) for a 
specific time period, as outlined specifically in each chapter. Following treatment, cells 
were washed twice with PBS and harvested as outlined in section 2.2.1 and 2.7.1.  













40mM Tris + 







DMSO (-20°C) 200mM Tocriscreen™ 




Table 2.1: Reagents used in cell treatment 
However, in case of UV treatment, medium was removed and adherent cells were 
exposed to UV dosage using a UV box, followed by recovery of treated cells by 
replacing fresh medium on the plate. UV dosage and recovery time is indicated in 
experimental details in results chapter(s).  
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2.3 Microbiological techniques 
2.3.1 Bacterial strains 
DH5α chemo-competent E. coli cells were used as the standard strain for routine 
propagation of bacterial plasmids including entry vectors and recombined destination 
vectors. SW102 is another recombineering competent E. coli strain, which was used as a 
host for recombineering cloning. Both strains were grown aerobically in liquid culture or 
on solid agar in order to obtain single bacterial colonies. 
For liquid culture, bacterial cells derived from a single colony were inoculated in LB 
broth (10g tryptone, 5g yeast extract, and 10g NaCl, all dissolved in 1litre distilled water 
and sterilized by autoclaving). Antibiotics were added to the media as required, to a final 
concentration of: ampicillin 100µg/ml; kanamycin 50µg/ml; chloramphenicol 34µg/ml.  
Bacterial cells were incubated at 37°C or 32°C on an orbital shaker for at least 4hr to a 
maximum of 18hr. For liquid cultures, the culture vessel was at least five times the 
volume of the medium to ensure proper aeration. 
For growth on solid media, bacterial cells were spread on LB-agar plates (10g tryptone, 
5g yeast extract, 10g NaCl, 15g sucrose, all dissolved in 1litre distilled water and 
sterilized by autoclaving). LB-agar plates were prepared by pouring liquefied LB-agar 
into 90mm petri dishes (Sterilin). When required, selective antibiotics were added to the 
liquefied LB-agar, immediately prior pouring into petri dishes, which was cooled until 
solidified. Plates were then dried at 37°C for up to 1hr prior to use. Bacteria were grown 
on agar plates at 37°C or 32°C for 18hr. 
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2.3.2 Bacterial glycerol stocks 
Bacteria cultures were stored long-term at -80°C in cryovials containing 200µl sterile 
glycerol and 800µl of an overnight liquid culture. Stocks were mixed by gentle agitation 
before storage at -80°C. 
2.3.3 Heat-shock competent bacterial cell preparation 
Glycerol stocks of the required E.Coli bacterial strain were inoculated into 3ml LB 
medium and allowed to grow overnight at 37°C. 250µl of the overnight culture were 
transferred into 50ml LB and incubated at 37°C until the O.D.600nm of the culture reached 
approximately 0.4. Cells were collected by centrifugation at 4000rpm for 15min at 4°C, 
resuspended gently in 16ml ice-cold buffer 1, pH5.8 (1.2g RbCl, 0.99g MnCl2∙4H2O, 
0.59g CH3COOK, 1.5g CaCl2∙2H2O and 15% v/v glycerol in 100ml distilled H2O) and 
left on ice for 10min. Then the cells were centrifuged again at 4000rpm for 15min at 4°C 
and gently resuspended in 2ml ice-cold buffer 2, pH6.8 (10mM MOPS pH6.8, 0.12g 
RbCl, 1.1g CaCl2∙2H2O and 15% v/v glycerol in 100ml distilled H2O). After 10min 
incubation on ice, the cells were snap-frozen as aliquots in liquid nitrogen and stored at -
80°C.  
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2.3.4 Recombineering competent bacterial cells preparation 
Glycerol stocks of the required SW102 bacterial strain were inoculated into 3ml LB 
medium and allowed to grow overnight at 32°C. 500µl of the overnight culture were 
transferred into 35ml LB and incubated at 32°C until the O.D.600nm of the culture reached 
approximately 0.4–0.6. Cells were split into two flasks: one was allowed to continue 
growing at 32°C for further 15min and the second was allowed to continue growing at 
42°C for further 15min to induce recombineered protein expression. Cells were then 
rapidly chilled on ice-water slurry for 10min. Cells were collected by centrifugation at 
4000rpm for 7min at 4°C. The pellet was washed with ice-cold distilled water three 
times. The final washed pellet was resuspended with 200µl sterilized ice-cold water. 
Recombineering competent cells were made freshly every time they were used and not 
subjected to long-term storage. 
2.3.5 Bacterial transformation (heat-shock method) 
An aliquot (50µl) of heat-shock competent cells was incubated on ice with an 
appropriate amount of plasmid (usually 50ng) for 30min. The cells were then subjected 
to heat-shock by incubating at 42°C for 45sec, and then left at room temperature for 
10min. LB medium was added to the competent cell/plasmid mixture and cultured for 
1hr at 37°C or 32°C to allow the growth of transformed bacterial cells. Finally cells were 
plated onto pre-prepared LB-agar plates with selection by antibiotics specific for the 
plasmid transformed. Plates were incubated at 37°C or 32°C overnight for colony 
formation. 
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2.3.6 Bacterial transformation (electroporation method) 
An aliquot (50µl) of competent cells with the desired amount of DNA (usually 0.1ng) 
was placed in a 2mm electroporation cuvette (Molecular BioProduct). Cuvettes were 
placed in a Gene Pulser MXcell Electroporation system (Bio-Rad) pre-set to 1.80kV, 
25µF capacitance and 200Ω resistance. Following electroporation, LB medium was 
added to competent cell/plasmid mixture and cultured for 1hr at 32°C to allow the 
recovery of transformed bacterial cells. 
2.3.7 Plasmids and BAC maintenance 
After transformation, single colonies were selected and allowed to grow overnight either 
in 5ml LB medium for mini-prep or 150ml LB medium for maxi-prep. To purify 
plasmids from culture, mini-preps or maxi-preps were carried out using the high speed 
mini-prep or maxi-prep kits from Qiagen following the manufacturer’s protocols. 
However, BAC mini-prep involved a slight adjustment to the Qiagen protocol, in which 
single colonies carrying BAC DNA were allowed to grow overnight in 5ml LB medium 
followed by pelleting 1.5ml of overnight culture by centrifugation in a 1.5ml tube at 
10,000rpm at room temperature for 1min. 100µl of Qiagen buffer I was used to suspend 
the pellet, followed by ice incubation for 5min. 200µl of Qiagen buffer II was added to 
the suspended cells, followed by gentle mixing and ice incubation for a further 5min. 
150µl of Qiagen buffer III was also added to the mixture followed by gentle mixing and 
ice incubation for a further 5min. The whole mixture was centrifuged at 10,000rpm for 
5min at 4°C. DNA from the supernatant was then ethanol precipitated by adding two 
volumes of 95% ethanol and placed on ice for 30min. Following incubation, the mixture 
was centrifuged at 10.000rpm for 10min at 4°C. Pellet was washed with 70% ethanol 
several times and air dried followed by resuspension in 30–50µl of distilled water. The 
concentration of BAC DNA and plasmids after purification was measured using an ND-
3300 Fluorospectrometer (NanoDrop Technologies), at 260nm. Purified DNA was 
stored at -20°C. 
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2.4 DNA and mRNA assays 
2.4.1 mRNA extraction 
mRNA was extracted from cells and tissues using the Qiagen RNeasy Mini kit following 
the manufacturer’s suggested procedures. Briefly, cells were lysed and homogenized 
using highly denaturing guanidine-thiocyanate buffer resulting in RNase inactivation to 
ensure an intact RNA purification. Ethanol was then added to provide suitable RNA 
binding condition allowing total RNA binding to the membrane of the RNeasy Mini spin 
column where contaminants were washed away; RNA was then eluted in 50μl water. 
The optional step of DNase treatment using the Qiagen RNase-free DNase set was also 
included. The concentration of the extracted mRNA was measured using the ND-3300 
Fluorospectrometer (NanoDrop Technologies) at 260nm. 
2.4.2 Reverse Transcription (RT) Polymerase Chain Reaction 
(PCR) 
Reverse transcription of mRNA was performed using the Omniscript RT kit from 
Qiagen following the manufacturer’s suggested protocols. Briefly, RNA from section 
2.4.1 was incubated with reverse transcription reaction buffer (10x), dNTP mix (5mM), 
oligo-dT primer (10μM), RNase inhibitor (10units/μl), and 4units of Omniscript reverse 
transcriptase in a 20μl total volume reaction. Mixture was incubated at 37°C for 60min. 
Reverse-transcribed cDNA was either used for standard PCR using pfu polymerase kit 
from Stratagene according to manufacturer’s suggestions or for qRT-PCR; see next 
section.  
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2.4.3 Real-time PCR (qRT-PCR) 
Real-time PCR or qRT-PCR was performed using the Solaris qPCR Gene Expression 
Assays (Dharmacon) following the manufacturer’s suggested protocols. Briefly, mRNA 
was extracted as 2.4.1. 500ng of extracted RNA were reverse transcribed as 2.4.2 to 
generate cDNA, which was diluted to make a stock concentration of 25ng/µl. 125ng of 
cDNA, 6.25µl of PCR water, 1.25µl of Solaris primers (Dharmacon), and 12.5µl of 
Solaris master mix were all mixed together, each sample was treated in quadruplicate for 
statistical significance. Samples were placed in the qRT-PCR machine using the 
following thermal cycling program: initial step at 95°C for 15min (enzyme activation) 
then 40 cycles of 95°C for 15sec (denaturation) and 60°C for 60sec (annealing and 
extension). 
 
2.4.4 Agarose gel electrophoresis 
DNA samples were mixed with 6x DNA loading buffer (30% v/v glycerol, 0.6% w/v 
SDS, 60mM EDTA and 0.1% w/v bromophenol blue) before loading on the gel. 
Agarose gels were made by dissolving agarose in heated 1xTris/Borate/EDTA (TBE) 
buffer (90mM Tris, 90mM Boric acid and 2mM EDTA). The percentage of agarose in 
the gel depended on the size of the DNA to be separated. As a size reference, a DNA 
marker from New England Biolabs was loaded next to the DNA samples. 
Electrophoresis was performed at 100V until a good resolution was observed under a 
UV transilluminator. The images of the gels were captured using the ChemiGenius2 
Bio-Imaging system from Syngene. 
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2.5 Genetic engineering and cloning 
2.5.1 Gateway® Cloning 
In order to clone PCR products into Gateway® plasmids, LR and BP cloning was used. 
A PCR product was amplified, using primers containing Gateway® sites, in a standard 
PCR reaction. Once amplified, the PCR product was cleaned using Qiagen PCR-clean 
up kit. BP Gateway® cloning kit from Invitrogen was used following the manufacturer’s 
suggested protocols. To further clone the PCR product from pDONR221 into 
pEF5/FRT/V5-Dest, the LR Gateway® cloning kit from Invitrogen was used according 
to manufacturer’s suggested protocols. The only adjustment to the manufacturer’s 
protocol was the incubation period, where in both cloning (LR and BP) tubes were 
incubated for 24hr at room temperature. 
2.5.2 DNA sequencing  
DNA sequencing reactions were carried out using the BigDye Terminator v3.1 cycle 
Sequencing Kit (Applied Biosystems) according to the manufacturer’s instructions. 
Automated sequencing was carried out by the DNA sequencing service in Genetics 
Core, University of Edinburgh, Western General Hospital, Edinburgh, UK. All 
sequencing primers used in this project are outlined in table 2.2. 
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Primer Name Primer Sequence 
3’ homologous arm check F 
5’-AGCCTCTGTTCCACATACAC-3’ 
 
3’ homologous arm check R 
5’-ATCTTCTTCCTCAGGGTTGC-3’ 
 
5’ homologous arm check F 
5’-CATTGCCTCCTGGCTATTGG-3’ 
 
















Table 2.2: Sequencing primers used through project. Homologous arm check primers 
were used to confirm the integration of homologous arms in pLSL-TOPO-β-catenin 
arms (chapter 3), M13 and T7 are standard primers used to confirm successful LR 
and PB reactions, and finally IRF-1 S1 and IRF-1 S7 were used to sequence wild type 
IRF-1 and W11R mutant. 
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2.5.3 DNA digestion and ligation 
Specific DNA digestion was achieved by DNA nucleases obtained from New England 
Biolabs. In general, 5units of each DNA nuclease were used to digest 1µg of DNA in a 
10 or 20µl reaction at 37°C for a minimum of 1hr. Following digestion, enzyme was 
deactivated at 65°C for 20min. Some DNA nucleases required the use of BSA (bovine 
serum albumin) to increase enzyme efficiency. DNA ligation was achieved using T4 
DNA ligase (New England Biolabs) where the reaction was always carried out in three 
different ratios of fragment:plasmid (1:1, 3:1, and 1:3); the  reaction was carried at 16°C 
for 24hr.  
2.5.4 Site direct mutagenesis 
In order to create certain mutations on specific sites of plasmid, the Quickchange™ Site-
Directed Mutagenesis kit from Stratagene was used, with the manufacturer provided 
protocols, to create IRF-1 W11R mutation (chapter 4). Primers for site-directed 
mutagenesis, as shown in section 4.2.2, were designed using the PrimerX software (Gao, 
2003) http://www.bioinformatics.org/primerx/index.htm 
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2.6 Southern blotting 
2.6.1 Southern blot immobilization  
Once agarose gel was run to desired distance it was then soaked in 0.2M HCL for 
10min. It was then rinsed once with distilled water and soaked in 0.4M NaOH and 0.6M 
NaCl for 30min. Immediately, the gel was placed on the blotting apparatus surrounded 
by 10x SSC (300mM sodium citrate, pH 7.0, and containing 1M sodium chloride) for an 
overnight immobilization on Biodyne® nylon membranes, as shown in figure 2.1. 
 
Figure 2.1: Blotting apparatus for Southern blots. 
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2.6.2 Southern blot probe hybridization 
Following overnight immobilization, the membrane with immobilized DNA was washed 
with 6x SSC for 5min. The membrane was then placed in a heat-sealable bag, 5ml of 
prehybridization solution (Sigma) was poured onto membrane, air was removed, and the 
membrane was incubated for 2hr at 68°C. Following prehybridization, buffer was 
poured away and 5ml of hybridization buffer (Sigma) containing 100ng of radiolabeled 
denatured probe was poured onto membrane.  
Probe hybridization took place at 58°C for 24hr. The following day, the membrane was 
submerged for 5min in a tray containing 200ml of washing buffer I (2x SSC and 0.5% 
SDS). The membrane was then transferred to a tray containing 200ml of washing buffer 
II (2x SSC and 0.1% SDS) and incubated for 15min at room temperature with gentle 
agitation. The membrane was then transferred into a further tray containing 200ml of 
washing buffer III (0.1x SSC and 0.5% SDS) and incubated for 30min at 37°C with 
gentle agitation. Membrane was then transferred into a tray containing 200ml of washing 
buffer III (0.1x SSC and 0.5% SDS) and incubated for 30min at 68°C with gentle 
agitation. Finally, the membrane was washed with washing buffer IV (0.1x SSC) and 
dried and wrapped to prevent contamination. Radiographic images were developed after 
exposing X-ray films to membrane for 24hr at -80°C. 
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2.7 Protein assays  
2.7.1 Protein extraction from mammalian cells 
In a typical experiment as outlined in 2.2.1, after being collected, the cells were spun at 
2000rpm for 1min and the supernatant was removed. The cell pellet was washed 3 times 
with PBS, followed by lysis in approximately 4 volumes of Nonidet P40 (NP40) lysis 
buffer (1% v/v NP40, 150mM NaCl, 25mM Tris pH 7.5, 1mM Dithiothreitol (DTT) and 
1x protease inhibitors). NP40 lysis buffer was applied to the cell pellet and left on ice for 
30min followed by centrifuging at 12,000rpm for 15min. Supernatant was collected and 
pellet was discarded.  
2.7.2 Protein concentration determination using Bradford 
Bradford reagent was prepared by diluting a 5x Bradford stock solution (Bio-Rad). 1µl 
of protein sample was mixed with 200µl of Bradford reagent, mixed and incubated at 
room temperature for 5min to develop the colour reaction. The absorbance of the 
mixture was tested at 565nm using a PowerwaveXS Microplate Spectrophotometer 
(Bio-Tek). The protein concentration was calculated using a BSA standard curve. 
2.7.3 Western Blotting 
Western blotting was composed of two main steps: sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) and immunoblotting. In SDS-PAGE, protein 
samples were first mixed with 4x SDS sample buffer (4% w/v SDS, 25mM Tris pH 6.8, 
20% v/v glycerol, 0.01% w/v bromophenol blue and 200mM DTT) and incubated at 
95°C for 2min before loading onto 8, 10, 12 or 15% polyacrylamide gel or 4–12% 
NuPAGE Bis-Tris gel (Invitrogen). The running gel was composed of 25% 1.5M Tris 
pH8.8, 0.1% SDS, 0.1% w/v Ammonium Persulphate (APS), 0.04% v/v 
Tetramethylethylenediamine (TEMED) and 41% of 30% w/v acrylamide mixture 
(National Diagnostics).  
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The stacking gel was composed of 25% 1M Tris pH 6.8, 0.1% w/v SDS, 0.1% w/v APS, 
0.1% v/v TEMED and 17% of 30% w/v acrylamide mixture. Samples were resolved by 
electrophoresis in SDS running buffer (0.1% w/v SDS, 0.192M glycine and 25mM Tris) 
in a Bio-Rad mini-protean 3 apparatus. Samples on 4–12% NuPAGE Bis-Tris gels were 
resolved by electrophoresis in MOPS buffer (Invitrogen) in a Novex XCell SurelLock 
gel apparatus. 
For immunoblotting, the resolved proteins were first transferred onto Hybond-C 
nitrocellulose membrane (Amersham Biosciences) in transfer buffer (0.192M glycine, 
25mM Tris and 20% v/v methanol) in a Bio-Rad transfer kit at 350mA for 2hr. An ice 
pack in the transfer tank was used to maintain low temperature to aid protein transfer. 
Following transfer, the membrane was incubated in PBS-Tween-20 (0.1% v/v Tween-20 
in PBS) (PBST) with 5% w/v dry skimmed milk (MARVEL) for 1hr at room 
temperature to block non-specific protein binding. After a brief wash with PBST, the 
membrane was incubated with the primary antibodies, at supplier-recommended 
dilutions in PBST with milk, and shaken at 4°C overnight (table 2.3). Blots were then 
washed three times, for 5min each, with PBST and incubated with species specific horse 
radish peroxidase (HRP) coupled secondary antibodies from DAKO in PBST with milk 
to detect specific antibody binding. Finally the blot was washed three times for 5min 
with PBST and incubated with electrochemiluminescence (ECL) solution mixture. ECL 
solution I was composed of 2.5mM luminol, 0.4mM coumaric acid and 100mM Tris pH 
8.5, and ECL solution II composed of 100mM Tris pH8.5 and 0.018% v/v H2O2 (Bio-
Rad). ECL solutions were kept in the dark at 4°C and mixed 1:1 prior to incubation with 
the blot. Specific bands were detected by exposing the membrane to ECL hyperfilm 
(Amersham Biosciences). Film exposure time varies between few seconds to one minute 
depending on the status of IRF-1. Interferon-γ or poly (I:C) stimulated IRF-1 can be 
detected within few seconds of exposure; however, endogenous un-stimulated  IRF-1 
requires a minimum of one minute exposure. In addition, DMSO has shown slight 
induction effect on IRF-1 (Figure 5.5); however, this effect was discarded as it was at 
very low level. 
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Mouse BD Bioscience 
1:1000 
 








AGR-2 antibody (K47) Rabbit In house antibody 
1:1000 
 
PKR antibody (N-18) Mouse Santa Cruz Biotechnology 
1:1000 
 
p21 antibody Mouse In house antibody 
  1:500 
 
CHOP antibody Rabbit Epitomics 1:1000 
 
Table 2.3: Primary antibodies used in Western Blots. 
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2.8 Luciferase reporter gene assay 
Reporter gene assays were performed using the Dual Luciferase® reporter system 
(Promega) according to the manufacturer’s instructions. In brief, A375 FRT7, A375 
FRT7 W11R, and A375 FRT7 conIRF-1 cells were seeded in 24-well plates 24hr before 
assay. The following day, cells were transiently co-transfected with pCMV-Renilla-
luciferase (60ng) and 14ng of hTLR3-luciferase gene constructs. When required, the 
total amount of DNA in each well was normalized using empty vector control pcDNA3 
(Invitrogen). Luminescence was measured for 100ms in a Fluoroskan Ascent F1 
luminometer (Labsystems). Signals were normalized using an internal control. However, 
in the case of reporter stable cell lines, cells were seeded in 24-well plates 24hr before 
assay. The following day, cells were treated with a kinase inhibitor library, as outlined in 
chapter 5. The following day, luciferase activity was measured according to the 
manufacturer’s instructions without normalizing to empty vector control. 
2.9 Statistical methods 
Microarray data analysis was done externally using (Fios Genomics, Edinburgh) raw 
data were QC analysed using the Array Quality Metrics package in Bioconductor 
(Kauffmann et al., 2009). Raw data were transferred using a Variance Stabilizing 
Transformation (VST) method prior to normalisation across all arrays using the Robust 
Spline Normalisation (RSN) method. 
Dual Luciferase assay data analysis involved standard analysis where signal from the 
Firefly plasmid was normalized to signal from Renilla. Samples were done in triplicate 
for mean calculation and standard deviation error bars representation.  
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3.1 Chapter abstract 
Cre-conditioned mouse models have become an essential requirement for any 
outstanding research project; however, generating a mouse model with a conditioned 
knock-in subtle mutation(s) has huge time and labour costs. This chapter outlines the 
generation, using recombineering technology, of a universal BAC targeting vector where 
a cre-conditioned STOP cassette can be targeted at a desired specific area. Also, 
different ways of creating these subtle mutation(s) on low/high copy plasmids have been 
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3.2 Chapter introduction 
In 2003, the completed draft of the human genome was sequenced and annotated. The 
challenge now is to determine how these genes function, independently and with other 
genes in the human genome. The function of many genes is unknown and scientists need 
to characterize them to reveal their secrets. Mouse models became an ideal model 
system for such studies not only because humans and mice share a similar genome but 
also for many other reasons, which include availability and ease of handling. 
Previously, any gene alternation, such as null mutation, subtle mutation, or gain of 
function mutation, could be introduced into the mouse germ line using traditional 
genetic engineering, using restriction endonucleases and DNA ligases, where the 
conditional inactivation of such genetic effects takes place only at certain tissue and/or 
certain developmental stages (Clarke, 2000). However, one big drawback in traditional 
genetic engineering is the difficulty of manipulating large linear DNAs; in addition, the 
need for complicated targeting and selection vectors is essential in this case where the 
production of such vectors is associated with the ability to find a unique and suitable 
restriction sites at vectors and genomic DNA. In most cases, this could be impossible as 
rare restriction sites occur frequently on large DNA sequences such as BACs and 
bacterial chromosomes (Copeland et al., 2001). 
The development of systems based on homologous recombination had eased the process 
of generating transgenic and knock-out constructs, making it possible to manipulate 
large pieces of DNA, such as yeast artificial chromosome (YAC), BAC and P1 artificial 
chromosome (PAC), using different recombination systems in different recombineering 
hosts (Murphy 1998; Zhang et al., 1998; Yu et al., 2000; Muyrers et al., 2001). In 1993, 
Agnes Baudin reported the first homologous recombineering in yeast (Baudin et al., 
1993); however, chromosome engineering in yeast (mainly Saccharomyces cervisiae) 
has a very efficient DNA double-stranded-break and-repair recombination pathway 
making it a good choice for manipulating mega sized genomic inserts.  
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However, yeast recombination is always active leading to unwanted genomic alteration. 
In addition, YACs are difficult to purify (Schedi et al., 1993) and single cell yeast could 
carry wild-type chromosome in addition to the modified YAC (Peterson et al., 1997). 
To overcome these difficulties in yeast as a host for recombineering, E. coli was 
engineered to allow the manipulation of BACs. Unlike yeast, the presence of RecBCD, 
an ATP-dependant exonuclease that initiates recombinational repair acting as a helicase 
and a nuclease (Pilarksi et al., 1973), within the E. coli genome causes instability of 
linear dsDNA in E. coli. To overcome this problem, an E. coli strain lacking RecBCD, 
generated by mutating recBC, must be used; in addition to the recBC mutation, sbcB and 
sbcC mutations should also be achieved to restore recombination activity (Lloyd et al., 
1985). However, recombination in E. coli RecBCD deficient strains will be limited, 
which restricts the use of E. coli for recombineering technologies. In addition, it has 
been reported that the recombination pathway is constitutively active, making 
continuous alterations and deletions in repeat sequences present in BACs and PACs 
(Copeland et al., 2001). 
To protect linear dsDNA from degradation by RecBCD in wild-type cells, a Chi site (5′-
GCTGGTGG-3′) is incorporated at each end of the linear dsDNA to protect from 
RecBCD digestion and provide activation sites on the DNA for RecBCD recombination 
(Dabert and Smith 1997). Once RecBCD encounters a Chi site, RecBCD loses its 
exonuclease activity but maintains its helicase activity leading to the production of 
ssDNA with a 3′ overhang end from the linear dsDNA, which allows recombination 
(Copeland et al., 2001). One big limitation of Chi sites in recombination is the fact that it 
is very inefficient (Copeland et al., 2001). 
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Stewart and his team (Zhang et al., 1998) have reported the possibility of using a phage 
encoded recombination system (RecET) using recBC sbcA strain where sbcA mutation 
activates the expression of recE and recT genes, which are encoded by a cryptic RAC 
prophage present in E. coli (Clark et al., 1994). Another recombination system is present 
in bacteriophage-λ, which is named as “Red”. Like RecET, the Red system has two 
distinct genes, redα (Exo) and redβ (Bet), analogous to recE and recT (Carter and 
Radding et al., 1971). Exo (a 5′–3′ exonuclease) acts on linear dsDNA followed by Beta 
binding to the Exo-generated ssDNA overhang allowing strand annealing simulation 
(Figure 3.1) (Takahashi et al., 1990). The bacteriophage-λ encoded Gam inhibits any 
RecBCD activity in the host cell (Murphy 1991).  
  
























Figure 3.1: An overview of the recombineering system of bacteriophage-λ. Exo has a 
5′ to 3′ exonuclease activity when bound to double stranded linear DNA resulting in 
3′ single stranded overhang ends, which allows Beta to bind and promote single 
stranded annealing and recombinant DNA generation. This results in replacing the 
knock-out DNA with the gene of interest (PCR). In addition to Exo and Beta, a third 
protein named as Gam is needed to block the activity of RecBCD from degrading 
double stranded linear DNA in the host cell. 
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This system of bacteriophage-λ has been reported to be 10–100 times more efficient than 
any other recombineering system, such as recBC, sbcBC or recD strains (Murphy, 
1998). The bacteriophage-λ system integrated in the E. coli chromosome has been 
modified to allow tight control of the expression of the recombineering proteins. Such 
modification involves the use of the λ-cI857 repressor, which causes repression of 
recombineering protein gene expression at 32°C, making Exo, Beta, and Gam levels 
undetectable; however, when the culture is shifted to 42°C for 15min, the repressor 
become inactivated and the recombineering proteins are expressed at high levels under 
the control of the λ-pL promoter (Copeland et al., 2001). This modified bacteriophage-λ 
system has been transferred to BAC host E. coli strains such as DH10B to allow BAC 
recombineering (Lee et al., 2001). DH10B was later modified for higher efficiency 
creating another strain called DY380 (Lee et al., 2001). A further E. coli recombineering 
host strain is SW102; this host strain has a relevant genome to DY380 strain acquiring 
the bacteriophage-λ recombineering system. SW102 was chosen to be used in this 
project for its ability for GalK counter-selection (explained later in discussion). 
To summarize, recombineering is adapted from homologous recombination, and it 
allows the precise insertion, deletion or even sequence alternation without the need for 
restriction sites or DNA ligases. Recombineering is a new in vivo method of genetic 
engineering that uses very short homologous arms, 20–70bp long (Copeland et al., 
2001), with the aid of recombineering protein in a recombineering host, usually E. coli, 
to achieve the desired knock-in or knock-out (Sharan et al., 2009). 
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The aim of the work presented in this chapter was to create, using recombineering 
technology, a universal BAC targeting vector that can be used to create cre-conditioned 
knock-in mutations in any BAC of interest. The working plasmid template is named 
pLoxP-STOP-LoxP-TOPO (pLSL-TOPO; Addgene, plasmid number 11584). The main 
characteristic of this plasmid is the four polyA sites (stop cassette) flanked by cre-
conditioned LoxP sites (Figure 3.2). However, the pLSL-TOPO to be used in BAC 
targeting, has to undergo certain modifications and adjustments, which are outlined next, 
to fulfil the requirement for BAC targeting using recombineering. 
Currently at pLSL-TOPO stop cassette, there is a puromycin resistance sequence which 
is regulated by the eukaryotic PGK promoter to aid selection of transformed embryonic 
stem cells; however, it’s not possible to use the puromycin sequence in prokaryotes 
unless a prokaryotic regulatory sequence, such as EM7, is cloned upstream of the 
sequence. In order to achieve this by recombineering, the whole puromycin sequence 
needs to be replaced by a new sequence containing EM7+kanamycin/puromycin; 
unfortunately, a prokaryotic regulated kanamycin sequence is already present in the 
plasmid backbone which will cause difficulties in selecting the desired recombined 
clones. Thus, the first step in modifying pLSL-TOPO was replacing the kanamycin 
sequence in the plasmid backbone with ampicillin (a good marker for selection in 
prokaryotes) followed by restoring kanamycin/puromycin resistance in the cassette. In 
addition, for BAC recombineering purposes, it is important to clone some unique 
restriction sites upstream of the LoxP-STOP-LoxP cassette to allow the conventional 
cloning of BAC recombineering homologous arms, which need to be done to allow the 
integration of the LoxP-STOP-LoxP cassette into the chosen BAC. Once the unique 
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Figure 3.2: pLSL-TOPO (Addgene). The stop cassette consists of four SV40 polyA 
sites (pink), puromycin resistance gene (yellow) regulated by the eukaryotic PGK 
promoter (blue) flanked by two LoxP sites (green). In addition, two different 
antibiotic resistance sequences at backbone: Kan-R (orange) and Zeo-R (gray). 
Figure created using SimVector 4.5. 
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3.3 Methods and results 
3.3.1 Replacing the original kanamycin resistance gene with 
an ampicillin resistance gene 
On receipt of pLSL-TOPO (Addgene), the E. coli host strain was grown at 30°C to 
increase plasmid stability and yield. DNA was purified according to the miniprep 
protocol (Qiagen) and 50µg of plasmid DNA was digested by NotI, BamHI and XhoI to 
confirm the plasmid template and number of SV40 polyA sites agreed with the 
manufacturer’s plasmid map (Figure 3.2) and (Figure 3.3.A). 
PCR primers (green) with homologous arms (blue) were designed to amplify the 
ampicillin resistance gene (without the regulatory sequence) from plasmid 
pRosa26/LacZeo (kindly given by Dr. Peter Hohenstein). 
Forward: 5′-ggcgcaggggatcaagctctgatcaagagacaggatgaggatcgtttcgcatgagtattcaacatttccgt-3′ 
Reverse: 5′-agatgcgtaaggagaaaataccgcatcaggaaattgtaagcgttaataatttaccaatgcttaatcagtga-3′ 
pRosa26/LacZeo was linearized by XhoI followed by DpnI digestion to minimise false 
colony formation post PCR reaction. Digested pRosa26/LacZeo (PCR template) was 
diluted 1:50, 1:100, and 1:500 and 1µl from each dilution was used in the PCR reaction. 
Each PCR cycle was performed at 95°C for 1min (denaturation step) followed by 56°C 
for 30sec (annealing step) followed by 72°C for 1min (elongation step) for 40 cycles. 
The PCR product was purified using a PCR clean-up kit (Qiagen) and size confirmed by 
separation on a 1% agarose gel (Figure 3.3.B). A combination of 20ng of pLSL-TOPO 
and a clean PCR product (100ng, 150ng, and 200ng) were then electroporated in heat 
induced and -un-induced (negative control) SW102 cells for recombination. Following 
recombination, cells were allowed to recover for 1hr at 32°C without antibiotic. 
Following the recovery hour, fresh LB containing ampicillin was added to the cells, 
which were grown overnight at 32°C. Plasmid was purified from tubes with positive 
growth by miniprep (Qiagen) and 0.1ng of plasmid DNA was re-electroporated into 
fresh SW102 to minimise the issue of copy number.  
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Potential clones were tested for their zeocin and ampicillin resistance and kanamycin 
sensitivity (Figure 3.3.C and 3.3.D). Clones were also digested with KpnI to confirm 
plasmid size to exclude any doubt of false-positive colony formation from 
pRosa26/LacZeo (PCR template) as KpnI will linearize both plasmids (pLSL-TOPO and 
pRosa26/LacZeo) into 9.3kb band 14kb band respectively (Figure 3.3.E). At this stage it 
was important to confirm the presence of the four SV40 polyA sites in the plasmid using 
BamHI digestion where a band of around 4kb confirms the intact of all 4 polyA sites 
(Figure 3.3.F). As this stage, the first version of the modified vector is named as pLSL-
TOPO-Amp (Figure 3.4).  
82 | P a g e  
 
 
Figure 3.3: The first step in adapting pLSL-TOPO for BAC recombineering. (A) The 
integrity of pLSL-TOPO and 4 SV40 polyA sites were confirmed (B) Ampicillin 
resistance gene with homologous arms was amplified from pRosa26/LacZeo and 
electroporated into SW102 with pLSL-TOPO for recombineering. Colonies with 
successful recombineering are zeocin and ampicillin resistant (C) and kanamycin 
sensitive (D). (E) General plasmid integrity was confirmed by the presence of an 8kb 
band as a result of linearizing pLSL-TOPO-Amp (E) and verification that the four 
SV40 polyA sites are still intact (F). 
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Figure 3.4: pLSL-TOPO-Amp. The plasmid map shows the ampicillin resistance gene 
instead of kanamycin (red), and the four intact SV40 polyA sites (pink). Figure 
created using SimVector 4.5. 
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3.3.2 Replacing the original puromycin resistance gene with 
the EM7 promoter and kanamycin resistance gene 
Once pLSL-TOPO-Amp was created, it was necessary to restore the 
kanamycin/neomycin resistance gene under the control of the EM7 promoter. PCR 
primers (green) with homologous arms (blue) were designed to amplify the 
kanamycin/neomycin resistance gene with the EM7 regulatory sequence from a pLoxP-
F3-neoF3 (kindly given by Dr. Peter Hohenstein). 
Forward: 5′-cctttcgacctgcatccatctagatctcgatcgagcagctgaagcttaccggttgacaattaatcatcggc-3′ 
Reverse: 5′-tggggtcgtgcgctcctttcggtcgggcgctgcgggtcgtggggcgggcgtcagaagaactcgtcaagaa-3′ 
pLoxP-F3-neoF3 was linearized by EcoRI followed by DpnI digestion to minimise 
plasmid replication and false-positive colony formation post PCR reaction. Digested 
pLoxP-F3-neoF3 (PCR template) was diluted 1:500 and 1µl was used in the PCR 
reaction. Each PCR cycle was performed at 95°C for 1min (denaturation step) followed 
by 56°C for 30sec (annealing step) followed by 72°C for 1min (elongation step) for 40 
cycles. PCR product was purified using PCR clean-up kit (Qiagen) and confirmed by 
separation on a 1% agarose gel (Figure 3.5.A). A combination of 20ng of pLSL-TOPO-
Amp and a clean PCR product (100ng, 150ng, and 200ng) were then electroporated in 
heat induced and -un-induced (negative control) SW102 cells for recombination. 
Following recombination, cells were allowed to recover for 1hr at 32°C without 
antibiotic. Following the recovery hour, fresh LB containing ampicillin and kanamycin 
was added to the cells, which were grown overnight at 32°C. Plasmid was purified from 
tubes with positive growth by miniprep (Qiagen) and 0.1ng of plasmid DNA was re-
electroporated into fresh SW102 cells to minimise the issue of copy number and plated 
on kanamycin-containing agar plates (Figure 3.4.B). Potential clones were digested with 
NotI and PstI to confirm the recombineering of EM7-Kan/Neo insert and to confirm the 
presence of the four intact SV40 polyA sites (Figure 3.5.C). As this stage, the second 
version of the modified vector is named as pLSL-TOPO-Neo (Figure 3.6). 
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Figure 3.5: The second step in adapting pLSL-TOPO for BAC recombineering. (A) EM7 
regulatory sequence + kanamycin/neomycin resistance gene with homologous arms 
was amplified from pLoxP-F3-neo-F3 and electroporated into SW102 with pLSL-
TOPO-Amp for recombineering. (B) Colonies with successful recombineering are 
kanamycin resistance. (C) Kanamycin resistant clones were tested using PstI and 
NotI digestion which should result in 3 bands 1196bp, 3328bp, and 4779bb. 
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Figure 3.6: pLSL-TOPO-Neo. The plasmid map shows the new kanamycin/neomycin 
resistance gene (dark blue) and EM7 promoter (black), the four intact SV40 polyA 
sites (pink). Figure created using SimVector 4.5.     
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3.3.3 Cloning unique restriction sites downstream of the LoxP-
STOP-LoxP cassette 
In order to insert unique restriction sites downstream of the LoxP-STOP-LoxP cassette, 
NotI at pLSL-TOPO-Neo was chosen. The following oligonucleotides were designed in 
such a way that they will looses the NotI site at pLSL-TOPO-Neo once they become 
ligated following pLSL-TOPO-Neo digestion with NotI. 
 
       AvrII   –   I-SceI   –   PmeI       –      I-CeuI      –      NdeI 
5′ -GGCCCCTAGGTAGGGATAACAGGGTAATGTTTAAACCGTAACTATAACGGTCCTAAGGTAGCGAACATATG 
    GGATCCATCCCTATTGTCCCATTACAAATTTGGCATTGATATTGCCAGGATTCCATCGCTTGTATACCCGG-3′  
 
The ordered oligos were resuspended in water, boiled at 95°C for 5min and allowed to 
cool down at room temperature to permit sequence annealing for 3hr; serial dilution of 
(1:10, 1:100, 1:1000, and 1:10,000) were made. pLSL-TOPO-Neo was single digested 
with NotI and 1µl of each oligonucleotide dilution was ligated into NotI cut pLSL-
TOPO-Neo by T4 DNA ligase. Following ligation, plasmid was re-cut again using NotI 
to cut any self ligated plasmid. 1µl of ligation mix was electroporated into un-induced 
SW102 and cells were allowed to recover for 1hr at 32°C without antibiotic. Following 
the recovery hour, fresh LB containing ampicillin and kanamycin was added to cells, 
which were grown overnight at 32°C. Plasmid was purified from tubes with positive 
growth by miniprep (Qiagen) and 0.1ng of plasmid DNA was re-electroporated into 
fresh SW102 cells and plated on kanamycin-containing agar plates (Figure 3.7.A). 
Potential clones were digested with NotI to confirm the loss of the NotI site (Figure 
3.7.B). In addition, clones were digested with the new unique NdeI restriction site 
(Figure 3.7.C, left) and, to confirm the intact of four SV40 polyA sites, clones were also 
digested by BamHI (Figure 3.7.C, right). The third version named as pLSL-TOPO-BAC 
(Figure 3.8) of the modified pLSL-TOPO was created. 
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Figure 3.7: The third step in adapting pLSL-TOPO for BAC recombineering. (A) 
Successful clones carrying the ligated unique sequence (AvrI - I-SceI – PmeI – I-
CeuI – NdeI) cloned into NotI digested pLSL-TOPO-Neo. (B) Two positive clones 
(clone 4 and 5) showing the loss of the NotI unique restriction site after successful 
ligation. (C, left) Positive clones show the acquisition of an NdeI unique restriction 
site after successful ligation. (C, right) The four SV40 polyA sites are still intact. 
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Figure 3.8: pLSL-TOPO-BAC. The new unique sequence (NdeI, PmeI, and AvrII) for 
homologous arm cloning is shown. The four SV40 polyA sites (pink) are still intact. 
Figure created using SimVector 4.5.     
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3.3.4 Cloning 3′ and 5′ β-catenin homologous arms into pLSL-
TOPO-BAC unique restriction sites 
β-catenin BAC was ordered from Geneservices (bMQ259H05) and BAC DNA was 
purified; 100ng of BAC DNA was used as a PCR template to amplify 3′ and 5′ 
homologous arms. The primers used in the PCR reaction were:   
5′ recombineering arm 
Forward primer(PacI site)extra site 
5′-CGCGTCGCTTAATTAACGTATGCCTACAATCTGTTT-3′ 
Reverse primer(AscI site)extra site 
5′-GCGCATCGTAGGCGCGCCGCCAGTGGTAGTGTGCAG-3′ 
3′ recombineering arm 
Forward primer(AvrII site)extra site 
5′-CGCGTCGCCCTAGGTTGGTGAAATAATCAGCAAGC-3′ 
Reverse primer(NdeI site)extra site 
5′-GCGCATCGTACATATGTGCTGCCAGTGGCTGAC-3′ 
Each PCR cycle was performed at 95°C for 1.5min (denaturation step) followed by 55°C 
for 30sec (annealing step) followed by 72°C for 45sec (elongation step) for 40 cycles. 
The PCR product was purified using a PCR clean-up kit (Qiagen) and run on 2% 
agarose gel to confirm successful PCR  (Figure 3.9.A and 3.10.A).  
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3.3.4.1 Cloning the 3′ β-catenin homologous arm into pLSL-TOPO-
BAC AvrII and NdeI sites 
To clone a 3′ homologous arm, 300ng of pLSL-TOPO-BAC and 5µl of the 3′ 
homologous arm (PCR product) were double-digested individually with NdeI and AvrII 
for 1hr. Three different ratios (1:1, 1:3, and 3:1) of cut-arm and cut-plasmid were ligated 
using T4 DNA ligase at 16°C for 18hr. The whole ligation mix was digested with PmeI 
for 1hr to minimize self-ligated plasmid transformation. Following digestion, DNA was 
transformed into DH5α bacteria strain and bacteria were then grown on ampicillin agar 
plates. Successful colonies were picked and digested again by PmeI (Figure 3.9.B). 
Successful clones were further tested by double digestion using NdeI and AvrII and 
successful cleavage of the 3′ arm confirms the integration (Figure 3.9.C). 
  
Figure 3.9: Cloning the 3′ homologous arm into pLSL-TOPO-BAC NdeI and AvrII 
sites. (A) Successful amplification of the 3′ homologous arm from β-catenin BAC. (B) 
Positive clones with successful ligation of the 3′ arm have lost the unique PmeI 
restriction site. (C) Positive clones can be double-digested with AvrII and NdeI to 
show cut version of the plasmid (left) and to cleavage of the clones 3′ arm (right).  
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3.3.4.2 Cloning the 5′ β-catenin homologous arm into pLSL-TOPO-
BAC AscI and PacI site 
To clone the 5′ homologous arm, 300ng of pLSL-TOPO-BAC and 5µl of the 5′ 
homologous arm (PCR product) were double-digested individually with AscI and PacI 
for 1hr. Three different ratios (1:1, 1:3, and 3:1) of cut-arm and cut-plasmid were ligated 
using T4 DNA ligase at 16°C for 18hr. The whole ligation mix was digested with MulI 
for 1hr to minimize self-ligated plasmid transformation. Following digestion, DNA was 
transformed into DH5α bacteria strain, and bacteria were grown on ampicillin agar 
plates. Successful colonies were picked and digested again by MulI (Figure 3.10.B). 
Successful clones were further tested by double digestion using AscI and PacI and 
successful cleavage of the 5′ arm confirms the integration (Figure 3.10.C, centre and 
left). The presence of four SV40 polyA sites was also checked using BamHI digestion 
(Figure 3.10.C, right). Once 3′ arm and 5′ arms had been successfully cloned into pLSL-
TOPO-BAC, the plasmid was sent for sequencing to confirm arm integration, and the 
final plasmid was named pLSL-TOPO-β-catenin. 
  




Figure 3.10: Cloning the 5′ homologous arm into pLSL-TOPO-BAC PacI and AscI 
sites. (A) Successful amplification of the 5′ homologous arm from β-catenin BAC. (B) 
Positive clones with successful ligation of the 5′ arm have lost the unique MulI 
restriction site. (C) Positive clones can be double-digested with PacI and AscI to 
show cut version of the plasmid (left) and to cleavage of the clones 5′ arm (middle); 
in addition, BamHI digestion (right), confirms the four polyA sites are still intact. 
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Figure 3.11: pLSL-TOPO-β-catenin arms. Both recombineering 3′ and 5′ arms are 
shown in yellow. NdeI and PacI could be used to cleave the BAC targeting cassette. 
NdeI could be used to digest the remaining backbone to minimise false-positive 
colony formation. 
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3.3.5 Cloning the LoxP-STOP-LoxP cassette into β-catenin 
BAC 
Once pLSL-TOPO β-catenin was created, it was important to retrieve the β-catenin 
exon/intron sequence fragment from the BAC. BAC DNA was purified and 
electroporated into SW102 cells, and the β-catenin BAC profile was checked on agarose 
gel after HindIII digestion. This revealed BAC instability in SW102 (data not shown); 
thus, the β-catenin BAC was left in original E.coli host strain and recombineering 
proteins (Exo, Beta, and Gam) were brought to the BAC hosting cells using pSim6 
plasmid (kindly given by Dr. Peter Hohenstein). The β-catenin BAC profile was checked 
again to confirm BAC stability following pSim6 electroporation into host strain (data 
not shown). 
A 6kb fragment containing 5′arm-LoxP-STOP-LoxP-EM7-PGK-KanR-NeoR-3′arm 
(Figure 3.12.A) was extracted from agarose gel after digesting pLSL-TOPO-β-catenin 
with NdeI, PacI, and ZraI for 2hr, the fragment was re-run on agarose gel after 
purification to confirm the presence of a clean-single band (Figure 3.12.B). 
Transforming 1µl of gel purified 6kb fragment into DH5α tested for the presence of any 
circular plasmid in the DNA; when no growth was observed on agar plates, 1µl of gel 
purified 6kb fragment was electroporated into the induced β-catenin BAC host strain 
containing pSim6 to allow recombination, and cells were allowed to recover for 1hr at 
32°C without antibiotic. Following the recovery hour, fresh LB containing ampicillin, 
kanamycin, and chloramphenicol was added to cells, which were grown overnight at 
32°C. 
Twelve clones were picked and BAC DNA was extracted. Using 50ng of BAC DNA for 
a PCR template, PCR primers were designed to test the integration of 6kb fragment into 
β-catenin BAC between exon 2 and 3 (Figure 3.13) by amplifying a product of 550bp 
that overlap 5′ arm and BAC sequence (upstream of fragment) and a product of 470bp 
that overlap 3′ arm and BAC sequence (downstream of fragment). 
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Each PCR cycle was performed at 95°C for 45sec (denaturation step) followed by 56°C 
for 30sec (annealing step) followed by 72°C for 1min (elongation step) for 40 cycles 
using the following primers: 
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Figure 3.12: Checking the right integration of LoxP-STOP-LoxP cassette into β-
catenin BAC. (A) Digestion of pLSL-TOPO-β-catenin with NdeI, PacI, and ZraI 
revealed a 6.5kb fragment containing the LoxP-STOP-LoxP cassette and the 
remaining plasmid backbone (1.5kb and 2.0kb). (B) The 6.5kb fragment containing 
the LoxP-STOP-LoxP cassette after gel extraction and clean-up. (C) Checking correct 
integration of LoxP-STOP-LoxP cassette into β-catenin BAC by PCR amplification 
revealed products of the expected size (550bp for the 5′ arm and 470bp for the 3′ 
arm). 
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3.4 Discussion 
It was important to check the working template of pLSL-TOPO once received from 
Addgene to make sure that the plasmid was as it should be. A few digestion tests using 
NotI (cut once) and BamHI (cut twice) confirmed the presence of the right plasmid 
(Figure 3.3.A). The main characteristic of pLSL-TOPO is the presence of LoxP-STOP-
LoxP (Figure 3.2), and it was important to confirm the presence of these four SV40 
polyA sites every time a modification is performed as losing one of these polyA site 
could affect the ability to control the expression of mutated protein; thus, regulation of 
expression of the knock-in gene would no longer be conditional. A good test plan was 
achieved using BamHI digestion, which cut upstream and downstream of the LoxP-
STOP-LoxP cassette resulting in a band of (3.9kb) – the right size for the expected 
cassette. Any loss of a polyA site during a modification step would be noted by the 
appearance of a band less than 3.9kb after BamHI digestion.  
The ampicillin gene was successfully amplified from pRosa26/LacZeo (Figure 3.3.A), 
where linearizing the template and digesting methylated DNA following PCR 
amplification helped to reduce the appearance of any false-positive colonies, as the PCR 
template (pRosa26/LacZeo) could cause ampicillin resistance. The issue of plasmid copy 
number in the host strain could cause some complications, as a single copy of the right 
plasmid in comparison to multiple copy of the wrong plasmid would still give antibiotic 
resistance even though the majority of copies of the plasmid in the cell are incorrect. To 
overcome this issue, re-transformation of the plasmid by electroporation is advisable 
(Thomason et al., 2007) after every step of modification. Successful cloning of the 
ampicillin gene was confirmed by ampicillin and zeocin resistance (Figure 3.3.B), 
kanamycin sensitivity (Figure 3.3.C), and KpnI single digestion, which resulted in  a 9kb 
band (Figure 3.3.D) – the expected size for the correct plasmid, and not a 14kb band 
which would indicate the presence of the PCR template. BamHI digestion also 
confirmed the presence of four polyA sites as expected (Figure 3.3.E). 
  
99 | P a g e  
 
The EM7/Kanamycin sequence was cloned using a similar approach to that for the 
ampicillin sequence, but a different testing strategy was designed. PstI should cut twice 
in the correct clone: once upstream of the four polyA sites and again in the Kan/Neo-R 
gene (Figure 3.6).  So PstI digestion, in one test, checked both the insertion of 
the Kan/Neo-R fragment and the number of polyA sites. However, a PstI digest would 
result in two almost equal sized fragments, which would not be clearly resolved by 
agarose gel electrophoresis. However, a double digest using PstI and NotI, which further 
digested one of the PstI fragments (the one that does not contain the four polyA sites), 
would resulted in three different-sized fragments [1196bp, 3328bp and 4779bp (Figure 
3.5)] that were easily separated on an agarose gel. The 4779bp fragment contains the 
four polyA sites, so any loss of polyA signal would have been identified by the 
production of a fragment smaller than 4779bp by 650bp for each polyA site lost. 
The 5′ homologous arm was slotted easily between the PacI and AscI sites upstream of 
the LoxP-STOP-LoxP cassette. However, the 3′ homologous arm needed to be slotted 
into a unique restriction site downstream of the LoxP-STOP-LoxP cassette, and such a 
site did not exist in the original plasmid. Thus, a unique DNA sequence was designed in 
a way that allowed the insertion of the following restriction endonuclease sites into the 
NotI site: AvrII – IsceI – PmeI – IceuI – NdeI. The oligos were designed so that the NotI 
site was abolished after successful ligation of the insert sequence. All these five sites are 
then unique in the plasmid. A simple conventional cloning step then involved digesting 
pLSL-TOPO-Neo with NotI followed by sequence ligation; however, a further NotI 
digestion after ligation and before transfection assisted in minimising false-positive 
colony formation (Figure 3.8). A final digestion test using NotI, NdeI, and BamHI 
confirmed the loss of the NotI site in two clones, clone 4 and 5 (Figure 3.7.B), 
acquisition of the new unique sites (Figure 3.7.C, left), and the presence of four polyA 
sites (Figure 3.7.C, right). 
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At this stage the pLSL-TOPO-BAC is a universal BAC targeting vector which can be 
used to target any BAC of interest. However, it is important at this stage to pick a gene 
and a desired subtle mutation(s) as the following steps are gene-dependent. It is very 
important when using this approach to have the LoxP-STOP-LoxP cassette toward the 
start of the gene (5′ end)  to eliminate any dominant negative effects of any stable 
partial-protein expression (up to the stop codon); in addition, it is also important to keep 
the distance between the LoxP-STOP-LoxP cassette and the actual mutation as small as 
possible since the selection during the embryonic stem cell targeting stage is done on the 
LoxP-STOP-LoxP cassette: the bigger the distance between cassette and mutation, the 
bigger the risk of picking up a clone that has the stop cassette but not the desired 
mutation (owing to a sliding holiday junction between the genomic DNA and the 
targeting construct resolving by chance before the actual mutation). After careful 
consideration of gene structure (exon/intron) and desired mutations, mouse β-catenin 
(Ctnna1 ENSMUSG00000037815) with the desired (S33Y) and (S45∆) mutations were 
chosen, as β-catenin and its desired mutation had the best genomic structure for this type 
of BAC targeting approach (Figure 3.13, B). 
  





Figure 3.13: β-catenin BAC DNA sequence. (A) The sequence of 5′ homologous 
retrieval arm (blue) and 3′ homologous retrieval arm (green). (B) A diagram 
showing the exact area between exon 2 and exon 3 where LoxP-STOP-LoxP cassette 
to be targeted, the location of desired mutation(s), and the distance between the 5′ 
end of β-catenin and the stop cassette. 
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An important consideration in 5′ and 3′ homologous arm primer design was the enzyme 
docking site, as most restriction endonucleases dock a few base pairs downstream of the 
actual cutting site so 8–10 random base pairs were attached to the PCR sequence to act 
as the enzyme docking site. It was also important to choose three unique restriction 
enzymes during arm cloning, where the arm is cloned between the first and the third site, 
and the second site is used to cut any undigested plasmid to minimise false-positive 
colony formation. These considerations increase the efficiency of homologous arm 
cloning into pLSL-TOPO-BAC vector.  
The 3′ arm (258bp) was amplified using the β-catenin BAC (Figure 3.9.A) and cloned 
between AvrII and NdeI, where PmeI (Figure 3.9.B) was used to cut any self-ligated 
plasmid. Once cloned, plasmid was digested once one using AvrII and PmeI to confirm 
arm cleavage and plasmid digestion (Figure 3.9.C). The 5′ arm (344bp) was amplified 
using the β-catenin BAC (Figure 3.10.A) and cloned between AscI and PacI, where MulI 
(Figure 3.10.B) was used to cut any self-ligated plasmid. Once cloned, plasmid was 
digested once one using AscI and PacI to confirm arm cleavage and plasmid digestion 
(Figure 3.10.C, left and middle). In addition, BamHI confirmed the presence of four 
polyA sites (Figure 3.10.C, right). 
Once homologous arms were cloned into the BAC targeting vector (Figure 3.11), it was 
important to cleave the stop cassette AND digest the remaining backbone (in an 
individual reaction) using ZraI or any another suitable enzyme, as this should cut any 
circular plasmid where the stop cassette hasn’t been cleaved because these plasmids 
could give false-positive colonies from the kanamycin resistance gene located on the 
backbone (Figure 3.12, A). In addition to this, it is advised to test the quality of the stop 
cassette extracted from the gel (Figure 3.12, B) by transforming a small amount into 
Dh5α cells to test for the presence of any circular plasmid in the gel fragment. All these 
considerations help to increase the efficiency of cloning the stop cassette into the desired 
BAC.  
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A correct integration could be confirmed by designing PCR primers that overlap an area 
of a few hundred base pairs between the BAC sequence and the homologous arm in both 
locations (3′ and 5′) and amplification of a product would confirm the integration of the 
stop cassette at the right location (Figure 3.12, C). 
At this stage, it has been confirmed that the LoxP-STOP-LoxP cassette has been targeted 
into β-catenin at the exact area between exon 2 and 3. BAC DNA containing the cassette 
was still present in the original BAC hosting strain where recombineering proteins are 
expressed by pSim6 plasmid (ampicillin resistance). Many attempts were made to create 
the desired S33Y and S45∆ mutation on the BAC sequence; however, all these attempts 
were unsuccessful but will be mentioned briefly (without showing the data) for 
discussion purposes.  
The first approach attempted is described by Yang et al (2003). This technique is 
designed for low copy, large plasmid manipulation such as BACs and involves a simple 
two-step method, named Hit-and-Fix, to generate subtle mutations in BACs. The method 
involves electroporating the denatured PCR fragment that contain 20bp of unique 
sequence (including an XhoI site) flanked by 80bp of sequence homologous to the area 
that needs to be targeted: after transfection, clones are tested by PCR for the unique 
sequence, followed by XhoI confirmation (one big limitation). Once the sequence is hit, 
it gets fixed by transfecting the original 20bp (containing the desired mutation) flanked 
by the same homologous arms used in the hit. We tried trouble shooting a few times 
before deciding to move on to the second approach. 
The second approach attempted is described by Warming et al (2005), and this approach 
is also designed for low copy, large plasmids such BACs. The technique involves hitting 
the desired sequence for mutation by GalK (galactokinase) flanked by homologous 
arms; this gene will allow the host strain to grow on minimal medium containing 
galactose as the only carbon source.  
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Once clones with GalK are selected, the GalK gene could be replaced using the same 
homologous arms with the desired mutation followed by growing cells on minimal 
medium, glycerol (carbon source), and DOG (2-deoxy-galactose) where cells with the 
GalK gene (but not carrying the desired mutation) will catalyse the phosphorylation of 
DOG leading to a toxic build-up of 2-deoxy-galactose-1-phosphate (Alper and Ames 
1975). However, it is important to use a strain which is GalK negative such as SW102 to 
allow GalK selection. No successful clones were achieved from this approach either. 
At this stage I had problems with BAC DNA purification and BAC stability; we decided 
to clone the desired β-catenin sequence from BAC into the final stem cell targeting 
vector (pL611-kindly given by Peter Hohenstein) then create the desired mutation on the 
plasmid. At this stage we were faced with two choices: to clone the BAC β-catenin 
sequence containing the LoxP-STOP-LoxP cassette into pL611 resulting in a plasmid 
with an excess size of 20kb, or to clone the BAC β-catenin sequence without the stop 
cassette (expected size 14kb) followed by cloning the stop cassette once mutation is 
created. We decided to clone the β-catenin sequence into pL611 without the stop 
cassette to deal with 14kb plasmid instead of 20kb as this should increase the chances of 
creating the desired mutation. 
PCR primers containing sequence homologous to the BAC DNA that need to be cleaved 
was used to amplify pL611, once amplified, pL611 was electroporated into BAC host 
cells with pSim18 (another recombineering protein vector, kindly given by Peter 
Hohesntein). Clones with a successful recombineering were picked and re-transformed 
into DH5α cells, plasmid DNA was purified and checked by digestion. At this stage, we 
successfully had cloned the desired 10kb fragment from β-catenin BAC into pL611, 
making a plasmid with a total size of 14.7kb (data not shown), and the plasmid was 
named (PL611- β-catenin). To test the possibility of cloning the LoxP-STOP-LoxP 
cassette after a mutation is created, we decided to test the efficiency of such a cloning 
procedure before progressing with the mutation. We successfully cloned the stop 
cassette into PL611- β-catenin, as shown before resulting in a plasmid with an excess 
size of 20.8kb (data not shown) plasmid was named PL611- β-catenin-STOP. 
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We repeated the GalK method and the Hit-&-Fix method on both PL611- β-catenin and 
PL611- β-catenin-STOP plasmids without any successful results, so we also attempted 
new approach described by Wang et al (2009) where sequence is first hit by a 
recombineering cassette containing kanamycin resistance and bacterial ribosomal 
protein rpsL
+
 gene. Once the cassette has integrated at the site, clones could be selected 
using kanamycin resistance followed by a second recombineering hit using the same 
homologous arms to knock out the cassette and knock in the mutation so cells could be 
selected on streptomycin plates, as rpsL
+
 confers streptomycin sensitivity (Stavropoulos 
and Strathdee 2001). As this approach involves kanamycin resistance in the first step it 
was only possible to perform it on PL611- β-catenin and β-catenin BAC. However, no 
positive clones with the desired mutation were obtained. In addition, we also attempted 
the GENRART
®
 Site-Directed Mutagenesis System for plasmid up to 14kb (Invitrogen) 
on PL611- β-catenin (14.7kb); however, all colonies tested were carrying multiple 
unwanted mutations. Finally, we tried one last approach – the In-Fusion
®
 PCR Cloning 
system from Clonetech; however, no positive clones were detected. 
  









Chapter 4: Developing an isogenic 
recombination-based synthetic gene model 
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4.1 Chapter abstract 
The Flp-In System™ from Invitrogen eased the generation of isogenic stable 
mammalian expression cell lines by adapting the DNA recombination system in 
Saccharomyces cerevisiae. Using this system, two isogenic stable cell lines were 
created: one overexpresses wild-type IRF-1 and the second overexpresses a mutant that 
abolishes IRF-1 DNA binding ability (W11R). Both cell lines were investigated, using 
microarray analysis, to identify the panel of IRF-1 downstream targets. Twelve potential 
targets were validated using qRT-PCR to confirm the increase in their expression level 
once IRF-1 is overexpressed. In addition, in-silico analysis of their putative promoter 
regions was undertaken to identify the presence of any common DNA binding motifs 
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4.2 Chapter introduction 
Genetically modified stable cell lines are standard tools in cancer studies; they are 
considered to be of more physiological relevance to the human body, compared to 
traditional transient transfection, making them a great tool in the cancer field. However, 
the random integration of a gene of interest during stable cell line creation is a big 
limitation in creating stable cell lines using the traditional method, especially when 
isogenic cell lines are required. There is a need for a modified method for creating stable 
cell lines where any gene of interest could be slotted in at a specific genomic location in 
the host cell line. Such a method could contribute toward cancer therapy and 
understanding the mechanism of cancer. 
4.2.1 The Flp-In System™ 
The Flp-In System
™ 
from Invitrogen introduced a new system for creating stable cell 
lines that allows the integration and the expression of any gene of interest in any 
mammalian host cells at a very specific genomic location called FRT site: a 34bp DNA 
sequence with two 13bp inverted repeats and an 8bp spacer. The system is adapted from 
the Saccharomyces cerevisiae-derived DNA recombination system that uses a 
recombinase (Flp) and site-specific recombination (Sauer 1994).  
There are three important steps in creating stable cell lines using this approach: the first 
step involves adapting the host stable cell line for FRT integration, and this is achieved 
by pFRT/lacZeo transfection into the chosen host cell line. Such transfection will allow 
the random genomic integration of lacZ–Zeocin (Figure 4.1) fusion gene, whose 
expression is controlled by the SV40 promoter, into the host cell line resulting in clones 
being zeocin resistant. The lacZ–Zeocin fusion gene contains an FRT site which has 
been inserted just downstream of the ATG initiation codon of the fusion gene (Figure 
4.1). The second step involves cloning the gene of interest into an FRT expression 
shuttle vector such as pEF5/FRT/V5-DEST (Figure 4.2) under the control of human EF-
1α promoter. Such cloning can be achieved easily using a standard LR reaction between 
a donor vector carrying the gene of interest and the pEF5/FRT/V5-DEST vector.   




Figure 4.1: Step one in creating FRT mammalian host cell line. pFRT/LacZeo is 
characterized by the lacZ–Zeocin fusion gene, whose expression is controlled by 
SV40 promoter, and the FRT site which has been inserted just downstream of the 
ATG initiation codon of the fusion gene (Adapted from Flp-In System, Invitrogen). 
 
 
Figure 4.2: pEF5/FRT/V5-DEST. Straightforward cloning of any gene of interest from 
any Gateway™ Donor vector is facilitated by attR1 and attR2 DNA sites where the 
resultant flipped gene will be under the regulatory control of the human EF-1α 
promoter (Adapted from pEF5/FRT/V5-DEST Gateway™ Vector, Invitrogen).
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Once a gene of interest is cloned into the FRT expression vector, this vector and a third 
vector named pOG44 are co-transfected into a host cell line containing the FRT site. 
pOG44 will then express Flp-recombinase, which will mediate DNA recombination 
(O’Gorman et al., 1991) between the gene of interest on the expression vector and the 
FRT site in the genomic DNA (Figure 4.3). As a result of a successful recombination the 
SV40 promoter and the ATG initiation codon are brought into proximity and frame with 
the hygromycin resistance gene, resulting in inactivation of lacZ–Zeocin fusion gene 
(Figure 4.3). Thus, clones can now be selected for hygromycin resistance and zeocin 
sensitivity. 
 
Figure 4.3: Flp-In System™. Illustrative diagram showing the recombineering 
cloning of a gene of interest from an expression vector into a host cell line with a 
FRT binding site (Adapted from Flp-In System, Invitrogen). 
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4.2.2 Interferon Regulatory Factor 1 
IRF-1 is a nuclear transcription factor first described in mice as a transcription factor 
that binds to the upstream regulatory cis element region positive regulatory domain I 
(PRDI), 5′–GAGAAGTGAAAGT–3′, of interferon-β gene following a viral infection 
(Miyamoto et al., 1988). The same group showed that IRF-1 is also involved in the 
regulation of different genes such as interferon-α and genes in the major 
histocompatibility complex (MHC) mainly class 1 (Miyamoto et al., 1988).  
As a DNA binding protein, the IRF-1 DNA binding domain has been determined and 
shown to include three α-helices (the third α-helix is characterized by a GAAA sequence 
major groove), four anti-parallel β-sheets and three loops thought to be similar to the 
HTH binding domain but reported to interact by a different mode (Escalante et al., 
1998). In all members of human interferon regulatory factors a DNA binding domain 
characterized by a winged type helix-loop-helix motif, with five tryptophan repeats 
located near the N-terminal, is present (Uegaki et al., 1995). By disturbing these five 
tryptophan repeats, and mutating tryptophan 11 into arginine, an IRF-1 mutant that 
abolishes DNA binding ability is created (Eason et al., 1999). 
Further studies showed that IRF-1 binds to a DNA consensus motif, termed interferon 









–3′ (Tanaka et al., 1993). The IRF-E motif overlaps with 
another IRF-1 binding motif named ISRE, characterized by a 5′–
 
A/G
NGAAANNGAAACT–3′ consensus (Darnell et al., 1994). The IRF-1 induced genes 
vary in function from antiviral/antibacterial response genes such as IFN-β, IFN-α 
(Harada et al., 1990; Matsuyama et al., 1993), Guanylate-binding protein GBP (Kimura 
et al., 1994), iNOS (Kamijo et al., 1994), gp91
phox
 (Eklund et al., 1998) and OAS2 
(Harada et al., 1998) to anti-proliferative response genes such as protein kinase R 
(Samuel et al., 1997) and p21
WAF/CIPI
 (Nguyen et al., 1997). In addition, IRF-1 can also 
induce some apoptosis genes such as Caspase 1 and Caspase 7 (Tamura et al., 1995; 
Taniguchi et al., 2001).  
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IRF-1 is also involved in triggering the expression of genes involved in cell 
transformation inhibition such as lysyl oxidase (Tan et al., 1996), TH1 type immune 
response such as interleukin-12 (Taki et al., 1997), inflammation, natural killer cell 
differentiation, such as interleukin-15 (Ogasawarak et al., 1998), and major 
histocompatibility complex class I (MHC) expression such as Class II transactivator 
(Hobart et al., 1997). These MHC, mainly class I, could enhance the formation of 
surface antigens in tumour cells that can be recognized by host defence/immune 
mechanisms and helping to eliminate tumour cells (De Andrea et al., 2002). In addition 
interferon-γ, with the aid of interleukin-2, can enhance T-cell activation leading to the 
expression of more major histocompatibility complex class II, in same response 
described earlier (De Andrea et al., 2002). Thus, interferon-based therapy for cancer has 
been introduced, with other current therapies such as chemotherapy/radiotherapy, to 
minimize the overall dose of therapy, aiming at a more effective outcome. 
However, the complete panel of IRF-1 downstream targets has not been fully 
characterized; thus, this chapter aimed to analyse IRF-1 targets using microarray 
technology. To achieve this, stable cell lines over-expressing wild-type IRF-1 needed to 
be created, as stable cell lines are more physiological relevant compared to transient 
transfections. To eliminate the possibility of activating genes indirectly through protein–
protein interaction, an isogenic stable cell line overexpressing an IRF-1 mutant (W11R) 
that abolishes DNA binding ability must be created in addition to the wild-type IRF-1. 
Once isogenic stable cell lines are created using the Flp-In System
™
 (Invitrogen), 
potential targets that are overexpressed in wild-type IRF-1, but not in W11R IRF-1, can 
be identified using microarray analysis. However, microarray analyses need to be 
validated using qRT-PCR to confirm the change in protein level expression. Successful 
candidates from qRT-PCR analysis are further examined in-silico at their promoter level 
to identify any common DNA binding motif such as ISRE or IRF-E.  
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4.3 Methods and results 
4.3.1 Creating a stable A375 Flp-In™ host cell line carrying an 
FRT site 
Human amelanotic melanoma cell line (A375) was chosen to be the host of the FRT site 
integration. 500ng of pFRT/LacZeo was digested using ScaI, then 100ng of digested 
plasmid was transfected into wild-type A375 using Attractene (Qiagen) and cells were 
allowed to recover for 24hr. Following the recovery period, cells were challenged with 
zeocin for two weeks. 
Twelve zeocin resistance clones were picked and expanded into 6cm tissue culture 
plates for Southern blot analysis. Genomic DNA was extracted using a DNeasy Blood & 
Tissue Kit (Qiagen), and 1µg of genomic DNA was digested with 100units of HindIII 
for 4hr. Digested genomic DNA was run on 0.8% agarose gel at 10V for 18hr to allow 
slow separation. Once separated, genomic DNA was immobilized onto Biodyne® nylon 
membranes (chapter 2). A PCR probe, recognizing 400bp on the lacZ-Zeocin fusion 
gene, was radiolabelled with [α-
32
P] dCTP and [α-
32
P] dATP using Prime-It
®
 II Random 
Primer Labelling Kit (Agilent Technologies) and hybridized onto immobilized genomic 
DNA for probe detection (Figure 4.4). 
It was important to ensure IRF-1 pathway integrity after the random integration of the 
FRT site into the A375 genome, thus three FRT clones (FRT7, FRT12, and FRT14) 
were tested for FRT integration effects on the IRF-1 pathway. Tested clones were 
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Figure 4.4: Identification of the A375 cell lines with a single FRT site integrated in 
the genome using Southern blotting. DNA of 12 clones was extracted, digested with 
HindIII followed by Southern blot analysis using a 32P radioactive labelled probe 
specified for a 400bp region on lacZ-Zeocin fusion gene. Results show six potential 
clones with single FRT site integration (black arrows). 
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Figure 4.5: Integration of an FRT site does not influence the IRF-1 pathway. Three 
clones with single FRT integrations were seeded on 6cm culture plates; 24hr later, 
cells were subjected to a 6hr time course of treatment with 25μg/ml poly (I:C). After 
harvesting, cells were lysed and subjected to immunoblotting; IRF-1 and β-actin 
were detected by their respective antibodies. All 3 clones with single FRT site 
integrations show identical IRF-1 expression level profiles as wild-type A375.  
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4.3.2 Creating stable A375 over-expressing wild-type IRF-1 
and W11R IRF-1 
Once the FRT host cell line was created, any gene of interest could be slotted in at the 
FRT sites to create stable expression cell lines. Two stable cell lines were created, one 
overexpressing wild-type IRF-1 and the second overexpressing an IRF-1 mutant 
(W11R) that abolishes IRF-1 DNA binding ability. An LR reaction was performed 
between pDonr221 carrying wild-type IRF-1 (kindly given by Dr. Vikram Naryan) and 
pEFF5/FRT/V5–DEST to create pKhal-1, which was sequenced using T7 standard 
primer to confirm the successful cloning of IRF-1. 




pKhal-1 (PCR template) was diluted 1:500 and 1µl was used in the PCR reaction. Each 
PCR cycle was performed at 95°C for 50sec (denaturation step) followed by 55°C for 
1min (annealing step) followed by 68°C for 18min (elongation step) for 15 cycles 
followed by a final elongation step at 68°C for 30min. Once amplified, the DNA was 
digested with DpnI for 2hr to cleave the DNA methylated sites (PCR template). DpnI-
digested PCR product was transformed into DH5α and grown on ampicillin agar plates 
overnight at 37°C. Plasmid DNA was extracted, profile digested (data not shown), and 
potential clones were sequenced using standard T7 primer to confirm the desired 
mutation. Positive clones with the W11R mutation were named pKhal-2. 
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A375 FRT7 and A375 FRT14 were seeded onto 10cm tissue culture plates to reach 60-
80% confluence the following day, 5µg and 10µg of total DNA pKhal1 or pKhal-2 and 
pOG44 (1:9 ratio respectively) was transfected using Attractene (Qigen). Transfected 
cells were left overnight at 32°C without antibiotics; the following day cells were 
transferred into a 37°C incubator and challenged with 200µg/ml hygromycin for two 
weeks or until complete death of no DNA control. Surviving clones were mixed together 
by trypsinzing the whole plates and re-seeding them onto fresh 6cm plates without 
antibiotic. Cells were tested for their IRF-1 overexpression level using immunoblotting 
and luciferase assays (Figure 4.6). 
  




Figure 4.6: The successful creation of wild-type IRF-1 and W11R IRF-1 stable 
expression cell lines. pKhal-1 or pKhal-2 and pOG44 were co-transfected into A375 
FRT7 and A375 FRT14 to create stable expression cell lines. (A) wild-type IRF-1 is 
overexpressed from A375 FRT7 conIRF-1 (lane 5) compared to A375 FRT7 (lane 1). 
Both A375 FRT14 W11R (lane 4) and A375 FRT7 W11R (lane 3) also overexpress 
mutant IRF-1 compared to empty vector control A375 FRT7 and FRT14 (lane 1 and 
2). (B) A downstream target of IRF-1 (ISG-20) is overexpressed as a result of 
overexpressing wild-type IRF-1 in A375 FRT conIRF-1 (lane 4); all remaining cell 
lines (lane 1, 2, and 3) show basal levels of ISG-20. (C) Luciferase assay showing 
TLR3 relative expression to IRF-1 in three different cell lines A375 FRT7, A375 FRT7 
W11R, and A375 FRT7 conIRF-1. 
119 | P a g e  
 
4.3.3 Microarray analysis to investigate the panel of IRF-1 
regulated targets 
RNA was extracted from A375 wild-type, A375 FRT7, A375 FRT7 W11R and A375 
FRT7 conIRF-1 using the RNeasy Mini Kit (Qiagen) and was biotinylated and amplified 
(cRNA) using the Illumina® TotalPrep RNA Amplification Kit (Applied Biosystems) 
for hybridization (RNA from each cell line was done in triplicate) making a total of 12 
samples. 10µl of cRNA (150ng/µl) from each sample was supplied to the Clinical 
Research Facility (Western General Hospital, Edinburgh) to quality check cRNA by 
Agilent 2100 Bioanalyser.  
 
12 samples were hybridized onto Human HT12_V3_0_R1_11283641_A (Illumina), 
each comprising 48802 features and run on the Illumina Beadstation to give signal 
intensity for each probe for each sample. Raw data were exported and passed to Fios 
Genomics (Edinburgh) for microarray data analysis.  
 
A total of 12 arrays were QC analysed using the Array Quality Metrics package in 
Bioconductor (Kauffmann et al., 2009) Arrays were scored to identify outliers on the 
basis of 3 metrics, namely MA plot (Figure 4.7.A), Box plot (Figure 4.7.B) and density 
plot (Figure 4.7.C). However, no outlier(s) has been identified in any 2 out 3 metrics in 
all replicate for each sample of A375 wild-type, A375 FRT7, A375 FRT7 W11R and 
A375 FRT7 conIRF-1. 
  











Figure 4.7: The Array Quality Metrics Bioconductor QC report. (A) MA Plot for the 12 
arrays where M = log2(I1) – log2(I2) and A = 1/2 (log2(I1) + log2(I2)). I1 is the 
intensity of the array studied and I2 is the intensity of a "pseudo"-array, which has 
the median value of all the arrays. Typically, each array is expected to have the mass 
of the distribution in an MA plot concentrated along the M = 0 axis. (B) Box plot for 
the 12 arrays, each box corresponds to one array. It gives a simple summary of the 
distribution of probe intensities across all arrays. Typically, all boxes should have a 
similar size (IQR) and Y position (median). If the distribution of an individual array 
is very different from the others, this may indicate an experimental problem. (C) 
Density plot, Kernel density estimates (smoothed histogram) of data, where each 
array is represented by a single line. Typically, the distributions should have similar 
shapes and ranges. 
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Once the quality check report confirmed that none of the replicates was an outlier, raw 
data were transferred using a Variance Stabilizing Transformation (VST) method prior 
to normalisation across all arrays using the Robust Spline Normalisation (RSN) method. 
Six comparisons: conIRF1 relative to A375, A375 FRT7 relative to A375, W11R 
relative to A375, conIRF1 relative to A375 FRT7, W11R relative to A375 FRT7, and 
finally W11R relative to onIRF1 were manually chosen to explore the data. 
Subsequently, empirical Bayesian analysis was applied, including vertical (within a 
given comparison) p value adjustment for multiple testing, which controls for false 
discovery rate. The Bioconductor package limma was used (Smith 2005). 
 
 
Figure 4.8: Pie chart of all six comparisons undertaken, with their significant array 
hits. In each case, the (/) sign between the two cell lines translates to "relative to" 
in common parlance. The number of significant array features at adjusted p≤ 0.05 is 
shown. Note that for statistical robustness, only those with an adjusted p value ≤ 








(W11R/FRT7), 189 (W11R/+IRF-1), 
483 
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The primary output from the empirical Bayesian analysis is fully annotated lists of genes 
differentially expressed in the comparison of interest. These lists have associated 
significance statistics, sorted by decreasing order of significance (up to a maximum of 
55,000 array features). However, A375 FRT7 conIRF-1 relative to A375 FRT7 gene list 





Figure 4.9: Venn diagram illustrating significant array distribution. A total of 221 
significant change (p value ≤ 0.05) in A375 FRT7 conIRF-1 relative to A375 FRT7 
where 89 arrays were up-regulated by 0.5 fold or more, compared to 45 arrays that 
were down regulated by 0.5 fold or more. A total of 87 arrays showed either up- or 










0.5 fold or 
more 
87 
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The A375 FRT7 conIRF-1 relative to A375 FRT7 gene list was checked for potential 
IRF-1 targets and 12 significant candidates (P value of ≤ 0.0065) showing up-regulation 
in their expression when wild-type IRF-1, but not W11R IRF-1 mutant, is over 
expressed were chosen, on the basis of having a role in cancer, cell adhesion, cellular 
migration, apoptosis, tumour suppressor target genes, cancer therapy, metastatic, cellular 
adhesion, invasion, and autophagy, for further testing using qRT-PCR. 
However, the most statistically significant probe sets may not have a large fold change. 
Conversely, it is frequently the case that large fold changes are not statistically 
significant, primarily due to the variances of those probe sets being comparatively great, 
although subsequent qRT-PCR or other methods may confirm the large fold change 
values. 
  








SORBS2 Sorbin and SH3 domain containing 2 1.5 2.40E-05 
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Table 4.1: Twelve potential IRF-1 targets with more than 0.5 fold change in their 
expression once IRF-1, but not W11R mutant, is over expressed. All candidates are 
highly significant with a P Value of ≤ 0.0065. Most targets have a role in cancer and 
cellular adhesion/migration. 
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4.3.4 Quantitative RT-PCR analysis confirms the role of IRF-1 
in the regulation of IRF-1 potential candidates 
 
A quantitative real-time PCR analysis of mRNA expression was performed to confirm 
the differential expression of the selected genes (table 4.1) relative to two house keeping 
genes β-actin and RPS18. Primers for qRT-PCR analysis and qRT-PCR master mix were 
ordered through Dharmacon (Thermo Scientific). 
 
mRNA was extracted from A375 FRT7 and A375 FRT7 conIRF-1 using the RNeasy 
Mini Kit (Qiagen). 500ng of extracted RNA were reverse transcribed using the 
Omniscript RT kit (Qiagen) to generate cDNA, which was diluted to make a stock 
concentration of 25ng/µl. 125ng of cDNA, 6.25µl of PCR water, 1.25µl of Solaris 
primers, and 12.5µl of Solaris master mix were all mixed together, each sample was 
treated in quadruplicate for statistical significance. Samples were placed in the qRT-
PCR machine using the following thermal cycling program: initial step at 95°C for 
15min (enzyme activation) then 40 cycles of 95°C for 15sec (denaturation) and 60°C for 
60sec (annealing and extension). 
 
Once qRT-PCR programme was completed, a melting curve for each sample was 
checked and outliners were eliminated. The Ct value for each replicate sample was noted 
and mean and standard deviation were calculated for each replicate. ∆Ct was calculated 
by subtracting the Ct (mean) for a house keeping gene from the Ct (mean) of a gene of 
interest for each condition (A375 FRT7 and A375 FRT7 conIRF-1). ∆∆Ct was then 
calculated by subtracting ∆Ct of a house keeping gene from ∆Ct of a gene of interest 
where the value (0) should be in all controls, as subtracting the ∆Ct of house keeping 
gene from itself is always (0). Relative gene expression is then calculated using (1+ 
primer efficiency) all to the power of −∆∆Ct where primer efficiency is set to be 90%. 
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Figure 4.10: Quantitative real-time PCR analysis of 12 IRF-1 target genes. (A) First 
round of screening where 4 target genes SPP1, IL24, EGR1, and PMEPA1 shows clear 
up-regulation relative to two house keeping genes (actin and RPS18) when IRF-1 is 
over expressed; SMG1 and SORBS2 show no significant change. (B) Second round of 
screening where two target genes IRF2BP2 and BNIP3L show clear up-regulation 
relative to two house keeping genes (actin and RPS18) when IRF-1 is over 
expressed; RUNX1, NEDd4L, SH3PXD2A, and HIPK2 show no significant change. 
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4.3.5 In-silico analysis of promoter regions 
In-silico analysis of the putative promoter region (up to 2 kb upstream to the predicted 
transcription site) for IRF2BP2, BNIP3L, SPP1, SMG1, IL24, EGR1 and PMEPA1 (all 
showed high levels of overexpression in qRT-PCR) was carried out using Galaxy 
https://main.g2.bx.psu.edu/ and UCSC genome browser 
http://genome.ucsc.edu/index.html?org=Human&db=hg19&hgsid=257732897. DNA 
sequence was obtained from the UCSC genome browser and uploaded into the Galaxy 
online tool. Once uploaded, an area of 1000bp or 2000bp upstream of the predicted 
transcription site was flanked using the “flanking tool”. Once flanked, sequence was 
fetched using the “fetched tool” for a consensus search using Fuzznuc. The analysis 
revealed all 7 genes have a potential ISRE consensus sequence in their promoter region 
to which IRF-1 can bind, and a site for putative binding of NFκB binding protein; table 
(4.2). 
Gene Consensus Area Mismatch Sequence 
IRF2BP2 ISRE Within 1kb 1 [AG]NGAAANNGAAACT 
IRF2BP2 NFκB Within 1kb 1 GGG[AG]NN[CT][CT]CC 
BNIP3L ISRE Within 2kb 1 [AG]NGAAANNGAAACT 
BNIP3L NFκB Within 1kb 0 GGG[AG]NN[CT][CT]CC 
SPP1 ISRE Within 2kb 2 [AG]NGAAANNGAAACT 
SPP1 NFκB Within 2kb 1 GGG[AG]NN[CT][CT]CC 
SMG1 ISRE Within 2kb 2 [AG]NGAAANNGAAACT 
SMG1 NFκB Within 1kb 1 GGG[AG]NN[CT][CT]CC 
IL24 ISRE Within 1kb 1 [AG]NGAAANNGAAACT 
IL24 NFκB Within 2kb 1 GGG[AG]NN[CT][CT]CC 
EGR1 ISRE Within 2kb 3 [AG]NGAAANNGAAACT 
EGR1 NFκB Within 2kb 0 GGG[AG]NN[CT][CT]CC 
PMEPA1 ISRE Within 2kb 1 [AG]NGAAANNGAAACT 
PMEPA1 NFκB Within 2kb 0 GGG[AG]NN[CT][CT]CC 
Table 4.2: Potential ISRE and NFκB consensus sequences in the promoter region of 7 
IRF-1 downstream target genes. Up two 2 kb upstream of the predicted 
transcription start site was analysed, using the Galaxy online tool, for potential ISRE 
and NFκB DNA binding motifs with up to 3 mismatches. 
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4.4 Discussion 
IRF-1 is a nuclear transcription factor that regulates a wide range of downstream targets 
through binding to defined motifs at promoter sites. IRF-1 can induce target genes 
individually or through association with other cofactors and IRF members, such as IRF-
8, creating transcriptional heterocomplexes that bind and regulate various promoters of 
many genes (Levi et al., 2002). To search for unidentified target genes for IRF-1, we 
overexpressed endogenous IRF-1 rather than stimulating IRF-1, as IRF-1 pathway 
stimulation might stimulate other signalling pathways leading to up-regulation of non-
IRF-1 specific genes. We have developed two isogenic stable cell lines over-expressing 
wild type IRF-1 and W11R IRF-1, using the Flp-In System™ (Invitrogen).  
Host cell lines after FRT integration were tested using Southern blotting to confirm the 
presence and the number of FRT site(s) (Figure 4.4). Six clones: A375 FRT1, A375 
FRT7, A375 FRT8, A375 FRT9, A375 FRT12, and A375 FRT14 have confirmed 
presence of a single FRT site in their genome by the appearance of single band in their 
profile digestion (black arrows, Figure 4.4). It is very important in the creation of 
isogenic stable cell lines to confirm the number of FRT site(s) integrated in the host 
genome, as the possession of more than one site can lead to non-isogenic creation as one 
gene of interest could be inserted at one site and a second gene of interest could be 
inserted at the second site, leading to non-identical expression profiles. 
As FRT site integration is random in the cellular genome, IRF-1 pathway integrity was 
tested after FRT integration to confirm the stability of the IRF-1 pathway. To achieve 
this, the IRF-1 pathway was stimulated using poly (I:C), a synthetic analogue of double-
stranded RNA, to simulate a viral infection through Toll-like receptor 3 (TLR3) and type 
I interferon (Matsumoto and Seya 2008). All three clones A375 FRT7, A375 FRT12, 
and A375 FRT14 showed IRF-1 pathway stability, when compared to wild-type A375 
(Figure 4.5). Thus, FRT integration does not disturb the IRF-1 pathway in A375 FRT7 
A375FRT12, and A375 FRT14. 
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Once FRT host cell lines had been tested for IRF-1 pathway stability, wild-type IRF-1 
and W11R IRF-1 were co-transfected with pOG44 to generate stable cell lines and 
successful clones overexpressed the desired protein when compared to an empty host 
cell line (Figure 4.6.A; lane 1, 3, and 5). Protein expression varied from one FRT clone 
to another due to the fact that FRT integration is random and thus could be affected by 
chromosomal location and chromatin packing.  
To confirm the elimination of DNA binding ability in stable cell lines overexpressing 
W11R mutant, interferon stimulated gene 20kDa (ISG-20) protein level was used as a 
marker. ISG-20 has a unique ISRE sequence at its promoter where IRF-1 can bind and 
initiate transcription once the IRF-1 pathway is induced by interferon type I or II 
(Congora et al., 2000). Only stable cell lines overexpressing wild type IRF-1 managed to 
induce ISG-20 overexpression (Figure 4.6.B, lane 4), where the basal level of ISG-20 
was based on stable cell lines overexpressing W11R mutant, thus mutant IRF-1 (W11R) 
can not directly bind ISRE. Further testing was also achieved using a luciferase reporter 
plasmid and the TLR3 promoter (Figure 4.6.C); excessive luciferase activity was only 
detected in cell lines overexpressing wild type IRF-1, where cell lines overexpressing 
W11R showed basal levels similar to A375 FRT7 (Figure 4.6.C). Thus, the DNA 
binding ability is lost in the W11R mutant. 
From the six comparisons undertaken by microarray data analysis, the majority of 
differentially-expressed loci were found in the first three comparisons, namely conIRF-1 
relative to A375, A375 FRT7 relative to A375, and W11R relative to A375. This 
observation suggests that random integrations of FRT loci are disturbing the genomic 
profile, since the expression profiles of the three constructs (FRT, wild-type IRF-1, and 
W11R IRF-1) differed quite substantially from the control, and thus attention should 
primarily be focussed on comparisons four to six (conIRF-1 relative to A375 FRT7, 
W11R relative to A375 FRT7, and W11R relative to conIRF-1). Within comparisons 
four to six, 645 array features, representing 566 different genes, were significant in one 
or more of the comparisons (Figure 4.8). 
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To identify IRF-1 downstream targets, comparison four (conIRF-1 relative to A375 
FRT7) was used. In comparison 4, there are 221 statistically significant arrays 
containing 89 features that were up-regulated more than 0.5 fold, compared to 45 
features that were down-regulated more than 0.5 fold. However, there are 87 features 
with less than 0.5 fold changes (Figure 4.9). In terms of observed fold change, no 
features exhibited either more than 2 fold up-regulation or 2 fold down-regulation; fold 
changes ranged from 1.7 fold up to 1.6 fold down. 
Among the genes whose expression was changed by overexpressing wild type IRF-1, we 
looked for those whose expression was not changed after overexpressing W11R IRF-1. 
We assumed that the expression observed in the W11R IRF-1 overexpression may result 
from the absence of wild type IRF-1, implying that these non-induced genes in the case 
of W11R but induced in the case of wild type IRF-1 are potentially regulated by IRF-1. 
After analysing the gene lists in comparison 4, we chose to further validate the 
microarray results for 12 potential IRF-1 targets (table 4.1) using qRT-PCR. 
To validate the 12 potential IRF-1 targets chosen from the microarray analysis (table 
4.1), qRT-PCR analysis was performed on all 12 genes using the mRNA obtained from 
cells over expressing IRF-1 (Figure 4.10). Seven genes: IRF2BP2, BNIP3L, SPP1, 
SMG1, IL-24, EGR1, and PMEPA1, showed clear up-regulation at the mRNA level 
when IRF-1 is over expressed, whereas RUNX1 and SH3PXD2A perhaps a less distinct 
increase. In addition, NEDD4L, HIPK2, and SORBS2 showed either no change or 
decrease in mRNA level. It is expected that there is variation between microarray and 
qRT-PCR results, as microarray probes and qRT-PCR primers could have picked two 
different splice variants, thus NEDD4L, HIPK2, and SORBS2 were eliminated from 
further study. 
As mentioned, we have looked at only nine of the many putative genes that are regulated 
by IRF-1. These genes are involved in key processes taking part in different cellular 
functions including apoptosis, the immune response, kinase activity, autophagy, 
cytokine signalling, cell linage differentiation during development, metastasis, tumour 
growth progression, invasion, and adhesion. The regulatory network for IRF-1 
overexpression in melanocytes is illustrated in figure 4.11. 




Figure 4.11: Schematic illustration of the IRF-1 regulatory network in melanocytes. 
Target genes are indicated by oval shapes. Biological function for each target gene is 
indicated, implying the role of IRF-1 in regulating such function. General IRF-1 
stimuli and regulatory pathways are indicated by dashed arrows. 
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Cell congregation and cell-cell interactions of melanocytes are fundamental events in 
cancer metastasis and invasion. To become malignant, cancerous cells overexpress 
metastasis and invasion proteins such as SPP1 and SH3PXD2A. SPP1 expression has 
been reported to be closely correlated with invasion and metastasis of gastric cancer 
(Zhang et al., 2005). In addition, SPP1 has been reported to be up-regulated and 
significantly overexpressed in metastatic melanomas and its expression is the first step 
in melanoma tissue invasion (Zhou et al., 2005). Thus, SPP1 is acquired early in 
melanoma development and progression, and may enhance tumour cell growth in 
invasive melanomas (Zhou et al., 2005). 
SH3PXD2A is a scaffolding protein containing SH3 and PX domains. Seals et al (2005) 
reported that SH3PXD2A is required for podosome formation and function and for the 
protease driven invasion of cancer cells. Podosomes are small, cylindrical adhesive 
structures containing focal contact proteins, and are found in malignant cells. Cells with 
reduced SH3PXD2A expression are poorly invasive through Matrigel; SH3PXD2A 
expression is required in breast cancer and melanoma cells (Courtneidge et al., 2005). In 
addition, Blouw et al (2008) confirmed the role of SH3PXD2A in tumour growth in 
vivo. 
The role of IRF-1 in regulating the expression of SPP1 and SH3PXD2A is unknown; 
however, Fu et al (2005) reported the hyperexpression of IRF-1 and SPP1 in addition to 
many genes when a mesangial cell line were stimulated by lipopolysaccharide, although 
it was not known whether SPP1 overexpression was caused by IRF-1 overexpression or 
lipopolysaccharide stimulation. Here we have proposed a role for IRF-1 in regulating 
both SPP1 and SH3PXD2A, suggesting a new role of IRF-1 in cancer cell metastasis 
and invasion. Further in-silico analysis revealed potential binding motifs for IRF-1 and 
NF-κB in SPP1 regulatory elements (table 4.2) suggesting that SPP1 might respond to 
similar signalling cues. It has been reported by Hijiya et al (1994) that the SPP1 
promoter region might contain a potential IRF-1 binding site, suggesting a binding motif 
for IRF-1.  
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As explained in section 1.4.3.3, IRF-1, as a tumour suppressor gene, plays an important 
role in apoptosis. IRF-1 has been shown to bind directly to the promoter of many pro-
apoptotic genes and thus initiate the process of apoptosis. Among these pro-apoptotic 
genes, we have identified three distinct apoptotic genes, EGR-1, PMEPA1, and IL-24. 
EGR-1 protein is an anti-proliferative signal for certain tumour cells and is required for 
apoptosis induced by stimuli that elevate intracellular Ca
+2
. To initiate such an apoptotic 
response, EGR-1 transactivates the promoter region of p53, leading to up-regulation of 
p53 RNA and protein levels and thus initiating apoptosis (Nair et al., 1997). There is 
little evidence so far for a link between IRF-1 and p53, however, our data proposes a 
cooperation between IRF-1 and p53 through EGR-1 in initiating an apoptotic response 
in melanocytes. 
 
PMEPA1 was originally identified as a highly androgen-induced gene by serial analysis 
of gene expression in androgen treated prostate cancer cells (Xu et al., 2000). Studies on 
PMEPA1 suggested its role in cell growth regulation, inhibition, and apoptosis (Xu et 
al., 2003; Chen et al., 2005). To date, there is no link between IRF-1 and PMEPA1. 
 
IL-24 or melanoma differentiation associated 7 (MDA-7) was originally identified as a 
tumour suppressor by its activity to supresses cancer growth (Jiang et al., 1996) and later 
it has been shown to have cytokine activity. IL-24 has been identified as a ligand for the 
JAK1/STAT signalling pathway (Novakova et al., 2009) and can induce cancer cell 
apoptosis, leading to its potential in cancer gene therapy strategies (Zhu et al., 2012). 
Here we identified PMEPA1, EGR-1 and IL-24 as downstream targets of IRF-1 during 
its apoptotic role. Further in-silico analysis (table 4.2) proposed the direct binding of 
IRF-1 and NF-κB on their regulatory elements through ISRE.  
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The link between IRF-1 and autophagy has been proposed recently. It has been shown 
that interferon-γ inhibits cellular growth of hepatocellular carcinoma by non-apoptotic 
cell death (Li et al., 2012). In addition, interferon-γ induces autophagosome formation, 
where IRF-1 overexpression also induces autophagy in hepatocellular carcinoma (Li et 
al., 2012). A further study proposed a novel role of IRF-1 and nitric oxide in the 
regulation of macrophage autophagy during lipopolysaccharide stimulation (Zhang et 
al., 2012). In addition, IRF-1 has been shown to regulate both immune cell apoptosis 
and autophagy in a murine endotoxemia model (Zhang et al., 2012). BNIP3L has been 
reported to be associated with autophagy (Velde et al., 2000) and it has been shown that 
arsenic trioxide induces autophagic cell death, but not apoptosis, and the induction of 
apoptosis in gliomoa cells is mediated by the mitochondrial cell death protein BNIP3 
and its homologue BNIP3L (Kanzawa et al., 2005). A further role of BNIP3 proteins in 
autophagy, cell death, and mitophagy has been described (Zhang et al., 2009; Youle et 
al., 2011). The mechanism of IRF-1 regulation of autophagy is not fully characterized; 
here we proposed the direct binding of IRF-1 to the regulatory element of BNIP3L to 
facilitate autophagy. 
RUNX1 is a transcription factor that regulates critical processes in many aspects of 
haematopoiesis (Lam et al., 2012). Many haematological diseases, such as 
myelodysplastic syndrome and acute myeloid leukaemia, have been associated with 
mutations in RUNX1 (Lam et al., 2012). To date, there is no link between IRF-1 and 
RUNX1 in the literature apart from the observation that both are mutated in some acute 
myeloid leukaemias. Here we also propose the direct binding of IRF-1 to a RUNX1 
regulatory element, as the in-silico analysis (table 4.2) revealed the potential of 
acquiring an ISRE binding motif.  
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SMG-1 is a gene involved in nonsense mediated mRNA decay as part of the mRNA 
surveillance complex (Yamashita et al., 2001). This involvement is through the 
phosphorylation of specific serine residues in major components of the surveillance 
complex (Yamashita et al., 2001). Thus, SMG-1 has a kinetic biological role. Gehen et 
al (2008) reported the direct phosphorylation of p53 at serine 15 by SMG-1, suggesting 
that SMG-1  is a proximal regulator of DNA damage signalling (Gehen et al., 2008). 
Here we propose a further cooperation between IRF-1 and p53, which might be 
mediated by SMG-1 during the DNA damage response. SMG-1 has been reported to 
regulate other biological roles including DNA repair, telomerase maintenance, 
embryogenesis, and apoptosis (Azzalin et al., 2006 and Cheung et al., 2011). SMG-1 
regulation by IRF-1 has broadened the biological role of IRF-1 to cover many other 
unreported roles of IRF-1. Finally, it is known that IRF-2 is a well-characterized 
repressor of IRF-1 (Harada et al., 1989), where IRF2BP2 is also co-repressor of IRF-2 
(Childs and Goodbourn, 2003), suggesting that activation of IRF2BP2 might be 
controlled by IRF-1. 
To reveal the role of these potential IRF-1 targets in signalling pathways, KEGG 
pathway functional enrichment analysis was undertaken for comparison four. Analysis 
shows 25 KEGG pathways were statistically enriched (appendix). Pathways enriched in 
up-regulated loci include those involved in Toll-like receptor signalling, prion disease, 
bladder cancer, small cell lung cancer, and the p53 signalling pathway; however, 
pathways enriched in down-regulation loci include the vascular endothelial growth 
factor signalling pathway and the mitogen-activated protein kinase signalling pathway. 
This chapter outlined the creation of two isogenic stable cell lines overexpressing either 
wild-type IRF-1 or W11R IRF-1. Both cell lines were created to screen potential IRF-1 
targets using microarray technology. We proposed new biological roles, which can be 
regulated by IRF-1 in melanocytes, including cellular invasion, adhesion, tumour growth 
metastasis, embryogenesis, DNA repair, and telomerase maintenance. In addition, we 
also validated current known biological roles of IRF-1 including apoptosis, autophagy, 
and tumour growth inhibition. 
  








Chapter 5: Developing synthetic reporters to 
screen chemical libraries for novel IRF-1 
modifiers 
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5.1 Chapter abstract 
Luciferase reporter assays have been used to analyse the activity of many transcriptional 
regulator elements. However, luciferase assays involve the transient transfection of a 
luciferase reporter plasmid containing a regulatory element into a chosen host cell line, 
and this can cause difficulties when large chemical libraries need to be screened. Thus, 
this chapter describes the development of a synthetic stable reporter cell line that can be 
used where large scale screening is needed. This developed stable reporter cell line was 
subsequently used to screen a kinase inhibitor library, which has revealed some new 
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5.2 Chapter Introduction 
High throughput screening (HTS) of chemical libraries against biological targets is a key 
requirement in the pharmaceutical industry. High quality screening assay methods are 
needed to translate specific bio-molecular phenomena into observable parameters 
detected using radioactivity, photon absorption or photon emission (Fan and Wood 
2007). By far, the most dominant methodological assay in designing HTS tool is photon 
emission due to its speed, accuracy, sensitivity, and broad adaptability to biological 
targets (Minor, 2006). This chapter will outline the steps used in creating a reporter 
stable cell line that can be used for HTS. In addition, the reporter cell line was used to 
screen a kinase library to identify potential new IRF-1 modifiers. 
5.2.1 Interferon signal transduction 
Interferon signalling involves membrane receptors designed either for class 1 interferon 
(INF-α or β) or class II interferon (INF-γ). Membrane receptors for class I interferon are 
composed of IFNAR1 and IFNAR2 and membrane receptors for class II interferon are 
composed of two pairs of IFNGR1 and IFNAR2 (Figure 5.1). Both types of receptors 
consist of transmembrane protein subunits with an extracellular and an intracellular 
domain.  
When class I receptors are stimulated by interferon-α or -β, the Janus family of protein 
tyrosine kinases (Jak1) and (Tyk2) (located near the intracellular domain of IFNAR1 
and IFNAR2) become activated, followed by site-specific tyrosine phosphorylation of 
STAT1 and STAT2 (Darnell et al., 1994) (Figure 5.1). The resultant phosphorylated 
STAT1 and STAT2, in combination with IRF-9, form a heterotrimeric transcription 
factor complex named as ISGF3. This binds to ISRE consensuses sequences at the 
promoter of an interferon-induced gene to initiate its transcription (Darnell et al., 1994).  
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In addition, the phosphorylated STAT1 also undergoes homo-dimerization to form an 
active transcription factor named interferon-γ activated factor/interferon-α activated 
factor (GAF/AAF) that can bind to GAS consensus sequences (TTCNNNGAA) and 
activate the transcription of IRF-1 and/or other interferon-induced genes (Darnell et al., 
1994) (Figure 5.1). 
In the case of the class II receptor, interferon-γ stimulates the dimerization and 
phosphorylation of IFNGR1 by Jak1 and IFNAR2 by Jak2 (Ihle, 1995) resulting in 
efficient STAT1 activation (Darnell et al, 1994); however, STAT2 can also become 
tyrosine phosphorylated after interferon-γ stimulation to form ISGF3 (not shown in 
Figure 5.1), but at a lower level compared to interferon-α/β stimulation (Takaoka et al., 
2000).  
  




Figure 5.1 Signal transduction pathways and cross talk in the interferon system. 
Interferon signal transduction involves a set of protein called tyrosine kinases 
belonging to the JAK protein family, which are important in phosphorylation process. 
Also, STAT proteins play roles in as signal transducers and as transcription factors by 
initiating the transcription of interferon-inducible genes. 
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5.2.2 Bioluminescence  
Bioluminescence is a form of chemiluminescence, which can be found in many living 
organisms such as jellyfish, fireflies, and sea pansies. It is an enzyme-catalysed process, 
where the enzymes are luciferases and the substrates are luciferins. In the firefly 
(Photinus pyralis), luciferase is a 61kDa monomeric enzyme, which does not require 
any post-translational modification for activity (De Wet et al., 1987). The mechanism 
involves combining luciferins with ATP to form luciferyl–AMP (Figure 5.2), which then 
reacts with oxygen to create another enzyme-bound intermediate in a high-energy state 
known as oxyluciferin. This intermediate, oxyluciferin, then emits energy in the form of 
yellow-green light with a spectral maximum of 560nm (Fan and Wood 2007). 
A different luciferase system can be found in sea pansy (Renilla reniformis) which is 
again a monomeric enzyme of 36kDa protein size that catalyses the oxidation of 
coelenterazine to yield coelenteramide and blue light with a spectral maximum of 
480nm (Lorenz et al., 1991). Since both systems have different spectra at which light is 
emitted, the Renilla system is often used to co-report in conjunction with the firefly 
system to check for experimental and reading errors. 
 
 
Figure 5.2: The firefly luciferase system. Briefly, luciferase catalyses the interation of 
luciferins with ATP to form luciferyl-AMP which then reacts with oxygen to create 
oxyluciferin, which then loses the excess energy in the form of light. 
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Light intensity from this type of reaction is used to represent and correlate biological 
parameters. This is achieved by holding two of the three reaction components (ATP, 
enzyme, and substrate) constant where the variable component can be correlated with 
the process of interest. Depending on the bioluminescence assay, the variable competent 
may be ATP, enzyme, or substrate. In this chapter, we develop a genetic reporter stable 
cell line that has luciferase enzyme concentration as a variable where, all other 
components are kept constant. 
 
Many applications used for HTS are based on genetic reporters, as the drug discovery 
process is associated with cellular events and genetic regulation. By cloning a regulatory 
element of choice (e.g. known promoter, portions of promoter, or known response and 
enhancer elements) upstream of a gene encoding luciferase, the cellular events resulting 
from a cloned element can be easily detected by a luminescent signal. 
 
As genetic reporters involve the transfection of a plasmid carrying the luciferase gene 
regulated by a chosen element, it is necessary to incorporate an internal control to 
minimise false hits resulting from variations in cell number or transfection technique, to 
achieve good data quality. An internal control could be a second luciferase system such 
as the Renilla luciferase co-transfected with the firefly luciferase system. However, 
introducing both systems requires a standard two plasmid approach where the first 
plasmid contains the chosen regulatory element and firefly luciferase gene and the 
second plasmid contains a constitutive promoter (SV40) controlling the Renilla 
luciferase gene.  
 
A dual luciferase reagent can then be used to measure signals of firefly and Renilla 
luciferases in the same sample. Readings from firefly luciferase could be normalised to 
the Renilla signal, to eliminate cell number and transfection errors. In most cases of 
HTS, there is no need for a transfection control as screening of chemical libraries is done 
using stable reporter cell lines where plasmid transfection is eliminated, thus one 
luciferase system, such as firefly, should be sufficient. 
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Previous studies in our lab have revealed that one of the best choices to analyse IRF-1 
transcriptional activity using a luciferase assay is to use the Toll-like receptor 3 
regulatory element. Thus, the IRF-1 genetic reporter stable cell line contains the toll-like 
receptor 3 regulatory element. This cell line was created, using the Flp-In System™ 
(chapter 4) and recombineering technology (chapter 3), by K. Belz under my direct 
supervision. A kinase inhibitor toolbox (Tocriscreen
TM
) containing 80 different kinase 
inhibitors was screened using the IRF-1 transcription reporter cell line to identify 
potential new IRF-1 modifiers. 
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5.3 Methods and results 
5.3.1 Creating IRF-1 reporter cell lines using the Flp-In™ 
System and recombineering technology 
A pGL3 luciferase reporter vector (Promega) containing 588bp of the human TLR3 
regulatory element (pGL3-hTLR3) was kindly given by Dr. Michael Rehli (University 
of Regensburg, Germany). The pGL3-hTLR3 was used as a PCR template to amplify a 
2.3kb fragment containing the hTLR3 regulatory element and the firefly luciferase gene 
flanked by attB1 and attB2 Gateway
®











Yellow: Gateway® recombineering sequence 
Green: Shine-Dalgarno sequence 
Blue: Kozak sequence 
Pink: Start 
Red: Stop 
Grey: PCR primers 
PCR product was then cloned into pDONR™221 (Invitrogen) using a BP reaction and 
successful clones were profile digested and sequenced to validate the successful cloning 
of PCR product. Once confirmed, an LR reaction between pDONR™221 and 
pEF5/FRT/V5-DEST (chapter 3) was performed to clone the TLR3-luciferase cassette 
into the FRT vector and clones were profile digested and sequenced to confirm fragment 
integration. The IRF-1 reporter cell lines were created by co-transfecting pOG44 and the 
FRT expression vector into A375-FRT7 (chapter 3) using Attractene, after which, cells 
were challenged with hygromycin for two weeks. Successful clones were tested for their 
luciferase activity; however, luciferase activity was undetectable (data not shown).  
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To create reporter cell lines using recombineering, the pGL3-hTLR3 reporter vector 
needed to have a selectable marker useable in eukaryotes. Thus, the 
kanamycin/neomycin selectable marker needed to be cloned into pGL3-hTLR3. PCR 
primers (dark grey) with homologous arms (light grey) were designed to amplify 
kanamycin/neomycin with PGK and EM7 regulatory elements from pLox-STOP-Lox-β-
catenin (Figure 3.11, chapter 3) and recombine the product into pGL3-hTLR3 reporter 
vector at an exact location just after the luciferase polyA signal. Successful 













pLox-STOP-Lox-β-catenin was linearized by ZraI followed by DpnI digestion to 
minimise false colony formation post PCR reaction. Digested pLox-STOP-Lox-β-
catenin (PCR template) was diluted and used in the PCR reaction. Each PCR cycle was 
performed at 95°C for 1min (denaturation step) followed by 64°C for 30sec (annealing 
step) followed by 72°C for 3min (elongation step) for 30 cycles. PCR product was 
purified using PCR clean-up kit (Qiagen) and run on 1% agarose gel to check the size. 
Once the PCR product was confirmed, a combination of 20ng of pGL3-hTLR3 and the 
cleaned PCR product (100ng, 150ng, and 200ng) were electroporated in heat-induced 
and -un-induced (negative control) SW102 for recombination.  
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Following recombination, cells were allowed to recover for 1hr at 32°C without 
antibiotic, then fresh LB containing ampicillin and kanamycin was added and cells were 
grown overnight at 32°C. Tubes with positive growth were taken for miniprep of DNA 
(Qiagen), which was digested with BamHI and 0.1ng of plasmid DNA was re-
electroporated into fresh SW102, to minimise the introduction of multiple copy 
numbers. The resulting vector pGL3-hTLR3-Luci was sequenced verified to confirm 
successful recombination.  
A375-FRT7 cells were transfected with pGL3-hTLR3-luci using Attractene and 24hr 
post transfection cells were challenged with geneticin (G418) for two weeks, or until 
complete death of a no DNA control. Single clones where picked and named as A375-
FRT7-Luci-clone 4; mixed clones were named as A375-FRT7-Luci-MIX. To test picked 
clones for luciferase activity, A375-FRT7-Luci-clone 4 and A375-FRT7-Luci-MIX were 
seeded on 6-well tissue culture plates. The following day, cells were treated with a 
titration of INF-γ for 4hr and 24hr. IRF-1 transcriptional activity and protein level were 
measured by luciferase assay and immunoblotting (Figure 5.3) and (Figure 5.4). Results 
show both clones A375 FRT7-Luci-MIX and A375 FRT7-Luci-clone 4 have acquired 
luciferase activity; however, A375-FRT7-Luci-MIX seems to have a better luciferase 
signal than A375-FRT7-Luci-clone 4. In addition, IRF-1 protein levels correlate with 
these findings as a result of INF-γ treatment. Thus, A375 FRT7-Luci-MIX was chosen 
clone for HTS. 
  







Figure 5.3: IRF-1 transcriptional activity in A375 FRT7-Luci-MIX and A375 FRT7-
Luci-clone 4. (A) Reporter cell lines were treated with a titration of INF-γ for 4hr 
followed by measurement of IRF-1 transcriptional activity using luciferase. (B) IRF-1 
protein levels, post INF-γ treatment, were detected using immunoblotting. 
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Figure 5.4: IRF-1 transcriptional activity in A375 FRT7-Luci-MIX and A375 FRT7-
Luci-clone 4. (A) Reporter cell lines were treated with a titration of INF-γ for 24hr 
followed by measurement of IRF-1 transcriptional activity using luciferase. (B) IRF-1 
protein levels, post INF-γ treatment, were detected using immunoblotting. 
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5.3.2 High throughput screening of Tocriscreen
TM
 kinase 
inhibitor library using A375 FRT7-Luci-MIX 
A375 FRT-Luci-MIX cells were seeded onto 96-well plates 18hr prior to treatment. The 
following day, cells were treated with eight different concentrations (50, 25, 12.5, 6.25, 
3.1, 0.8, and 0.4µM) of each kinase inhibitor for 24hr, after which cells were washed 
three times with PBS and luciferase activity was measured. 
Results revealed 40 different kinase inhibitors caused a decrease in IRF-1 transcriptional 
activity whereas eight kinase inhibitors caused an increase in its activity; the remaining 
32 inhibitors showed no significant change in IRF-1 transcriptional activity (data not 
shown). The library was decoded and six kinase inhibitors were picked and short-listed 
for further analysis (table 5.1). 
 
Code Target Description Effect 
H3 EGFR Orally active, selective EGFR inhibitor Repress 
 
C3 VEGFR Potent inhibitor of VEGFR tyrosine kinase 
Repress 
 
E4 EGFR Highly selective EGFR kinase inhibitor 
Repress 
 
E9 VEGFR Potent, selective inhibitor of VEGFR2 
Repress 
 
F6 FLT3 Potent FLT3 inhibitor Stimulate 
 
D11 CK2 




Table 5.1: Six kinase inhibitors were short-listed for further analysis. A375 FRT-Luci-
MIX cells were seeded onto 96-well plates. Cells were treated with eight different 
concentrations for each kinase inhibitor for 24hr. The following day cells were 
washed three times with PBS and luciferase activity was measured. Four (H3, C3, E4, 
and E9) showed a decrease in IRF-1 transcriptional activity by luciferase reporter, 
and two (F6 and D11) showed an increase. 
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The six short-listed kinase inhibitors were subjected to a second round of screening to 
confirm the reproducibility of the results. A375 FRT7-Luci-MIX cells were seeded onto 
96-well plates 18hr prior to treatment. The following day cells were treated with seven 
different concentrations (50, 25, 12.5, 6.25, 3.1, 0.8, and 0.4µM) for each kinase 
inhibitor for 24hr. Following treatment, cells were washed three times with PBS and 
luciferase activity was measured. Results revealed that C3 and F6 showed reproducible 
results similar to the first rounds, whereas E9 and D11 results were not reproducible and 
thus were eliminated from further study. However, other kinase inhibitors, such as E4, 
and H3, show reproducible effects but only at high concentrations i,e 25 and 50µM (data 
not shown). 
To validate outcomes from round II and to identify minimum inhibitory concentrations 
and minimum inhibitory times required for each of the six short-listed kinase inhibitors, 
a third screening round was done in which A375 FRT7-Luci-MIX cells were treated 
with 4 different concentrations (50, 25, 12.5, and 6.25µM) for each kinase inhibitor for 
2, 4, 8, 24, and 48hr. Following treatment cells were washed with PBS 3 times and 
luciferase activity was measured. The third round of screening (data not shown) revealed 
that results for some kinase inhibitors (D11 and E9) were not reproducible (compared 
with round II) and thus they were eliminated from further studies. However, some kinase 
inhibitors (H3 and E4) showed reproducible results but their effect was only noticeable 
at high concentrations (25 and 50µM) and after long treatment times (24hr or 48hr). F6 
and C3 showed a reproducible pattern even at low concentrations (data not shown). 
To test whether these kinase inhibitors have an effect on IRF-1 protein levels, A375 
FRT7-Luci-MIX cells were seeded onto 6-well tissue culture plates 18hr pre treatment; 
the following day, cells were treated with three different concentrations (5, 25, and 
50µM) for each kinase inhibitor (C3, F6, H3, and D11) for 24hr. Following treatment, 
protein lysate was subjected to immunoblotting and luciferase activity measurement 
(Figure 5.5). Results show that the effects of C3 are reproducible even at low dosage 
(5µM) where F6 still stimulates IRF-1 transcriptional activity and H3 has effects at high 
dosage only (50µM). There was no change in IRF-1 protein level as a result of kinase 
inhibition. 







Figure 5.5: IRF-1 transcriptional activity in A375 FRT7-Luci-MIX. (A) Reporter cell 
line was treated with 5, 25, and 50µM of C3, F6, H3, or D11 followed by measuring 
IRF-1 transcriptional activity using luciferase. (B) IRF-1 protein levels were detected 
using immunoblotting after kinase inhibitor treatment. 
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To test whether these kinase inhibitors have an effect on IRF-1 transcriptional activity 
after induction using INF-γ, A375 FRT7-Luci-MIX cells were seeded onto 6-well tissue 
culture plates 18hr pre treatment. The following day cells were treated with 2units/ml 
INF-γ and either 25µM or 50µM of C3, E9, F6, or H3 for 24hr. Following treatment, 
protein lysate was subjected to immunoblotting and luciferase activity measurement 
(Figure 5.6). Results shows that C3 overcame the induction of IRF-1 by interferon-γ and 
thus confirmed the reproducibility, even at a low dosage (25µM) where F6 is further 
stimulating IRF-1 transcriptional activity. There was no change in IRF-1 transcriptional 
activity after E9 kinase inhibitor treatment, and the H3 effect is only seen at high dosage 
(50µM). IRF-1 protein level correlates with interferon-γ activity. 
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Figure 5.6: IRF-1 transcriptional activity in A375 FRT7-Luci-MIX. (A) Cell line was 
treated with 2units/ml of INF-γ and 25µM or 50µM of C3, E9, F6 or H3, followed by 
measuring IRF-1 transcriptional activity using luciferase. (B) IRF-1 protein levels 
were detected using immunoblotting after kinase inhibitor treatment. 
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5.3.3 The effect of VEGFR tyrosine kinase inhibitors on IRF-1 
downstream targets  
To test the effect VEGFR (C3) inhibitor on IRF-1 downstream target genes, A375 FRT7 
conIRF-1 was seeded onto 6-well tissue culture plates 18hr prior to treatment. The 
following day cells were treated with 25µM or 50µM of C3 for 12hr. After treatment, 
























Actin house keeping gene +C3 Kinase inhibitor In response to actin
RPS18 house keeping gene +C3 Kinase inhibitor In response to RPS18




Figure 5.7: Quantitative real-time PCR analysis of 7 IRF-1 target genes. (A) First 
round of screening where 3 target genes SPP1, SMG1, and EGR1 show clear 20%-
40% down regulation in response to actin house keeping gene once A375 FRT7 
conIRF-1 treated by VEGFR kinase inhibitor. (B) Second round of screening where 4 
target genes RUNX1, IRF2BP2, BNIP3L, and SH3PXD2A show clear 45%-90% down 
regulation in response to actin or RPS18 house keeping gene once A375 FRT7 
conIRF-1 treated by VEGFR kinase inhibitor. IRF-1 and TLR3 positive control show 





















Actin house keeping control +C3 Kinase inhibitor In response to actin
RPS18 house keeping gene +C3 Kinase inhibitor In response to RPS18
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5.4 Discussion 
We have successfully created a stable reporter cell line that can be used for high 
throughput screening for IRF-1 modifiers. We attempted to create a reporter cell line 
using Flp-In™ System as described previously, however, we found that luciferase 
activity was un-detectable, suggesting that the Flp-In™ System is only practicable for 
protein coding sequences and not regulatory sequences. Therefore we attempted a 
different method using traditional cloning. Both clones (A375 FRT7-Luci-MIX and 
A375 FRT7-Luci-clone 4) showed luciferase activity when the reporter cell lines were 
treated with interferon-γ (Figure 5.3 and 5.4); such stimulation of IRF-1 is transduced 
via IFNAR2 and IFNGR1 receptors through the GAF/AAF complex (Figure 5.2). The 
IRF-1 protein level is over expressed, in correlation with interferon-γ dosage, when 
compared to non-treated cells (Figure 5.3.B and 5.4.B). In addition, TLR3 stimulation 
depends on similar IRF elements, which constitutively bound IRF-2 and recruited IRF-1 
after stimulation (Heinz et al., 2003). Thus, the use of TLR3 regulatory elements can 
report the activity of IRF-1.  
The luciferase cassette was integrated randomly in the genome of A375 FRT7, resulting 
in different clones with different luciferase activity; the mixed clone showed better 
luciferase activity when compared to clone 4 and thus the mixed clone was chosen. Five 
units/ml of interferon-γ is sufficient to induce IRF-1, whereas more than this causes 
receptor saturation with undetectable differences (Figure 5.3.A and 5.4.A). Treatment 
time varied between 4–24hr, where 2units/ml of interferon-γ for 16hr was the optimum 
(data not shown). 
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The first round of screening revealed that 40 different kinase inhibitors caused a 
decrease in IRF-1 transcriptional activity whereas 8 kinase inhibitors caused an increase 
in its activity. However, the remaining 32 inhibitors showed no significant change in 
IRF-1 transcriptional activity (data not shown). Among those that showed either a 
stimulation or repression, we picked six kinase inhibitors that showed an interesting 
pattern after the first round of screening (table 5.1). We also noticed that, within the 
picked group, more than one kinase inhibitor hit the same target (H3 and E4 target 
EGFR) where (C3 and E9 target VEGFR). EGFR, VEGFR, and FLT3 are all members 
of a large receptor family named receptor tyrosine kinases (RTKs), suggesting a role of 
RTK in IRF-1 signalling.  
The RTK family comprises cell-surface receptors that regulate proliferation, 
differentiation, cell survival, metabolism, cell migration, and the cell cycle (Blume-
Jensen and Hunter, 2001). Humans have 58 known RTKs, falling into 20 different 
families, including FLT3, EGFR and VEGFR. RTKs have a wide role in human 
diseases, where RTK pathway disturbances by genetic mutation have been linked to 
cancer, diabetes, inflammation, severe bone disorders, arteriosclerosis, and angiogenesis 
(Lemmon and Schlessinger, 2010). Angiogenesis is an important process in tumour 
development (Risau, 1997) as the development of new blood vessels from pre-existing 
vasculature is essential for supplying oxygen and nutrients for the growing tumour 
(Yancopoulos et al., 2000). VEGF is a key player in angiogenesis as it stimulates 
proliferation and migration in endothelial cells (Ferrara et al., 2002). 
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The mechanism of action of kinase inhibitors used in this study has been revealed; 
kinase inhibitors used here do not influence the IRF-1 protein levels (Figure 5.5) thus, 
all findings were based on reduction in IRF-1 transcriptional activity and not reduction 
in IRF-1 protein levels. As a result, these kinase inhibitors influence IRF-1 
transcriptional activity. In addition, we also revealed that these kinase inhibitors could 
reduce (C3) or stimulate (F6) interferon-γ stimulated IRF-1 transcriptional activity 
(Figure 5.6). Thus, we propose that these kinase inhibitors target proteins that cooperate 
and/or play a role in IRF-1 transcriptional activity. To further confirm this hypothesis, 
we investigated the effect of these kinase inhibitors on other IRF-1 downstream target 
genes identified in chapter four. We chose the C3 kinase inhibitor as it showed 
reproducible results throughout all screening rounds, and shows its reduction effect at 
very low concentrations (0.4μM).  
We confirmed the reduction in the mRNA levels of IRF-1 downstream targets following 
C3 treatment (Figure 5.7) and thus confirmed C3 as a modifier that disturbs IRF-1 
transcriptional activity, leading to the reduction in the transcription of IRF-1 
downstream target genes. The kinase inhibitor C3, at the concentration used, targets 
VEGFR and PDGFR tyrosine kinases, where one or both seem to play a role in 
regulating IRF-1 transcriptional activity in melanocytes.  
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C3 inhibitor targets both PDGFR and VEGFR tyrosine kinases, however it was 
important to dissect the pathway to identify the exact IRF-1 modifiers, therefore new, 
potent and selective inhibitors specifically targeting PDGFR, VEGFR, EGFR or FLT3 
were obtained (Merck) and a further round of screening performed (data not shown). 
Results of this revealed that IRF-1 transcriptional activity is reduced when treated with 
PDGFR and EGFR inhibitor but not with VEGFR inhibitor, whereas IRF-1 
transcriptional activity was increased when treated with FLT3 inhibitor. However, 
immunoblotting revealed that IRF-1 protein levels were reduced as a result treatment 
with PDGFR, VEGFR, and EGFR kinase inhibitors. Thus, the study using the Merck 
inhibitors was discontinued, as they influence IRF-1 protein levels and not its 
transcriptional activity. 
There is no evidence in the literature for a link between IRF-1 and RTK; however, it has 
been reported that IRF-1 as a transcription factor induces EGFR promoter activity up to 
200-fold, compared to a 3–10-fold induction by other regulators (Rubinstein et al., 
1998). Thus, IRF-1 has been identified as a major regulator of EGFR gene expression. In 
addition, IRF-1 has been found to inhibit endothelial cell angiogenesis, inhibit tube 
formation, and reduce the expression of angiogenesis proteins following VEGF 
stimulation (Lee et al., 2008). As a result, IRF-1 has proven to have an anti-angiogenic 
role, which may have therapeutic value for cancer and angiogenesis-associated 
disorders. 
Within the RTK family, EGFR, PDGFR, and VEGFR share a common regulatory 
mechanism involving receptor dimerization and activation of tyrosine kinase, as well as 
creation of docking sites for signal transduction (Olsson et al., 2006). RTK signalling is 
thought to be a complicated and interlinked network, as some RTKs, such as EGFR, 
have multiple (5–12) auto-phosphorylation sites that could each recruit different SH2 
domain-containing proteins (Lemmon and Schlessinger, 2010); in addition, a given 
adaptor or a scaffold protein can interact with multiple signalling molecules 
(Schlessinger, 2000) suggesting that RTK signalling is highly interconnected, forming a 
complex and dynamic signalling network.  
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Stimulation of EGFR can initiate the transcription of downstream target genes by the 
formation of the STAT1 and STAT3 transcription complex (Lemmon and Schlessinger, 
2010); however, it has been reported by Anderson et al (2008) that stimulation of EGFR 
can induce IRF-1 expression in human cancer cells in which signalling cascades of other 
members of the TRK family, such as VEGFR, could be also present.  
 
Figure 5.8: Schematic illustration of IRF-1 modifier in melanocytes. C3 has been 
identified as an IRF-1 modifier that regulates IRF-1 transcriptional activity by 
inhibiting PDGFR and/or VEGFR. As a result, IRF-1 downstream targets are reduced 
or inhibited.  
We have proposed a model (Figure 5.8) where C3 as an IRF-1 modifier can regulate 
IRF-1 transcriptional activity. This regulation is mediated by inhibiting PDGFR and/or 
VEGFR tyrosine kinase. As a result, IRF-1 downstream targets including TLR3, SPP1, 
SMG1, RUNX1, IRF2BP2, and BNIP3L are reduced at their mRNA levels, whereas 
SH3PXD2A and EGR1 are inhibited at their mRNA levels. It is still unknown exactly 
how PDGFR and/or VEGFR inhibition by C3 influences IRF-1 transcriptional activity 
and, further testing will be required to reveal the regulatory mechanism. Meanwhile, the 
A375 FRT-Luci-MIX has been proven to be an excellent synthetic reporter tool for high 
throughput screening for identifying new IRF-1 modifiers. 
  








Chapter 6: Synthetic cassette to study effects of a 
novel oncoprotein on IRF-1 signalling: 
Identification of AGR-2 as a novel inhibitor of 
IRF-1 protein stability 
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6.1 Chapter abstract 
To further validate the synthetic Flp-In™ cassette, we decided to test the system using a 
novel oncoprotein model. We have developed a stable cell line that overexpresses an 
oncoprotein named anterior gradient-2 (AGR-2). This novel AGR-2 model was used to 
test the effect of such a model on a tumour suppressor (IRF-1) activity. Results show 
that both poly (I:C) and AGR-2 suppress p53 and IRF-1 whereas interferon-γ overcame 
the suppression, as interferon-γ is p53-independent. We also identified AGR-2 as a 
cellular survival element. In conclusion, the Flp-In™ cassette has been validated and it 
can be used as a tool for cancer studies. 
 
 
Chemical genetic manipulation of IRF-1 using synthetic biology  
Flp-In™ System validation by determining the  effects of novel 
oncoprotein on IRF-1 signaling 
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6.2 Chapter Introduction 
Intracellular organelles play an important role in tumorigenesis and cancer progression. 
One important intracellular organelle in this regard is endoplasmic reticulum (ER) 
(Moenner et al., 2007). ER is an organelle in eukaryotic cells that forms an interacting 
network of tubules and vesicles where protein and lipid synthesis, regulation of calcium, 
carbohydrate metabolism, and drug detoxification take place (Chevet et al., 2001). To 
achieve and maintain such functions, ER must coordinate the actions of protein 
translocation, protein folding, protein export, protein degradation and ER stress 
signalling (Chevet et al., manuscript in preparation). Some of the proteins controlling 
ER functions have been shown to acquire a role in cancer development (Moenner et al., 
2007). The same observation has been noted for components of oxidative protein folding 
which includes the protein disulphide isomerase (PDI) family (Chevet et al., manuscript 
in preparation and Benham et al., 2011). The human PDI protein family has 20 members 
and is characterized by the presence of thioredoxin motifs CXXC. AGR-2 belongs to the 
PDI family. In this chapter, a stable cell line overexpressing human AGR-2 is developed 
in which the effect of its overexpression on the IRF-1 tumour suppressor is studied.  
6.2.1 The AGR gene family 
The anterior gradient (AGR) gene family is composed of three members named AGR-1, 
AGR-2, and AGR-3, where AGR-2 is the most studied and understood. The AGR family 
was first identified in Xenopus laevis and named XAG-1, XAG-2, and XAG-3. XAG-1 
and XGA-2 have a specific expression pattern in the cement gland, and XAG-2 specifies 
the fate of the dorso-anterior ectoderm and induces the development of the forebrain 
(Chevet et al., manuscript in preparation). In addition, XAG-2 acts as signalling 
molecule inducing cement gland differentiation. It has been reported that, during early 
development, XAG-1 and XAG-2 are expressed in a gradient (hence the name) within 
ectoderm-derived organs such as the cement gland, a mucus secreting gland located at 
the anterior of the frog head (Aberger et al., 1998).  
167 | P a g e  
 
Anterior gradient proteins have subsequently been identified in zebrafish, pufferfish, 
Atlantic salmon, human and mouse (Shih et al., 2007). In mouse embryos, mAGR-2 
(XAG-2 homologue) is highly expressed at the mRNA level in gut: mainly stomach, 
intestines, and colon (Komiya et al., 1999). Using proteomic analysis of multiple human 
breast tumour-derived cell lines, AGR-3 was first identified in humans as a unique 
protein named BCMP11, later named AGR-3. AGR-3 has no known function but its 
expression correlates with oestrogen receptor in human breast cancer (Adam et al., 
2002). AGR-3 and AGR-2 show 71% sequence identity and both are located in the same 
genomic segment (Chevet et al., manuscript in preparation). However, AGR-2 has the 
more critical role in carcinogenesis, as AGR-3 has not been identified in many human 
cancers (Chevet et al., manuscript in preparation). The third and final group member is 
AGR-1, identified using its similarity to classic thioredoxin fold proteins containing the 
CXXC motifs (Alanen et al., 2003). AGR-1 functions in the formation of disulfides with 
client proteins in the ER (Jessop et al., 2009), it has not, however, been identified in 
human cancer and thus its role in tumorigenesis is still unknown (Chevet et al., 
manuscript in preparation). 
6.2.2 The AGR2 member of the AGR family 
In normal cells, AGR-2 appears to be expressed in mucus secreting cells located in 
organs derived mainly from endoderm; these cells ensure tissue homeostasis and 
integrity. In addition, AGR-2 has been reported to be stimulated by oestrogen and found 
to be up-regulated in response to oestradiol in epithelium and stroma of normal human 
breast tissue (Thompson et al., 1997 and Wilson et al., 2006). In addition to AGR-2 
stimulation by oestrogen, other groups have reported direct binding of transcription 
factors including forkhead fox (FOXA1 and FOXA2), hepatic nuclear factor 1 (HNF1), 
ZNF217, and NF-κB, and SOX9 to the AGR-2 regulatory element. Most of these 
transcription factors have been implicated in maintaining goblet cell function (Zheng et 
al., 2005 and Krig et al., 2007). 
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In terms of ligand and receptors, AGR-2 has been reportedly induced following 
treatment with tunicamycin, an inhibitor of N-linked glycosylation and an inducer of ER 
stress (Zweitzig et al., 2007) through the activation of ATF6 and IRE1 arms of the 
unfolded protein response (UPR) (Higa et al., 2011).  
In addition to tunicamycin, AGR-2 has been reportedly induced by androgen, where this 
induction is time and dosage dependent and requires the presence of androgen receptor 
(Zhang et al., 2005). 
The biological role of AGR-2 is unknown; however, possible functions may be linked to 
AGR-2 as a result of its similarity with XAG-1 and XAG-2, proposing an involvement 
in the proliferation of mammalian tissue. In addition, Liu et al (2005) reported that 
AGR-2 could mediate metastasis in animal models and this proposal was validated when 
Dumartin et al (2011) showed that AGR-2 is a cell surface antigen, promoting tumour 
cell dissemination through the activation of cathepsins B and D. 
6.2.3 AGR-2 and cancer 
To investigate the role of AGR-2 in cancer, assays that involve overexpression and/or 
suppression of AGR-2 have been employed. Results showed that AGR-2 exhibits the 
basic features of a pro-oncogenic activity. AGR-2 can enhance cancer cell survival 
rather than inhibit cell growth (Hrstka et al., 2010). Subsequently, AGR-2 silencing was 
shown to inhibit proliferation, invasion and survival in vitro in pancreatic 
(Ramachandran et al., 2008) and breast cancer cell lines (Vanderlaag et al., 2010). Also, 
AGR-2 has been described by Wang et al (2008) as an oncogene, supporting a role in 
cellular transformation and adenocarcinoma growth.  
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Tamoxifen is an anti-oestrogen used to treat human breast cancers that are mainly 
estrogen receptor positive (ER+); however, acquired resistance to Tamoxifen in 
cancerous cells is a rising problem in breast cancer management. It has been suggested 
that some genes that might contribute to Tamoxifen resistance may act as agonists of 
Tamoxifen, thus minimizing its activity and functionality. From a pharmaceutical point 
of view, identifying oestrogen-responsive genes that are induced by Tamoxifen have 
been a key aim in resolving the puzzle of Tamoxifen resistance in breast cancer.  
Reasons for suggesting that AGR-2 is one of the genes that mediate Tamoxifen 
resistance in breast cancer, include observations in cancer patients treated with the 
oestrogen suppressor “Letrazole”. The AGR-2 gene was one of the main suppressed 
genes in biopsies from patients that respond well to the drug, suggesting that resistance 
to anti-oestrogen might be due to failure to suppress AGR-2.  
In addition, AGR-2 was second in the list of genes induced by Tamoxifen in a 
proteomics screen. Further investigation using chromatin immunoprecipitation revealed 
that this induction is a result of direct activation of ERα, which is bound to the AGR-2 
promoter in the presence of Tamoxifen. Luciferase assays using an AGR-2 regulatory 
element confirmed the induction of AGR-2 when cells were treated with Tamoxifen. 
Understanding the molecular basis behind Tamoxifen selectivity in inducing AGR-2, 
while acting as an anti-oestrogen for the other oestrogen-responsive genes, might 
identify novel drug targets. 
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6.2.4 AGR2 and p53 tumour suppressor activity 
Previous work in our lab has studied the relation between AGR-2 and p53. It is known 
that wild-type p53 is maintained in 30–80% of Barrett’s metaplasia; however, we were 
interested in whether or not p53 function was being attenuated via an alternative 
mechanism. Studies showed AGR-2 is up-regulated in Barrett’s metaplasia compared to 
normal oesophageal tissue, suggesting a role in oesophageal cancer progression. We also 
found that AGR-2 could function similarly to a mutant oncogenic p53 allele after 
noticing a similar pattern in enhancing colony formation when compared to a p53 
mutant (HIS175 allele). In addition, the p53 transcriptional level was reduced when co-
transfected with AGR-2, suggesting that AGR-2 might have a kinase inhibitory role, 
especially on Ser15 and Ser392 phosphorylation.  
To further investigate this model linking AGR-2 and another tumour suppressor (IRF-1), 
and to validate the Flp-In™ cassette, we decided to create a stable cell line that 
overexpresses wild-type AGR-2 using the Flp-In™ System. This model will help to 
validate the Flp-In™ cassette and to facilitate whether AGR-2 can also attenuate other 
tumour suppressors such as IRF-1. 
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6.3 Methods and results 
6.3.1 Creating a stable A375 Flp-In™ host cell line 
overexpressing AGR-2: AGR-2 attenuates p53 in human 
melanoma 
A stable cell line overexpressing human AGR-2 was created using the Flp-In™ System 
as described in chapter four. The pDONR221 carrying human AGR-2 cDNA was a kind 
gift from Dr. Euan Murray; cell lines were made by Asia Ansari, under my direct 
supervision, using the A375 FRT7 clone. 
Once created, the stable cell line was tested for AGR-2 overexpression (data not shown). 
Once this was confirmed, both cell lines (A375 FRT and A375 AGR-2) were seeded 
onto 6cm tissue plates and exposed to an increasing dosage of UV radiation: 0, 1, 2, 5, 
10, 20, and 40J/m
2
. After treatment, cells were allowed to recover for either 4 or 24hr. 
Following recovery, cell lysate was subjected to immunoblotting (Figure 6.1). 
Results showed that p53 protein level increased in response to UV treatment in both cell 
lines (A375 FRT and A375 AGR-2); however, p53 level is attenuated as a result of 
overexpressing AGR-2. This attenuation of p53 protein level is more noticeable after 
24hr recovery compared to 4hr recovery (Figure 6.1.A and B-top panel); p21 protein 
levels correspond to p53 protein levels in both cell lines whereas a greater reduction in 
p21 level is noticeable in the cell line overexpressing AGR-2 after 24hr recovery (Figure 
6.1.A and B-second top panel). Both AGR-2 and β-actin protein levels confirm 
overexpression of AGR-2 in A375 AGR-2 compared to the empty vector control when 
an equal amount of protein is loaded in each well. 
  






Figure 6.1: The effect of UV on p53 in the presence of AGR-2. A375 FRT and A375 
AGR-2 were seeded on 6cm culture plates and, 24hr later, cells were subjected to an 
increased dosage of UV (0, 1, 2, 5, 10, 20, and 40J/m2) followed by either 4 or 24hr 
recovery. After harvesting, cells were lysed and subjected to immunoblotting. p53, 
p21, AGR-2, and β-Actin were detected by their respective antibodies.  
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6.3.2 AGR-2 attenuates IRF-1 and p53 basal levels in human 
melanoma 
To test the effect of AGR-2 overexpression on p53 and IRF-1 basal levels, A375 FRT 
and A375 AGR-2 were seeded onto 6cm tissue plates. The following day, cell lysate was 
subjected to immunoblotting (Figure 6.2A). 
To test the effect of AGR-2 overexpression on IRF-1 induced by poly (I:C). A375 FRT 
and A375 AGR-2 were seeded onto 6cm tissue plates and treated with a fixed dosage of 
20µg/ml of poly (I:C) for 4hr (Figure 6.2.B.Left) or a time course of 1, 2, 4, 6, and 24hr 
(Figure 6.2.B.Right). Following treatment, cell lysate was subjected to immunoblotting 
(Figure 6.2.B). 
To test the effect of AGR-2 overexpression on interferon-γ induced IRF-1, A375 FRT 
and A375 AGR-2 were seeded onto 6cm tissue plates and treated with a fixed dosage of 
2units/ml of interferon-γ for a time course of 1, 2, 4, 6, and 24hr (Figure 6.2.C). 
Following treatment, cell lysate was subjected to immunoblotting (Figure 6.2.C). 
Results show that AGR-2 overexpression attenuates both IRF-1 and p53 basal levels and 
the effect is clearly shown when 50µg or more of total protein lysate is used (Figure 
6.2.A). AGR-2 attenuates the induction of the IRF-1 pathway that is induced by 20µg/ml 
poly (I:C) at 4hr fixed time point (Figure 6.2.Right). This is also confirmed using a 
downstream target of IRF-1; the double-stranded RNA-activated protein kinase R (PKR) 
is attenuated as a result of AGR-2 overexpression (Figure 6.2.Left). Interferon-γ seems 
to overcome the AGR-2 overexpression signal as IRF-1 and PKR protein levels do not 
change in response to AGR-2 overexpression (Figure 6.2.C). 
 










Figure 6.2: AGR-2 attenuates IRF-1 and p53 basal levels. (A) A375 FRT7 and A375 
AGR-2 were seeded on 6cm culture plates; 24hr later, cells were subjected to 
immunoblotting: p53 and IRF-1 basal levels are reduced as a result of AGR-2 
overexpression. (B) A375 FRT7 and A375 AGR-2 were seeded on 6cm culture plates, 
24hr later, cells were subjected to poly (I:C) treatment, PKR protein level is reduced 
as a result of AGR-2 overexpression. (C) A375 FRT and A375 AGR-2 were seeded on 
6cm culture plates; 24hr later, cells were subjected to interferon-γ. Interferon-γ 
seems to overcome the effect of AGR-2 signalling on IRF-1 pathway. 
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6.3.3 AGR-2: a cellular survival factor 
To test the potential of AGR-2 as a survival factor, ER stress was initiated using 
tunicamycin. A375 FRT7 and A375 AGR-2 were seeded onto 6cm tissue plates and 
treated with 1, 2, or 4µg/ml tunicamycin for 0, 1, 2, 4, and 6hr. Following treatment, cell 
lysate was subjected to immunoblotting (Figure 6.3). 
Results show that AGR-2 overexpression attenuates IRF-1 basal levels, where the effect 
is clearly shown during 2μg/ml tunicamycin treatment (Figure 6.3.A.Right). ER stress 
initiation following 4hr treatment is confirmed by C/EBP homologous protein (CHOP) 
overexpression (Figure 6.3). AGR-2 overexpression increases ER stress to sustain 
cellular survival, an effect confirmed by the increasing CHOP protein levels at 4hr time 
point (Figure 6.3.Box). 
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Figure 6.3: AGR-2: a cellular survival factor. A375 FRT7 and A375 AGR-2 were 
seeded on 6cm culture plates; 24hr later, cells were treated with 1, 2, or 4μg/ml 
tunicamycin for 1, 2, 4, and 6hr to initiate ER stress, followed by immunoblotting: 
IRF-1 basal level is reduced as a result of AGR-2 overexpression; ER stress is 
initiated by CHOP overexpression following 4hr of treatment. AGR-2 overexpression 
restores cellular survival, an effect noted by CHOP protein levels during AGR-2 
overexpression (Box).   
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6.4 Discussion 
Currently, we are investigating the proposed model of AGR-2 being a p53 kinase 
inhibitor, as discussed in the introduction; a stable cell line that overexpresses AGR-2 is 
a better tool than transient transfection. We have showed that the stable AGR-2 cell line 
responds as expected to UV irradiation. It is known that p53 accumulates in response to 
ionizing radiation (Kastan et al., 1991), where UV is also considered as a potent 
activator of p53 protein (Lu et al., 1993). Both cell lines, A375 FRT7 and A375 AGR-2, 
respond to UV in respect of p53 induction, and AGR-2 overexpression seems to 
attenuate this induction, especially at high UV (40 J/m
2
) and with a longer recovery 
(24hr), compared to A375 FRT7 (Figure 6.1). The signalling mechanism in both UV and 
ionizing radiation involves some distinct steps; like ionizing radiation, UV also arrests 
cells in G1 phase (Li et al., 1996).  
p21
WAF1
 was identified as an inhibitor of cyclin dependent kinase and a gene whose 
transcription is enhanced by p53 (EL-Deiry et al., 1993). Here we report the reduction in 
p21 protein level as UV dosage increases; however, this p21 reduction is more 
noticeable in the cell line overexpressing AGR-2, where p53 is attenuated (Figure 6.1). 
Thus, AGR-2 overexpression attenuates p21 and p53 protein levels following UV 
treatment and after 24hr recovery. The Flp-In™ cassette was validated using p53-AGR-
2 model and thus the cassette has proven to be a great tool for use in cancer biology. 
Some studies showed that p21 decreases after UV irradiation of human tumour cells 
(Maki et al., 1997 and Allan et al., 1999) where other studies showed an increase in p21 
protein after UV irradiation of fibroblasts in the absence of p53 (Loignon et al., 1997 
and Haapajrvi et al., 1999). To reconcile this conflict it was proposed that p21 protein 
levels increase or decrease after UV irradiation depending on the cell type or the level of 
transformation (Fotedar et al., 2004).  
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Other studies showed that low UV (<40 J/m
2
) leads to p21 degradation in diploid 
untransformed fibroblast (Bendjennat et al., 2003). Thus UV-induced degradation of p21 
protein at low doses is independent of cell transformation and p53 although, p21 
transcription increases after low dose UV irradiation of cells containing p53, where p21 
protein is still degraded (Fotedar et al., 2004). 
To test whether AGR-2 has an attenuating effect on other tumour suppressers, we tested 
the basal level of IRF-1 during AGR-2 overexpression (Figure 6.2.A). Results confirmed 
that IRF-1 basal protein level is reduced when AGR-2 is overexpressed, suggesting the 
ability of AGR-2 to act as a survival factor. This finding is similar to our observation 
with p53 and AGR-2, as studies in our lab suggested p53 transcriptional activity is 
reduced when co-transfected with AGR-2. This was found to be caused by AGR-2 
acting as a kinase inhibitor, which blocks the phosphorylation of serine 15 and serine 
392 modified by ataxia telangiectasia mutated (ATM) and CK2 respectively. 
We have confirmed that this attenuation affects IRF-1 transcriptional activity, as PKR 
protein level was reduced when AGR-2 is overexpressed (Figure 6.2). PKR is known as 
a serine/threonine kinase with tumour suppressor activity, where its induction is caused 
by IRF-1 activation (Kirchhoff et al., 1995). Here we showed AGR-2 overexpression 
attenuates IRF-1 protein levels, resulting in reduction of its transcriptional activity.  
We have not examined IRF-1 phosphorylation during AGR-2 overexpression, thus we 
are not sure whether this attenuation is p53 dependent or independent. Therefore, we 
decided to investigate the effect of AGR-2 overexpression on interferon-γ and poly 
(I:C)-induced IRF-1 (Figure 6.2.B and C). We have found the attenuation effect is only 
noticeable on poly (I:C) treatment but not on interferon-γ treatment. Thus, we propose 
that the IRF-1 attenuation effect is p53 dependent, as poly (I:C) is p53 dependent and 
interferon-γ is p53 independent. 
  
180 | P a g e  
 
Tanka et al (1996) first reported the cooperation between IRF-1 and p53 in response to 
DNA damage. It is known that their expression is independent of one another, however, 
both are required for p21 transcription, as the p21 promoter is activated, directly or 
indirectly, by both. Later, Dornan et al (2004) reported that IRF-1 and p53 synergize at 
the p21 promoter, and p21 transcription relies on the ability of IRF-1 to bind the 
coactivator p300 and to stimulate p53 dependent transcription.  
A further hypothesis was based on the reports that showed that IRF-1 regulation during 
genotoxic stress involves the ATM signalling pathway (Pamment et al., 2002) or CKII 
signalling (Lin and Hiscott 1999).  Here IRF-1 attenuation could be caused directly by 
AGR-2 acting as a kinase inhibitor of ATM and/or CKII kinetic activity (Figure 6.3). 
Interferon-γ has managed to overcome the AGR-2 signal, resulting in stabilization of 
IRF-1 transcriptional activity and proposing a potential therapeutic use by its ability to 
restore cellular tumour suppressor activity and overcome an oncogenetic signal. 
However, interferon-γ has a toxic effect on patients, thus reducing its potential in clinics 
(Sriskandan et al., 1986). 
 
Figure 6.4: Proposed model for IRF-1 attenuation resulting from AGR-2 
overexpression. AGR-2 can act as a kinase inhibitor resulting in blocking the 
phosphorylation of IRF-1 by CKII and/or ATM and leading to the reduction in IRF-1 
transcriptional activity. 
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Protein folding in the ER could be impaired under various physiological and 
pathological conditions called ER stress (Kaufman, 1999). To overcome such ER stress, 
cells can initiate a response by a specific signalling pathway, termed the ER stress 
response pathway, which involves at least four responses (Ron, 2002). The fourth is 
apoptosis, which occurs when ER is severely impaired, and which protects the organism 
by eliminating damaged cells (Ferri and Kroemer, 2001; Oyadomari et al., 2002). One of 
these apoptotic pathways is the CHOP pathway leading to the activation of caspase-3, 
suggesting that ER stress signals are finally transmitted to the mitochondria (Oyadomari 
and Mori 2004). Thus CHOP overexpression is an indication of the ER response 
indicating an attempt at cellular survival before forcing the final choice of apoptosis. 
Here we have reported the initiation of the ER stress response by CHOP overexpression 
following tunicamycin treatment (Figure 6.3). AGR-2 overexpression in A375 AGR-2 
enhances CHOP overexpression as a result of tunicamycin treatment; however, this is 
only noticeable at the 4hr time point (Figure 6.3.Box). This observation proposed a role 
of AGR-2 overexpression is sustaining cellular survivors. In addition, an identical 
observation has been noted when AGR-2 was knocked-down in Hela cells using AGR-2 
siRNA; the levels of CHOP were down-regulated when cells were treated with 
tunicamycin for 8hr (Higa et al., 2011). 
A further study using different ER stress inducers, thapsigargin, which promotes ER 
stress by depletion of ER calcium stores, and dithiothreitol which disrupts disulphide 
bond formation, has showed that the proliferation rate and cellular survival rate increases 
once wild-type AGR-2 is overexpressed during thapsigargin treatment (E. Murry 
unpublished date). All these finding from our lab suggest an important role for AGR-2 in 
cellular survival during ER stress response. 
  











Chapter 7: Final conclusions and future 
perspective 
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This study described the creation and the validation of synthetic tools that can aid and 
speed progress in scientific research and development. We have used IRF-1 to validate 
these developed tools showing their potential for research use and drug development. 
First, we have outlined the steps used in designing a novel targeting cassette that can be 
used to create cre-conditioned mouse models using recombineering technology. We 
have successfully developed a pLSL-TOPO-BAC vector, a universal BAC targeting 
vector, that can be used for any gene of interest where homologous arms can easily be 
slotted in, followed by the creation of desired mutations. Once created, cre-conditioned 
mouse models are easily developed. 
I have also discussed different methods used for desired mutation creation; however, I 
recommend two untested new methods named ZFNs or CompoZr
®
 (zinc finger nuclease 
technology) and TALENs™ (transcription activator-like effector nucleases) to create the 
required mutation following STOP cassette recombineering into the desired BAC. ZFNs 
are a class of engineered DNA-binding proteins that have the ability to recognize and 
bind onto a specific DNA location facilitating target editing by creating double-strand 
breaks in DNA followed by sequence alteration at the desired site using the cellular 
natural DNA-repair process, namely homologous recombination and non-homologous 
end joining. Sigma-Aldrich provides a custom-made ZFN service for genomic 
engineering in any species of cell line. We recommend the use of such a service to 
obtain custom-made ZFN for desired genomic alterations on BACs following the STOP 
cassette integration. Once a BAC subtle mutation is created, the whole BAC fragment 
carrying the STOP cassette, desired mutation and homologous fragments can be slotted 
into a stem cell targeting vector, such as pL611 for embryonic stem cell use, prior to 
selection and blastocyst injection. 
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Similar to ZFNs, TALENs is a recent development in the field of gene-editing nucleases, 
where a DNA-binding motif has been identified in proteins termed transcription 
activator-like effectors (TALEs), which nucleases can be attached to (Baker 2011). 
These TALENs have been proven to be easier to design and capable of performing the 
same function of zinc finger proteins in ZFNs. TALEs have very similar structure, 
except for the one section in the middle. This section is highly repetitive, made up of 
sequences that are each about three dozen amino acids long (Baker 2011). Within each 
TALE, the repeat sequences differ from each other by two residues termed repetitive 
variable di-residues (RVD) (Baker 2011). Further, it has been noticed that the number of 
repeats in some TALEs was approximately equal to the number of nucleotides to which 
it binds (Baker 2011) leading to the hypothesis that each variable di-residue in a TALE 
repeat bound to a single nucleotide, which was later proven to be the TALE code (Baker 
2011). The implication of TALE proteins was striking, as it means that proteins can 
easily be designed to bind any DNA sequence. 
TALENs are easier to design than ZFNs, and other reports showed that TALENs are 
more specific and less toxic than ZFNs; however, this does not mean that TALENs are 
automatically the technology of choice. ZFNs have been used for more than a decade, 
but only recently nonspecific cutting across the genome has been reported. There is not 
enough evidence to declare that TALENs are a better technology than ZFNs as most 
research report the successful use of TALENs without reporting how frequently a 
TALEN fails to work. At the end, we seek a platform with the least off-target effects and 
the highest success rate. 
Some companies such as Cellectis offer a TALENs™ custom service; however, the cost 
for customized TALENs or ZFNs exceeds the budget of a standard lab. Designing our 
own ZFNs or TALENs is not impossible as many public domains offer databases for ZF 
and TALEs DNA-binding sequences. However, labour, knowledge of this field, and 
time availability are all requirements for a successful TALEN or ZFN design. 
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The second part of this study showed the development of the Flp-In System™ from 
Invitrogen to ease the generation of isogenic stable mammalian expression cell lines. We 
have validated the system by creating two isogenic stable cell lines, one overexpresses 
wild-type IRF-1 and the second overexpresses a mutant that abolishes IRF-1 DNA-
binding ability. Using microarray studies and quantitative real-time PCR, we have used 
the system to identify a new role of IRF-1 in cancer biology; we have successfully 
identified SH3PXD2A and SPP1 as new IRF-1 target genes confirming a new biological 
role for IRF-1 in cellular adhesion, invasion, and tumour growth progression. In addition 
to SPP1 and SH3PXD2A, we have identified new IRF-1 target genes with known 
biological roles of IRF-1 in autophagy, cell linage differentiation, apoptosis, tumour 
growth inhibition, DNA repair, signal transduction, and telomerase maintenance (Figure 
4.11). Further in-silico analysis of the regulatory element of these identified genes 
revealed that it is highly likely that an IRF-1 binding domain, such as ISRE, is contained 
in the promoter region of those genes identified using microarray and qRT-PCR.  
To further validate these results, we suggest the use of luciferase reporter technology 
where the regulatory element of these identified genes can be cloned downstream of a 
firefly luciferase gene on pGL3 backbone. Once cloned, a dual luciferase assay can 
report the activation of the regulatory element during IRF-1 overexpression and/or IRF-1 
stimulation by interferon-γ or poly (I:C). This assay should confirm the direct activation 
of these genes by IRF-1 transcription factor to further validate our hypothesis. 
To confirm the newly discovered role of IRF-1 in cellular adhesion and metastasis we 
suggest the use of commercially available cell invasion assays designed for cellular 
migration, invasion and wound healing. Using this assay, A375 conIRF-1 can be tested 
for its ability to enhance metastasis and invasion on comparison to it the control, A375 
W11R, that abolishes DNA-binding ability and thus reduces IRF-1 blockage to SPP1 
and/or SH3PXD2A.  
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The third tool we have developed in this study is the IRF-1 reporter cell line that can be 
used for high throughput screening. We have used this reporter cell line to screen a 
library of kinase inhibitors in order to identify new IRF-1 modifiers. Following many 
screening and validating rounds, we have identified a new IRF-1 modifier that regulates 
IRF-1 transcriptional activity by inhibiting platelet-derived growth factor receptor 
(PDGFR) and/or vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. 
Phosphorylation of IRF-1 using these two tyrosine kinases has not been reported 
previously. However, we suggest further investigation by determining any potential of 
IRF-1 phosphorylation by these two tyrosine kinases using kinase activity assays, 
enzyme-linked immunosorbent assay (ELISA), in-gel kinase assays and in vitro protein 
kinase assay. Linking IRF-1 phosphorylation by these tyrosine kinases will prove the 
validity of such tools in the field of life science. 
Last but not least, we have used the Flp-In System™ to generate a stable cell line that 
overexpresses an oncogene termed AGR-2. We validated the AGR-2 p53 model where 
previous work in this lab showed that AGR-2 can act as a kinase inhibitor preventing 
p53 phosphorylation by ATM and CKII and, thus, reducing p53 activity. We used the 
system to identify whether AGR-2 can attenuate the activity of another tumour 
suppressor, and we found that AGR-2 can attenuate IRF-1 basal protein levels as well as 
levels of poly (I:C) induced IRF-1 in human melanocytes. We proposed that this 
attenuation is p53 dependent, as other stimuli such as interferon-γ (p53 independent) can 
overcome the AGR-2 effect. In addition, AGR-2 has been identified as a cellular 
survival factor, where its overexpression aids cells to increase the production of proteins 
that play a role in unfolded protein responses.  
In conclusion, this study described the creation and the validation of synthetic tools: 
synthetic cassette for cre-conditioned mouse creation, the Flp-In System™ for isogenic 
stable cell line creation, and IRF-1 reporter cell line for high throughput screening. All 
the synthetic tools were validated and used to investigate IRF-1, a transcription factor 
that plays a role in cancer and immune system. 
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